

2024, we closed a registered direct offering of 458,632 shares of common stock and pre-funded warrants to purchase an aggregate of 626,368 shares of common stock (the "July 2024 Pre-Funded Warrants"). In a concurrent private placement, we issued common warrants to the purchaser to purchase up to 2,170,000 shares of common stock at an exercise price of \$2.86 per share. Net proceeds after deducting placement agent commissions and other offering expenses were approximately \$2.8 million. On August 21, 2024, we closed a registered direct offering of 1,360,731 shares of common stock and pre-funded warrants to purchase an aggregate of 339,269 shares of common stock (the "August 21, 2024 Pre-Funded Warrants"). In a concurrent private placement, we issued common warrants to the purchaser to purchase up to 1,700,000 shares of common stock at an exercise price of \$5.00 per share. Net proceeds after deducting placement agent commissions and other offering expenses were approximately \$7.9 million. On August 30, 2024, we closed a registered direct offering of 837,500 shares of common stock and pre-funded warrants to purchase an aggregate of 138,110 shares of common stock (the "August 30, 2024 Pre-Funded Warrants"). In a concurrent private placement, we issued common warrants to the purchaser to purchase up to 975,610 shares of common stock at an exercise price of \$5.00 per share. Net proceeds after deducting placement agent commissions and other offering expenses were approximately \$4.6 million. On September 25, 2024, we entered into a Sales Agreement and established an "At-the-Market" continuous offering program (the "ATM Program"), pursuant to which the Company may offer and sell, from time to time through its sales agent, shares of its common stock. During the third quarter of 2024 we sold 84,600 shares of our common stock through the ATM Program at a weighted-average price of \$2.51 per share, raising \$206,003 of net proceeds, after deducting commissions to the sales agent and other related expenses. As of September 30, 2024, we had \$4,274,260 available under the ATM Program.

7. Warrant Exercises During the first quarter of 2024, we issued 269,032 shares of our common stock upon the exercise of prefunded warrants issued in December 2023 (the "December 2023 Pre-Funded Warrants"). During the second quarter of 2024, we issued (i) 238,000 and 582,844 shares of our common stock upon the exercise of the December 2023 Pre-Funded Warrants and the May 2024 Pre-Funded Warrants, respectively; (ii) 2,549 shares of our common stock upon the cashless exercise of 4,000 warrants issued in June 2020, and (iii) 826,998 shares of our common stock upon the exercise of common warrants issued in December 2023 (the "December 2023 Common Warrants"), with net cash proceeds to us of \$1,389,363. During the third quarter of 2024, we issued (i) 626,368, 339,269 and 138,110 shares of our common stock upon the exercise of the July 2024 Pre-Funded Warrants, the August 21, 2024 Pre-Funded Warrants, and the August 30, 2024 Pre-Funded Warrants respectively; (ii) 3,398 shares of our common stock upon the cashless exercise of 4,000 warrants issued in June 2020, and (iii) 582,000 shares of our common stock upon the exercise of the December 2023 Common Warrants, with net cash proceeds to us of \$977,770. **Other Common Stock Transactions** During the first quarter of 2024, we issued 6,703 shares of our common stock pursuant to a professional relations and consulting agreement and we issued 55,422 shares of our common stock for the roundup of fractional shares associated with the reverse stock split. **Stock Options** We have stock-based incentive plans (the "Plans") pursuant to which our Board of Directors may grant stock options and other stock-based awards to our employees, directors and consultants. During the nine months ended September 30, 2024, we granted 200,000 new stock options with a weighted-average exercise price of \$2.23 per share and 961 stock options were cancelled. As of September 30, 2024, there are 333,648 stock options outstanding, with a weighted-average exercise price of \$12.71 per share and a weighted-average remaining contractual term of 7.2 years. Including the outstanding stock options, a total of 333,648 shares of our common stock are reserved for future issuance pursuant to the Plans. **Stock Purchase Warrants** The table below summarizes information concerning warrants outstanding as of September 30, 2024.

Issue Date	Number of Shares	Exercise Price	Expiration
September 2020	159,781	\$ 75.00	September 2025
September 2021	6,668	\$ 195.00	September 2026
			May 2024
			1,605,688
			\$ 1.68
			May 2029
			July 2024
			2,170,000
			\$ 2.86
			November 2029
			August 2024
			2,675,610
			\$ 5.00
			August 2029
			Outstanding
			at September 30, 2024
			6,617,747
			\$ 7.
			Stock-Based Compensation Expense
			Stock-based compensation expense related to stock options is
			recognized on a straight-line basis over the requisite service period for the award and is allocated to research and development expense or
			general and administrative expense based upon the classification of the individual to whom the award is granted. Stock-based compensation
			expense related to stock option grants was \$129,923 and \$335,132 during the three-month and nine-month periods ended September 30,
			2024, respectively, as compared to \$227,114 and \$681,166, respectively, during the same periods of 2023. As of September 30, 2024, there is
			\$655,314 of unrecognized compensation expense that we expect to recognize over a weighted-average period of 1.9 years. We have also
			issued shares of our restricted common stock to consultants and recognize the related expense over the terms of the related agreements.
			During the three-month and nine-month periods ended September 30, 2024 we recorded stock-based compensation expense of \$-0 and
			\$54,167, respectively, associated with common stock issued for consulting services, as compared to \$70,833 and \$132,333, respectively, for
			the same periods of 2023. 8. Revenue from Government Contract On June 12, 2024, GeoVax was awarded a contract (the "BARDA Contract") through the Rapid Response Partnership Vehicle (RRPV) to advance the clinical development of GEO-CM04S1, the Company's next-generation COVID-19 vaccine. The RRPV is a consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS). Under the BARDA Contract, GeoVax will sponsor a 10,000-participant, randomized, Phase 2b double-blinded clinical trial to assess the efficacy, safety, and immunogenicity of GEO-CM04S1 compared with a U.S. Food and Drug Administration (FDA)-approved mRNA COVID-19 vaccine. The direct award to GeoVax, currently approximately \$26.2 million and which may increase to as much as \$45 million, is funding the manufacturing of clinical materials and support for the Phase 2b clinical trial, including regulatory activities. BARDA has made a separate award through its Clinical Studies Network to fully fund the execution of the study by Allucent, a global clinical research organization; the funding provided directly to Allucent will not be recognized in GeoVax's financial statements. GeoVax's role in the project is being funded in whole or in part with federal funds from BARDA under Other Transaction 75A50123D00005. Allucent's role in the project is being funded in whole or in part with federal funds from BARDA under contract 75A50120D00016/75A50123F33005. During the three-month and nine-month periods ending September 30, 2024, GeoVax recognized revenue of \$2,789,484 and \$3,090,161, respectively, associated with the BARDA contract. We record revenue associated with this contract as the reimbursable costs are incurred. 9. Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. The Company's potentially dilutive securities, which include stock options and stock purchase warrants, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. The securities that could potentially dilute basic earnings per share in the future and that have been excluded from the computation of diluted net loss per share totaled 6,951,395 and 1,026,862 shares at September 30, 2024 and 2023, respectively. 10. Income Taxes No provision for income taxes was recorded in either of the nine-month periods ended September 30, 2024 and 2023. The Company remains in a cumulative loss position with a full valuation allowance recorded against its net deferred income tax assets as of September 30, 2024. 11. Subsequent Events During October 2024 we issued 826,761 shares of our common stock through the ATM Program at a weighted-average price of \$2.20 per share, raising \$1,761,309 of net proceeds, after deducting commissions to the sales agent and other related expenses. On October 15, 2024, we increased the maximum aggregate offering price of the shares issuable under the ATM Program from \$4,486,846 to \$30,000,000. Item 2 Management's Discussion and Analysis of Financial Condition And Results of Operations The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to help the reader understand our results of operations and financial condition. This MD&A is provided as a supplement to, and should be read in conjunction with, our condensed consolidated financial statements and the accompanying notes thereto and other disclosures included in this Quarterly Report on Form 10-Q (this "Quarterly Report"), and our audited financial statements and the accompanying notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (the "SEC") on February 29, 2024. Forward-Looking Statements Information included in this Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. All statements in this Quarterly Report, other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, future governmental grants, projected costs, prospects, plans, intentions, expectations and objectives could be forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. We operate in a highly competitive, highly regulated and

rapidly changing environment and our business is constantly evolving. Therefore, it is likely that new risks will emerge, and that the nature and elements of existing risks will change, over time. It is not possible for management to predict all such risk factors or changes therein, or to assess either the impact of all such risk factors on our business. We assume no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this Quarterly Report. **Overview** **GeoVax** is a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases using novel vector vaccine platforms.

GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against advanced head and neck cancer. Additional preclinical research and development programs include preventive vaccines against Mpox (formerly known as monkeypox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), and Zika virus, as well as immunotherapies for solid tumors. Our corporate strategy is to advance, protect and exploit our differentiated vaccine/immunotherapy technologies leading to the successful development of preventive and therapeutic vaccines and immunotherapies against infectious diseases and various cancers. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third party resources through collaborations and partnerships for preclinical and clinical testing with multiple government, academic and corporate entities. Our programs are in various stages of development, the most significant of which are summarized below along with recent developments: **GEO-CM04S1** **Next Generation COVID-19 Vaccine**: On June 12, 2024, **GeoVax** was awarded a contract (the “BARDA Contract”) through the Rapid Response Partnership Vehicle (RRPV) to advance the clinical development of **GEO-CM04S1**. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS). Under the agreement, **GeoVax** will sponsor a 10,000-participant, randomized, Phase 2b double-blinded study to assess the clinical efficacy, safety, and immunogenicity of **GEO-CM04S1** compared with a U.S. Food and Drug Administration (FDA)-approved mRNA COVID-19 vaccine. The direct award to **GeoVax**, currently approximately \$26.2 million and which may increase to as much as \$45 million, is funding the manufacturing of clinical materials and support for the Phase 2b clinical trial, including regulatory activities. BARDA has made a separate award of approximately \$343 million through its Clinical Studies Network to Allucent, a global clinical research organization, to execute the clinical trial as part of BARDA’s Clinical Studies Network. Target clinical sites are confirmed and manufacturing activities are underway for production of the vaccine product needed for study activation. **GEO-CM04S1** is currently undergoing a Phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT04977024), evaluating its safety and efficacy as a preventive COVID-19 vaccine in high-risk immunocompromised patients (i.e. patients with blood cancers who have previously received either an allogeneic hematopoietic cell transplant, an autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T cell therapy). Data published from the safety lead-in portion of the trial indicates that **GEO-CM04S1** is highly immunogenic in these patients, inducing broad and durable neutralizing antibody and T cell responses. **GEO-CM04S1** is also undergoing the Phase 2 portion of a Phase 1/2 trial (ClinicalTrials.gov Identifier: NCT04639466), evaluating two vaccine dose levels as a heterologous COVID-19 booster vaccine to current FDA-approved mRNA vaccines from Pfizer/BioNTech and Moderna. In February 2024, we announced positive interim safety and immune responses findings following vaccine administration. Consolidated data (blinded to vaccine dose) from all subjects tested one-month post-vaccination, documented statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants, ranging from the original Wuhan strain through Delta and Omicron XBB 1.5. An investigator-initiated Phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT05672355) of **GEO-CM04S1** is evaluating its use as a COVID-19 vaccine booster in patients with chronic lymphocytic leukemia (CLL) compared to the Pfizer/BioNTech mRNA-based vaccine. **Gedeptin**: **Gedeptin** recently completed a Phase 1/2 clinical trial (PNP-002) (ClinicalTrials.gov Identifier: NCT03754933) for treatment of patients with advanced head and neck squamous cell carcinoma (HNSCC). This trial is being funded in part by the U.S. Food & Drug Administration (FDA) pursuant to its Orphan Products Clinical Trials Grants Program. In July 2024, we announced that a special clinical advisory board completed a comprehensive review of the PNP-002 trial results, together with the previously completed Phase 1 trial (PNP-001). This review concluded that **Gedeptin** demonstrated an acceptable safety and efficacy profile to support continued development. In addition, the therapy has demonstrated sufficient tumor stabilization/reduction activity to support plans to advance clinical development of **Gedeptin** therapy in an expanded Phase 2 clinical trial. We have initiated activities in support of a Phase 2 trial in first-recurrence head and neck cancer. The primary goal of this trial will be to establish efficacy of neoadjuvant **Gedeptin** therapy combined with an immune checkpoint inhibitor in squamous cell head and neck cancer. This trial is anticipated to be a single cycle trial with surgery to follow in approximately 36 patients with pathologic response rate as the primary endpoint. We have initiated the necessary planning activities, including protocol development, manufacturing and CRO selection, with the trial activation anticipated during the first half of 2025. **GEO-MVA**: **GEO-MVA** is the Company vaccine candidate in development for protection against Mpox and Smallpox. MVA is the vaccine recommended by both the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) against both Mpox and Smallpox, recognized for its safety and efficacy among all patient populations, including pregnant women, children and immunocompromised individuals. MVA is the vaccine currently used and stockpiled in the United States Strategic National Stockpile for immunization against potential bioterrorism threats based on the smallpox virus. We have produced and released the cGMP Master Seed Virus for **GEO-MVA** and are currently producing the cGMP Working Virus Seed (WVS) bank. We expect to complete cGMP production of a clinical batch of **GEO-MVA** before year-end 2024, which will then be reviewed with stakeholders for potential clinical use. Our additional research programs for vaccines and immunotherapies at various stages of preclinical development. **General Corporate**: On May 23, 2024, we received a notice from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it no longer complied with the \$2,500,000 minimum stockholders’ equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”), because the Company’s stockholders’ equity as reported in its Form 10-Q for the period ended March 31, 2024 did not meet the required minimum. On July 18, 2024, we received notice from Nasdaq granting our request for an extension of time to regain compliance with the Stockholders’ Equity Requirement until November 19, 2024. As a result of several financing transactions completed during the quarter ended September 30, 2024, we believe that, as of the date of this Quarterly Report, the Company has regained compliance with the Stockholders’ Equity Requirement. Nasdaq will continue to monitor our ongoing compliance with the Stockholders’ Equity Requirement and, if at the time of our next periodic report, we do not evidence compliance, the Company may be subject to delisting. **Financial Overview** **Revenue**: Our revenues to date have been related to government grants and contracts and other collaborative arrangements in support of our product development activities. We have not generated any revenue to date from the sale of the products we are developing. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use and will require significant costs for commercialization. **Research and development expenses**: Since our inception, we have focused and we continue to focus significant resources on our research and development activities, including developing our vector platform and analytical testing methods, conducting preclinical studies, developing manufacturing processes, and conducting clinical trials. Research and development costs are expensed as incurred and consist primarily of the following: personnel costs in our research and development functions, including salaries, benefits and stock-based compensation; expenses incurred under agreements with contract research organizations (“CROs”), for the conduct of clinical trials; expenses incurred under agreements with contract manufacturing organizations (“CMOs”), that manufacture product used in clinical trials; expenses incurred in procuring materials and for analytical and release testing services required to produce vaccine candidates used in clinical trials; process development expenses to improve the efficiency and yield of the bulk vaccine; laboratory supplies, vendor expenses and other third-party contract expenses related to preclinical research activities; technology license fees; consultant expenses for services supporting our clinical, regulatory and manufacturing activities; and facilities, depreciation and other general overhead expenses. We expect our research and development expenditures to increase as we advance our existing and future product candidates into and through clinical trials and pursue regulatory approval, especially with regard to the **Gedeptin** and **GEO-CM04S1** clinical programs. We do not provide forward-looking estimates of costs and time to complete our research programs due to the many uncertainties associated with biotechnology research and development. Due to these uncertainties, our future expenditures are likely to be highly volatile in future periods depending on the outcomes of the trials and studies. As we obtain data from preclinical studies and clinical trials, we may elect to discontinue or delay certain development programs to focus our resources on more promising product candidates. Completion of preclinical studies and human clinical trials may take several years or more, but the length of time can vary substantially depending upon several factors. The duration and the cost of future clinical trials may vary significantly over the life of the project because of differences arising during development of the human clinical trial protocols, including the length of time required to enroll suitable patient subjects, the number of patients that ultimately

participate in the clinical trial, the duration of patient follow-up, and the number of clinical sites included in the clinical trials. General and administrative expenses Our general and administrative expenses consist primarily of personnel costs in our executive, finance and investor relations, business development and administrative functions, including stock-based compensation. Other general and administrative expenses include consulting fees, professional service fees for accounting and legal services, lease expenses related to our offices, insurance premiums, intellectual property costs incurred in connection with filing and prosecuting patent applications, depreciation and other costs. We expect our general and administrative expenses to continue to increase in the future as we support expanded research and development activities, prepare for potential commercialization of our current and future product candidates, maintain compliance with requirements of Nasdaq and the SEC, and other general corporate activities. Critical Accounting Policies and Estimates This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates and adjusts the estimates as necessary. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. For a description of critical accounting policies that require significant judgments and estimates during the preparation of our financial statements, refer to the Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no significant changes to our critical accounting policies from those disclosed in our 2023 Annual Report. Recent Accounting Pronouncements Information regarding recent accounting pronouncements is contained in Note 2 to the condensed consolidated financial statements, included in this Quarterly Report. Off-Balance Sheet Arrangements We have no off-balance sheet arrangements that are likely or reasonably likely to have a material effect on our financial condition or results of operations, other than the operating lease for our office and laboratory space. Results of Operations The following table summarizes our results of operations for the three-month and nine-month periods ended September 30, 2024 and 2023:

Period	Revenue from government contract	Operating expenses	Interest income	Interest expense	Net loss
Three Months Ended September 30, 2024	\$ 2,789,484	\$ 2,789,484	\$ 53,191	\$ (137,745)	\$ (5,815,468)
Three Months Ended September 30, 2023	\$ 2,789,484	\$ 2,789,484	\$ 190,936	\$ (14,083)	\$ (8,408,818)
Nine Months Ended September 30, 2024	\$ 3,090,161	\$ 3,090,161	\$ 191,611	\$ (18,374,354)	\$ (16,729,642)
Nine Months Ended September 30, 2023	\$ 3,090,161	\$ 3,090,161	\$ 190,936	\$ (21,375)	\$ (18,374,354)

For the three-month and nine-month periods ended September 30, 2024, we reported \$2,789,484 and \$3,090,161, respectively, of revenues associated with the BARDA Contract. There were no revenues reported during the comparable 2023 periods. Research and Development Expenses For the three-month and nine-month periods ending September 30, 2024, research and development expenses increased by \$454,905 (6.5%) and \$1,618,584 (11.2%), respectively, versus the comparable 2023 periods. The overall increase during the nine-month period of 2024 versus 2023 relates primarily to costs of manufacturing materials for use in our clinical trials of GEO-CM04S1 and other costs associated with the BARDA Contract. Research and development expenses for the three-month and nine-month periods of 2024 include stock-based compensation expense of \$59,384 and \$163,654, respectively; as compared to \$77,873 and \$232,516, respectively, for the comparable 2023 periods. General and Administrative Expenses For the three-month and nine-month periods ending September 30, 2024, general and administrative expenses decreased by \$410,599 (24.9%) and \$777,734 (17%), respectively, versus the comparable 2023 periods. The overall decrease during the 2024 periods relates primarily to lower stock-based compensation expense, consulting costs, legal and patent costs and franchise tax cost. General and administrative expenses for the three-month and nine-month periods of 2024 includes stock-based compensation expense of \$70,538 and \$225,645, respectively; as compared to \$220,075 and \$580,983, respectively, for the comparable periods of 2023. Other Income Interest income for the three-month and nine-month periods ended September 30, 2024 was \$53,191 and \$91,611, respectively, as compared to \$190,936 and \$674,835, respectively, for comparable periods of 2023. The overall decrease during the 2024 periods is primarily attributable to cash available for investment. Interest expense for the three-month and nine-month periods ended September 30, 2024 was \$14,083 and \$21,375, respectively, associated with certain notes payable issued during May 2024 and repaid in August 2024. There was no interest expense during the comparable periods of 2023. Liquidity and Capital Resources The following tables summarize our liquidity and capital resources as of September 30, 2024 and December 31, 2023, and our cash flows for the nine-month periods ended September 30, 2024 and 2023:

Period	Cash and cash equivalents	Working capital	Net cash provided by (used in):	Operating activities	Investing activities	Financing activities	Net cash used in operating activities	Net increase (decrease) in cash and cash equivalents
September 30, 2024	\$ 8,592,523	\$ 6,452,589	\$ 19,082,548	\$ (16,921,961)	\$ (14,895,694)	\$ 19,082,548	\$ (16,921,961)	\$ 2,139,934
December 31, 2023	\$ 8,261,251	\$ 4,365,861	\$ 19,082,548	\$ (16,921,961)	\$ (20,653)	\$ 19,082,548	\$ (16,921,961)	\$ (29,997)
Nine Months Ended September 30, 2024	\$ 8,592,523	\$ 6,452,589	\$ 19,082,548	\$ (16,921,961)	\$ (14,895,694)	\$ 19,082,548	\$ (16,921,961)	\$ 2,139,934
Nine Months Ended September 30, 2023	\$ 8,261,251	\$ 4,365,861	\$ 19,082,548	\$ (16,921,961)	\$ (20,653)	\$ 19,082,548	\$ (16,921,961)	\$ (29,997)

Net cash used in operating activities of \$16,921,961 for the nine months ended September 30, 2024, was due to our net loss of \$16,729,642, offset by non-cash items such as depreciation and amortization expense and stock-based compensation expense, and by changes in our working capital accounts. Net cash used in operating activities of \$14,895,694 for the nine months ended September 30, 2023, was due to our net loss of \$18,374,354, offset by non-cash items such as depreciation expense and stock-based compensation expense, and by changes in our working capital accounts. Investing Activities Net cash used in investing activities was \$20,653 and \$29,997 for the nine-month periods ended September 30, 2024 and 2023, respectively, and relates primarily to purchases of laboratory equipment. Financing Activities Net cash provided by financing activities was \$19,082,548 and \$-0- for the nine-month periods ended September 30, 2024 and 2023, respectively. Net cash provided by financing activities for the 2024 period primarily relates to offerings of our common stock and warrants and exercise of previously issued warrants. Funding Requirements and Sources of Capital To date, we have not generated any product revenue. We do not know when, or if, we will generate any product revenue and we do not expect to generate significant product revenue unless and until we obtain regulatory approval and commercialize one of our current or future product candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We are subject to all of the risks incident to the development of new products, and may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business. We anticipate that we will need substantial additional funding in connection with our continuing operations. We have funded our operations to date primarily from sales of our equity securities and from government grants and clinical trial assistance. During the nine months ended September 30, 2024, we closed four registered direct offerings of our common stock and warrants, as well as established the ATM Program (see footnote 6 to the financial statements included in this Quarterly Report). Net proceeds to us from these offerings, after deducting commissions to the placement agent and sales agent, as applicable, and other related offering expenses, were approximately \$16.7 million. We also received approximately \$2.4 million upon the exercise of warrants. As of the date of this Quarterly Report, we believe that our existing cash and cash equivalents are sufficient to fund our operations into the first quarter of 2025. We plan to pursue additional cash resources through public or private equity or debt financings, government grants/contracts, arrangements with strategic partners, or from other sources. There can be no assurance that necessary funding will be available on favorable terms or at all. These factors collectively raise substantial doubt about the Company's ability to continue as a going concern. Management believes that we will be successful in securing the additional capital required to continue the Company's planned operations, but that our plans do not fully alleviate the substantial doubt about the Company's ability to operate as a going concern. We will need to continue to raise additional capital to support our future operating activities, including progression of our development programs, preparation for commercialization, and other operating costs. We may fund a significant portion of our ongoing operations through partnering and collaboration agreements which, while reducing our risks and extending our cash runway, will also reduce our share of eventual revenues, if any, from our vaccine candidates. We may be able to fund certain activities with assistance from government programs. The sale of additional equity would result in additional dilution to our stockholders. We may also fund our operations through debt financing, which

would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market vaccine candidates that we would otherwise prefer to develop and market ourselves. Any of these actions could harm our business, results of operations and prospects. A Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties and is based on assumptions that may prove to be wrong; actual results could vary materially. Our projection takes into consideration contractual commitments we have made, and expect to make, in the normal course of operating our business, which include (i) obligations to our employees, (ii) our lease obligations, (iii) payments due under license agreements for various technologies and patent rights associated with our product development activities, (iv) arrangements with contract research organizations (â€œCROsâ€), contract manufacturing organizations (â€œCMOsâ€), and other third-party vendors for clinical trials services and production of materials for use in our clinical trials, and (v) other various firm purchase commitments and contractual obligations related to production and testing of our product candidates and the general operation of our business. A We have based our projections of operating capital requirements on assumptions that may prove to be incorrect, and we may use our available capital resources sooner than we expect. Our future capital requirements will depend on many factors, which include but are not limited to: A â—the timing and costs of our ongoing and planned clinical trials; A â—the timing and costs of manufacturing material for use in clinical trials; A â—the number and scope of our research programs and the speed at which they are advanced; A â—the progress and success of our preclinical and clinical development activities; A â—the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; A â—the costs to attract and retain skilled personnel; A â—the costs to maintain and expand our infrastructure to support our operations, our product development, and planned future commercialization efforts; A â—the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; A â—the costs associated with any products or technologies that we may in-license or acquire; and A â—the costs and timing of regulatory approvals. A 15 A Item 3 Quantitative and Qualitative Disclosures About Market Risk A Not applicable to smaller reporting companies. A Item 4 Controls and Procedures A Evaluation of disclosure controls and procedures A Disclosure controls and procedures are controls and other procedures that are designed to ensure that the information required to be disclosed in reports filed or submitted under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), is (1) recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms and (2) accumulated and communicated to management, including the Chief Executive Officer and Principal Financial and Accounting Officer, as appropriate to allow timely decisions regarding required disclosure. A Our management has carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial and Accounting Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15 or 15d-15 as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms. A Changes in internal control over financial reporting A There were no significant changes in our internal control over financial reporting that occurred during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. A Limitations on Controls A Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. A 16 A PART II -- OTHER INFORMATION A Item 1 Legal Proceedings A None. A Item 1A Risk Factors A For information regarding factors that could affect our results of operations, financial condition or liquidity, see the risk factors discussed under â€œRisk Factorsâ€ in Item 1A of our most recent Annual Report on Form 10-K. See also â€œForward-Looking Statements,â€ included in Part I - Item 2 of this Quarterly Report on Form 10-Q. As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 1A concerning any material changes from the risk factors previously disclosed in our most recent Annual Report on Form 10â€K. A Item 2 Unregistered Sales of Equity Securities and Use of Proceeds A There were no sales of unregistered equity securities during the period covered by this report that have not previously been reported on Form 8-K. A Item 3 Defaults Upon Senior Securities A None. A Item 4 Mine Safety Disclosures A Not applicable. A Item 5 Other Information A During the period covered by this report, none of our directors or executive officers adopted or terminatedA any â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangementâ€ (as each term is defined in Item 408(a) of Regulation S-K). A During the period covered by this report, there was no information required to be disclosed by us in a Current Report on Form 8-K that was not so reported, nor were there any material changes to the procedures by which our security holders may recommend nominees to our board of directors. A A 17 A Item 6 Exhibits A Exhibit Number Description 3.1 Restated Certificate of Incorporation filed April 12, 2024 (2) 3.2. Bylaws (3) 4.1 Form of Pre-Funded Warrant, dated July 12, 2024 (4) 4.2 Form of Common Warrant, dated July 12, 2024 (4) 4.3 Form of Pre-Funded Warrant, dated August 21, 2024 (5) 4.4 Form of Common Warrant, dated August 21, 2024 (5) 4.5 Form of Pre-Funded Warrant, dated August 30, 2024 (6) 4.6 Form of Common Warrant, dated August 30, 2024 (6) 10.1 Securities Purchase Agreement, dated July 11, 2024 (4) 10.2 Securities Purchase Agreement, dated August 20, 2024 (5) 10.3 Securities Purchase Agreement, dated August 28, 2024 (6) 10.4 Sales Agreement, by and between the Company and A.G.P./Alliance Global Partners, dated September 25, 2024 (7) 31.1* Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934 31.2* Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934 32.1* Certification pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002 32.2* Certification pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002 101.INS Inline XBRL Instance Document (1) 101.SCH Inline XBRL Taxonomy Extension Schema Document (1) 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document (1) 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document (1) 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document (1) 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document (1) 104 Inline XBRL for the cover page of this Quarterly Report on Form 10-Q and included in the Exhibit 101 Inline XBRL Document Set (1) A * Filed herewith ** Indicates a management contract or compensatory plan or arrangement A (1) These interactive data files shall not be deemed filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under these sections. (2) Incorporated by reference from the registrants Quarterly Report on Form 10-Q filed May 14, 2024. (3) Incorporated by reference from the registrantâ€™s Current Report on Form 8-K filed May 23, 2024. (4) Incorporated by reference from the registrantâ€™s Current Report on Form 8-K filed July 12, 2024. (5) Incorporated by reference from the registrantâ€™s Current Report on Form 8-K filed August 21, 2024. (6) Incorporated by reference from the registrantâ€™s Current Report on Form 8-K filed August 30, 2024. (7) Incorporated by reference from the registrantâ€™s Current Report on Form 8-K filed September 25, 2024. A 18 A SIGNATURES A Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this quarterly report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized. A A GEOVAX LABS, INC. A A (Registrant) A A A A Date: A November 12, 2024 By: /s/A Mark W. Reynolds A A A Mark W. Reynolds A A A Chief Financial Officer A A A (duly authorized officer and principal financial officer) A A 19 EX-31.1 2 ex_744201.htm EXHIBIT 31.1 ex_744201.htm Exhibit 31.1 A CERTIFICATION PURSUANT TO RULE 13a-14(a) or 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 A I, David A. Dodd, President and Chief Executive Officer of GeoVax Labs, Inc. certify that: A A (1) I have reviewed this quarterly report on Form 10-Q of GeoVax Labs, Inc.; A A (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; A A (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; A A (4) The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: A a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; A b. Designed such internal control over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to

provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; **A. c.** Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and **A. d.** Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and **A. (5)** The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions): **A. a.** All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and **A. b.** Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. **A. A. A.** Dated: November 12, 2024 /s/ **David A. Dodd** **David A. A.** President & Chief Executive Officer **A. A. A. 1 A. A.** EX-31.2 3 ex_744202.htm EXHIBIT 31.2 ex_744202.htm Exhibit 31.2 **CERTIFICATION PURSUANT TO RULE 13a-14(a) or 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934** **A. I.** **Mark W. Reynolds**, Chief Financial Officer of GeoVax Labs, Inc. certify that: **A. A. (1)** I have reviewed this quarterly report on Form 10-Q of GeoVax Labs, Inc.; **A. A. (2)** Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; **A. A. (3)** Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; **A. A. (4)** The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: **A. a.** Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; **A. b.** Designed such internal control over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; **A. c.** Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and **A. d.** Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and **A. A. (5)** The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions): **A. a.** All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and **A. b.** Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. **A. A. A.** Dated: November 12, 2024 /s/ **Mark W. Reynolds** **Mark W. Reynolds A. A.** Chief Financial Officer **A. A. A. 1 A. A.** EX-32.1 4 ex_744203.htm EXHIBIT 32.1 ex_744203.htm **A. Exhibit 32.1** **CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** **A.** In connection with the quarterly report of GeoVax Labs, Inc. (the "Company") on Form 10-Q for the three months ended June 30, 2024, I, **David A. Dodd**, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that to the best of my knowledge: **A. 1.** The quarterly report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and **A. 2.** The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company. **A. A. A. A.** Dated: November 12, 2024 /s/ **David A. Dodd** **David A. A.** President & Chief Executive Officer **A. A. A. 1 A. A.** EX-32.2 5 ex_744204.htm EXHIBIT 32.2 ex_744204.htm **A. Exhibit 32.2** **CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** **A.** In connection with the quarterly report of GeoVax Labs, Inc. (the "Company") on Form 10-Q for the three months ended June 30, 2024, I, **Mark W. Reynolds**, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that to the best of my knowledge: **A. 1.** The quarterly report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and **A. 2.** The information contained in the annual report fairly presents, in all material respects, the financial condition and results of operations of the Company. **A. A. A. A.** Dated: November 12, 2024 /s/ **Mark W. Reynolds** **Mark W. Reynolds A. A.** Chief Financial Officer **A. A. A. 1 A. A.** EX-101.SCH 6 govx-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Nature of Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Balance Sheet Components link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Notes Payable - Related Parties link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Commitments link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Stock-Based Compensation Expense link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Revenue From Government Contract link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Net Loss Per Share link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 995462 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995463 - Disclosure - Note 3 - Balance Sheet Components (Tables) link:calculationLink link:definitionLink link:presentationLink 995464 - Disclosure - Note 6 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Note 3 - Balance Sheet Components - Prepaid Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 3 - Balance Sheet Components - Schedule of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 3 - Balance Sheet Components - Schedule of Other Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 3 - Balance Sheet Components - Schedule of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 4 - Notes Payable - Related Parties (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 5 - Commitments (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 6 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 6 - Stockholders' Equity - Schedule of Stock Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 7 - Stock-Based Compensation Expense (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 8 - Revenue From Government Contract (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 9 - Net Loss Per Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 10 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 11 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 7 govx-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 govx-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Other income (expense): Note To Financial Statement Details Textual us-

gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One Significant Accounting Policies Note 3 - Balance Sheet Components Note 6 - Stockholders' Equity Note 3 - Balance Sheet Components - Prepaid Expenses (Details) Note 3 - Balance Sheet Components - Schedule of Property and Equipment (Details) Note 3 - Balance Sheet Components - Schedule of Other Assets (Details) Note 3 - Balance Sheet Components - Schedule of Accrued Expenses (Details) Note 6 - Stockholders' Equity - Schedule of Stock Warrants (Details) Notes To Financial Statements Income Tax Disclosure [Text Block] Notes To Financial Statements [Abstract] Other assets Total other assets Stock-based compensation expense us-gaap_LiabilitiesCurrent Total current liabilities us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Schedule of Other Assets [Table Text Block] Operating expenses: us-gaap_AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) Warrants Expiration 1 [Member] The first warrant expiration period. Warrants Expiration 2 [Member] The second warrant expiration period. Warrants Expiration 3 [Member] The third warrant expiration period. Warrants Expiration 4 [Member] The fourth warrant expiration period. Warrants Expiration 5 [Member] The fifth warrant expiration period. Fractional share roundup following reverse split Reduction in value of shares as a result of reverse stock split. us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio Depreciation and amortization expense us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share us-gaap_AssetsCurrent Total current assets Equity [Text Block] Equipment and Furnishings [Member] Represents equipment and furnishings. Grant [Member] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Issued and outstanding shares â€" 8,609,308 and 1,977,152 at September 30, 2024 and December 31, 2023, respectively Adjustments to reconcile net loss to net cash used in operating activities: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common stock, authorized (in shares) Common Stock, Shares Authorized (in shares) Common Stock, Shares, Issued (in shares) Common Stock, Par or Stated Value Per Share (in dollars per share) us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Accrued expenses us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance Statistical Measurement [Domain] Maximum [Member] Accounts payable Weighted Average [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Product and Service [Axis] Expense Related To Consulting And Investment Banking Agreements [Member] Disclosure of expense related to consulting and investment banking agreements. Product and Service [Domain] Statistical Measurement [Axis] Office and Laboratory Lease Agreement [Member] Information pertaining to office and laboratory lease agreement. Other prepaid expenses us-gaap_PolicyTextBlockAbstract Accounting Policies Prepaid rent Property, Plant and Equipment [Table Text Block] Prepaid insurance premiums Revenue from government contract Revenue from Contract with Customer, Including Assessed Tax us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of equipment Current liabilities: Government Grants and Contracts [Text Block] Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction. Supplemental Balance Sheet Disclosures [Text Block] us-gaap_Assets Total assets Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Cash flows from operating activities: us-gaap_OperatingLeaseExpense Operating Lease, Expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Commitments Disclosure [Text Block] Statement [Line Items] Accounts receivable Accrued clinical trial costs Amount of accrued clinical trial costs. govx_DebtInstrumentOriginalIssueDiscountRate Debt Instrument, Original Issue Discount Rate Original issue discount rate under debt instrument. Share-Based Payment Arrangement [Text Block] Additional paid-in capital Leasehold Improvements [Member] govx_DebtInstrumentMaturityRequirementMinimumGrossProceedsFromCommonStockIssuance Debt Instrument, Maturity Requirement, Minimum Gross Proceeds From Common Stock Issuance Minimum amount of gross proceeds received from issuance of common stock for debt to mature under debt instrument. us-gaap_NonoperatingIncomeExpense Total other income (expense) Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] The Notes [Member] Represents the notes. May 2024 Common Warrants [Member] Represents May 2024 Common Warrants. Award Type [Domain] May 2024 Pre-funded Warrants [Member] Represents May 2024 Pre-funded Warrants. December 2023 Pre-funded Warrants [Member] Represents December 2023 Pre-funded Warrants. May 2024 Offering [Member] Represents May 2024 offering. govx_StockIssuedDuringPeriodSharesWarrantCashlessExercise Stock Issued During Period, Shares, Warrant Cashless Exercise (in shares) Number of shares issued during period from warrants cashless exercised. Registered Direct Offering [Member] Represents registered direct offering. Net loss Net loss govx_ClassOfWarrantOrRightWarrantsExercised Class of Warrant or Right, Warrants Exercised (in shares) Number of warrants exercised during the period. Award Type [Axis] BARDA Contract [Member] Represents BARDA Contract. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Assets [Abstract] Warrants Issued in December 2023 [Member] Represents Warrants Issued in December 2023. Interest income Deposits Warrants Issued in June 2020 [Member] Represents Warrants Issued in June 2020. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase (decrease) in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities July 2024 Offering [Member] Represents July 2024 Offering. Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Loss from operations Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities July 2024 Common Warrants [Member] Represents July 2024 Common Warrants. Share-Based Payment Arrangement, Option [Member] Prepaid expenses Total prepaid expenses us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities July 2024 Pre-funded Warrants [Member] Represents July 2024 Pre-funded Warrants. Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] August 21 2024 Offering [Member] Represents August 21 2024 Offering. August 30 2024 Common Warrants [Member] Represents August 30 2024 Common Warrants. us-gaap_EquityAbstract Stockholdersâ€™ equity: August 30 2024 Offering [Member] Represents August 30 2024 Offering us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation and amortization Property and equipment, net Total property and equipment, net August 21 2024 Common Warrants [Member] Represents August 21 2024 Common Warrants. August 21, 2024 Prefunded Warrants [Member] Represents August 21, 2024 Prefunded Warrants. us-gaap_InterestPayableCurrentAndNoncurrent Interest Payable govx_StockOfferingMaximumAggregateOfferingPrice Stock Offering, Maximum Aggregate Offering Price Maximum aggregate offering price for stock offering. Total property and equipment At-the-Market Program [Member] Represents At-the-Market Program. August 30 2024 Prefunded Warrants [Member] Represents August 30 2024 Prefunded Warrants. Warrants to Purchase Common Stock [Member] Represents warrants to purchase common stock. us-gaap_AccruedLiabilitiesCurrentAndNoncurrent Total accrued expenses us-gaap_GovernmentAssistanceAwardAmount Government Assistance, Award Amount govx_StockOfferingSharesAvailableForIssuanceValue Stock Offering, Shares Available for Issuance, Value Amount of equity available for future issuance. Issuance of common stock upon warrant exercise The gross value of stock issued during the period upon the exercise of warrants. govx_StockIssuedDuringPeriodSharesWarrantExercise Stock Issued During Period, Shares, Warrant Exercise (in shares) Number of shares issued during the period as a result of warrant exercise. Other accrued expenses Payroll-related liabilities us-gaap_ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities Total adjustments Cash flows from investing activities: Net proceeds from warrant exercise Proceeds from Warrant Exercises Basic and diluted: Retained Earnings [Member] Earnings

Per Share [Text Block] us-gaap_ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock Accounts payable and accrued expenses Additional Paid-in Capital [Member] Common Stock [Member] us-gaap_IncomeTaxExpenseBenefit Income Tax Expense (Benefit) Equity Components [Axis] Equity Component [Domain] Exercise Price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Prepaid clinical trial costs (current portion) Amount of prepaid clinical trial expenses in the next 12 months Prepaid clinical trial costs (noncurrent portion) Amount of prepaid clinical trial expenses after the next 12 months Number of Shares (in shares) us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) us-gaap_OperatingExpenses Total operating expenses General and administrative Cash and cash equivalents us-gaap_InterestExpenseNonoperating Interest expense Stock Incentive Plan 2020 [Member] Represents information related to 2020 stock incentive plan. us-gaap_AllocatedShareBasedCompensationExpense Share-Based Payment Arrangement, Expense Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding. Document Quarterly Report Entity Incorporation, State or Country Code Amendment Flag Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report dei_CityAreaCode City Area Code Basis of Accounting, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] dei_EntityInteractiveDataCurrent Entity Interactive Data Current Fractional share roundup following reverse split (in shares) Stock Issued During Period, Shares, Reverse Stock Splits (in shares) us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common Stock, Shares, Outstanding (in shares) Title of 12(b) Security Other assets us-gaap_IncreaseDecreaseInOtherOperatingAssets Current Fiscal Year End Date us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Prepaid expenses and other current assets Document Fiscal Period Focus Government Assistance, Type [Axis] Document Fiscal Year Focus Government Assistance, Type [Domain] dei_DocumentPeriodEndDate Document Period End Date dei_EntityFileName Entity File Number Nonmonetary Transaction Type [Domain] Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount dei_DocumentType Document Type Interim Period, Costs Not Allocable [Domain] Entity Small Business dei_EntityShellCompany Entity Shell Company Nonmonetary Transaction Type [Axis] Document Information [Line Items] Document Information [Table] us-gaap_AreaOfRealEstateProperty Area of Real Estate Property Nature of Expense [Axis] Entity Filer Category Debt Instrument [Axis] dei_EntityCurrentReportingStatus Entity Current Reporting Status Debt Instrument, Name [Domain] us-gaap_RepaymentsOfNotesPayable Repayment of notes payable â€“ related parties us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Net proceeds from issuance of notes payable â€“ related parties Stock option expense us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Entity Tax Identification Number Entity Central Index Key dei_EntityRegistrantName Entity Registrant Name Entity [Domain] Legal Entity [Axis] Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] Weighted average shares outstanding (in shares) ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Net loss per common share (in dollars per share) Entity Address, State or Province Prepaid technology license fees Represents prepaid technology license fees. ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Material Terms of Trading Arrangement [Text Block] Net proceeds from sale of common stock and warrants The cash inflow from issuance of common stock and warrants. Statement of Cash Flows [Abstract] dei_EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding (in shares) Statement of Stockholders' Equity [Abstract] Lease Contractual Term [Domain] Lease Contractual Term [Axis] Income Statement [Abstract] us-gaap_ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt Schedule of Accrued Liabilities [Table Text Block] Issuance of common stock upon warrant exercise (in shares) Number of new shares of common stock issued during the period upon exercise of warrants. Trading Symbol Nature of Operations [Text Block] dei_LocalPhoneNumber Local Phone Number us-gaap_TableTextBlock Notes Tables Cash flows from financing activities: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Sale of common stock and warrants for cash (in shares) Stock Issued During Period, Shares, New Issues (in shares) Issuance of common stock for services Issuance of common stock for services (in shares) Stock Issued During Period, Shares, Issued for Services (in shares) us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholdersâ€™ equity Sale of common stock and warrants for cash Accumulated deficit Research and development Debt Disclosure [Text Block] us-gaap_InterestExpenseDebt Interest Expense, Debt Changes in assets and liabilities: us-gaap_StockholdersEquity Total stockholdersâ€™ equity Balance Balance us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Subsequent Event [Member] Class of Stock [Axis] Class of Stock [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Events [Text Block] EX-101.PRE 9 govx-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.CAL 10 govx-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 12, 2024 Document Information [Line Items] Ä Ä Document Type 10-Q Ä Document Quarterly Report true Ä Document Period End Date Sep. 30, 2024 Ä Document Transition Report false Ä Entity File Number 001-39563 Ä Entity Registrant Name GEOVAX LABS, INC. Ä Entity Incorporation, State or Country Code DE Ä Entity Tax Identification Number 87-0455038 Ä Entity Address, Address Line One 1900 Lake Park Drive, Suite 380 Ä Entity Address, City or Town Smyrna Ä Entity Address, State or Province GA Ä Entity Address, Postal Zip Code 30080 Ä City Area Code 678 Ä Local Phone Number 384-7220 Ä Entity Current Reporting Status Yes Ä Entity Interactive Data Current Yes Ä Entity Filer Category Non-accelerated Filer Ä Entity Emerging Growth Company false Ä Entity Small Business true Ä Entity Shell Company false Ä Entity Common Stock, Shares Outstanding (in shares) Ä 9,436,069 Entity Central Index Key 0000832489 Ä Current Fiscal Year End Date --12-31 Ä Document Fiscal Year Focus 2024 Ä Document Fiscal Period Focus Q3 Ä Amendment Flag false Ä Common Stock [Member] Ä Ä Document Information [Line Items] Ä Ä Title of 12(b) Security Common Stock \$0.001 par value Ä Trading Symbol GOVX Ä Security Exchange Name NASDAQ Ä Warrants to Purchase Common Stock [Member] Ä Ä Document Information [Line Items] Ä Ä Title of 12(b) Security Warrants to Purchase Common Stock Ä Trading Symbol GOVXW Ä Security Exchange Name NASDAQ Ä X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same

value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_Data Type: dei:submissionTypeItem Type Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_Data Type: dei:stateOrProvinceItem Type Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centralIndexKeyItem Type Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_Data Type: dei:filerCategoryItem Type Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_Data Type: dei:edgarStateCountryItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_Data Type: dei:edgarExchangeCodeItem Type Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=govx_WarrantsToPurchaseCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD (\$) Sep. 30, 2024 Dec. 31, 2023 Assets [Abstract] Å Cash and cash equivalents \$ 8,592,523 \$ 6,452,589 Accounts receivable 547,574 0 Prepaid expenses 1,729,326 1,433,153 Total current assets 10,869,423 7,885,742 Property and equipment, net 171,615 209,689 Other assets 71,010 1,187,788 Total assets 11,112,048 9,283,219 Current liabilities: Å Accounts payable 2,147,952 2,802,950 Accrued expenses 460,220 716,931 Total current liabilities 2,608,172 3,519,881 us-gaap_EquityAbstract Å Issued and outstanding shares Å 8,609,308 and 1,977,152 at September 30, 2024 and December 31, 2023, respectively 8,609 1,977 Additional paid-in capital 129,588,694 110,125,146 Accumulated deficit (121,093,427) (104,363,785) Total stockholders' equity 8,503,876 5,763,338 Total liabilities and stockholders' equity \$ 11,112,048 \$ 9,283,219 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common

stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_AmountOfAssetRecognizedForPresentRightToEconomicBenefit -Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-45-25>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 235 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 12: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 19: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 30: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 8: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-5>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section

S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 21: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-7>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478451/942-360-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrl.org/2003/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrl.org/2003/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - \$ / shares Sep. 30, 2024 Dec. 31, 2023 Common Stock, Par or Stated Value Per Share (in dollars per share) \$ 0.001 \$ 0.001 Common stock, authorized (in shares) 150,000,000 600,000,000 Common Stock, Shares Authorized (in shares) 150,000,000 600,000,000 Common Stock, Shares Outstanding (in shares) 8,609,308 1,977,152 Common Stock, Shares Issued (in shares) 8,609,308 1,977,152 X - DefinitionFace amount or stated value per share of

common stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Unaudited) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue from government contract \$ 2,789,484 \$ 0 \$ 3,090,161 \$ 0 Operating expenses: Research and development 7,402,884 6,947,979 16,105,480 14,486,896 General and administrative 1,241,176 1,651,775 3,784,559 4,562,293 Total operating expenses 8,644,060 8,599,754 19,890,039 19,049,189 Loss from operations (5,854,576) (8,599,754) (16,799,878) (19,049,189) Other income (expense): Interest income 53,191 190,936 91,611 674,835 Interest expense (14,083) 0 (21,375) 0 Total other income (expense) 39,108 190,936 70,236 674,835 Net loss \$ (5,815,468) \$ (8,408,818) \$ (16,729,642) \$ (18,374,354) Basic and diluted: Net loss per common share (in dollars per share) \$ (0.91) \$ (4.75) \$ (4.52) \$ (10.42) Weighted average shares outstanding (in shares) 6,404,797 1,769,604 3,701,145 1,762,856 X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 45 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1> + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2:

[Topic 220](http://www.xbrl.org/2009/role/commonPracticeRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: [Topic 280](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: [Topic 280](http://www.xbrl.org/2003/role/exampleRef) -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [Topic 220](http://www.xbrl.org/2009/role/commonPracticeRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 4: [Topic 270](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 5: [Topic 280](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32> + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: [Topic 250](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: [Topic 250](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [Topic 805](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: [Topic 740](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: [Topic 220](http://fasb.org/us-gaap/role/ref/legacyRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: [Topic 235](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: [Topic 323](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: [Topic 825](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: [Topic 220](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: [Topic 250](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [Topic 250](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: [Topic 815](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: [Topic 250](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [Topic 250](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: [Topic 250](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: [Topic 250](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: [Topic 946](http://www.xbrl.org/2003/role/exampleRef) -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: [Topic 946](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [Topic 944](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: [Topic 946](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: [Topic 946](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: [Topic 470](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: [Topic 470](http://www.xbrl.org/2009/role/commonPracticeRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: [Topic 470](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 25: [Topic 470](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 26: [Topic 470](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 27: [Topic 470](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: [Topic 470](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: [Topic 470](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 30: [Topic 470](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 31: [Topic 470](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: [Topic 260](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: [Topic 205](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: [Topic 230](http://fasb.org/us-gaap/role/ref/legacyRef) -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [Topic 220](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: [Topic 220](http://www.xbrl.org/2003/role/disclosureRef) -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: [Topic 942](http://fasb.org/us-gaap/role/ref/legacyRef) -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary

business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 7: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482916/730-10-50-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479532/912-730-25-1> + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-41>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 4: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479941/924-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-4> + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-10> + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD (\$) Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total Balance (in shares) at Dec. 31, 2022 1,755,664 Å Å Balance at Dec. 31, 2022 \$ 1,756 \$ 104,995,301 \$ (78,397,023) \$ 26,600,034 Issuance of common stock for services (in shares) 7,246 Å Å Issuance of common stock for services \$ 7 74,993 0 75,000 Stock option expense 0 228,039 0 228,039 Net loss \$ 0 0 (4,037,916) (4,037,916) Balance (in shares) at Mar. 31, 2023 1,762,910 Å Å Balance at Mar. 31, 2023 \$ 1,763 105,298,333 (82,434,939) 22,865,157 Balance (in shares) at Dec. 31, 2022 1,755,664 Å Å Balance at Dec. 31, 2022 \$ 1,756 104,995,301 (78,397,023) 26,600,034 Net loss Å Å (18,374,354) Balance (in shares) at Sep. 30, 2023 1,779,686 Å Å Balance at Sep. 30, 2023 \$ 1,780 105,888,943 (96,771,377) 9,119,346 Balance (in shares) at Mar. 31, 2023 1,762,910 Å Å Balance at Mar. 31, 2023 \$ 1,763 105,298,333 (82,434,939) 22,865,157 Stock option expense 0 226,013 0 226,013 Net loss \$ 0 0 (5,927,620) (5,927,620) Balance (in shares) at Jun. 30, 2023 1,762,910 Å Å Balance at Jun. 30, 2023 \$ 1,763 105,524,346 (88,362,559) 17,163,550 Issuance of common stock for services (in shares) 16,776 Å Å Issuance of common stock for services \$ 17 137,483 0 137,500 Stock option expense 0 227,114 0 227,114 Net loss \$ 0 0 (8,408,818) (8,408,818) Balance (in shares) at Sep. 30, 2023 1,779,686 Å Å Balance at Sep. 30, 2023 \$ 1,780 105,888,943 (96,771,377) 9,119,346 Balance (in shares) at Dec. 31, 2023 1,977,152 Å Å Balance at Dec. 31, 2023 \$ 1,977 110,125,146 (104,363,785) 5,763,338 Issuance of common stock for services (in shares) 6,703 Å Å Issuance of common stock for services \$ 7 37,493 0

37,500 Issuance of common stock upon warrant exercise (in shares) 269,032 Δ Δ Issuance of common stock upon warrant exercise \$ 269 (269) 0 0 Fractional share roundup following reverse split (in shares) 55,422 Δ Δ Fractional share roundup following reverse split \$ 55 (55) 0 0 Stock option expense 0 103,569 0 103,569 Net loss \$ 0 0 (5,850,132) (5,850,132) Balance (in shares) at Mar. 31, 2024 2,308,309 Δ Δ Balance at Mar. 31, 2024 \$ 2,308 110,265,884 (110,213,917) 54,275 Balance (in shares) at Dec. 31, 2023 1,977,152 Δ Δ Balance at Dec. 31, 2023 \$ 1,977 110,125,146 (104,363,785) 5,763,338 Net loss \$ 0 0 (16,729,642) Balance (in shares) at Sep. 30, 2024 8,609,308 Δ Δ Balance at Sep. 30, 2024 \$ 8,609 129,588,694 (121,093,427) 8,503,876 Balance (in shares) at Mar. 31, 2024 2,308,309 Δ Δ Balance at Mar. 31, 2024 \$ 2,308 110,265,884 (110,213,917) 54,275 Issuance of common stock upon warrant exercise (in shares) 1,650,391 Δ Δ Issuance of common stock upon warrant exercise \$ 1,651 1,387,712 0 1,389,363 Stock option expense 0 101,640 0 101,640 Net loss \$ 0 0 (5,064,042) (5,064,042) Sale of common stock and warrants for cash (in shares) 220,000 Δ Δ Sale of common stock and warrants for cash \$ 220 1,209,318 0 1,209,538 Balance (in shares) at Jun. 30, 2024 4,178,700 Δ Δ Balance at Jun. 30, 2024 \$ 4,179 112,964,554 (115,277,959) (2,309,226) Issuance of common stock upon warrant exercise (in shares) 1,689,145 Δ Δ Issuance of common stock upon warrant exercise \$ 1,688 976,082 0 977,770 Stock option expense 0 129,923 0 129,923 Net loss \$ 0 0 (5,815,468) (5,815,468) Sale of common stock and warrants for cash (in shares) 2,741,463 Δ Δ Sale of common stock and warrants for cash \$ 2,742 15,518,135 0 15,520,877 Balance (in shares) at Sep. 30, 2024 8,609,308 Δ Δ Balance at Sep. 30, 2024 \$ 8,609 \$ 129,588,694 \$ (121,093,427) \$ 8,503,876 X - DefinitionNumber of new shares of common stock issued during the period upon exercise of warrants. + ReferencesNo definition available. + Details Name: govx_StockIssuedDuringPeriodSharesWarrantsExercised Namespace Prefix: govx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in value of shares as a result of reverse stock split. + ReferencesNo definition available. + Details Name: govx_StockIssuedDuringPeriodValueReverseStockSplits Namespace Prefix: govx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the exercise of warrants. + ReferencesNo definition available. + Details Name: govx_StockIssuedDuringPeriodValueWarrantExercise Namespace Prefix: govx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480483/718-10-35-2> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481089/718-20-55-1> Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481089/718-20-55-12> + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1> Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2> Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1> Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3> Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28> Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6> Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3> Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1> Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1> Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8> Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11> Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11> Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4> Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10> Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7> Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1> Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1> Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A> Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A> Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A> Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A> Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A> Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B> Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B> Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B> Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B> Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2> + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478009/946-205-45-4>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD (\$) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Δ Net loss \$ (16,729,642) \$ (18,374,354) Adjustments to reconcile net loss to net cash used in operating activities: Δ Depreciation and amortization expense 73,727 51,956 Stock-based compensation expense 389,299 813,499 Changes in assets and liabilities: Δ Accounts receivable (547,574) 0 Prepaid expenses and other current assets 312,840 707,084 Other assets (1,116,778) (986,498) Accounts payable and accrued expenses (911,709) 2,333,791 Total adjustments (192,319) 3,478,660 Net cash used in operating activities (16,921,961) (14,895,694) Cash flows from investing activities: Δ Purchase of equipment (20,653) (29,997) Net cash used in investing activities (20,653) (29,997) Cash flows from financing activities: Δ Net proceeds from issuance of notes payable to related parties 135,000 0 Repayment of notes payable to related parties (150,000) 0 Net proceeds from sale of common stock and warrants 16,730,415 0 Net proceeds from warrant exercise 2,367,133 0 Net cash provided by financing activities 19,082,548 0 Net increase (decrease) in cash and cash equivalents 2,139,934 (14,925,691) Cash and cash equivalents at beginning of period 6,452,589 27,612,732 Cash and cash equivalents at end of period \$ 8,592,523 \$ 12,687,041 X - DefinitionThe cash inflow from issuance of common stock and warrants. + ReferencesNo definition available. + Details Name: govx_ProceedsFromIssuanceOfCommonStockAndWarrants Namespace Prefix: govx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22> + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -

Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section 99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services

and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromNotesPayable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Nature of Business 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Nature of Operations [Text Block] 1. Nature of Business Â GeoVax Labs, Inc., headquartered in the Atlanta, Georgia metropolitan area, is a clinical-stage biotechnology company incorporated under the laws of the State of Delaware. GeoVax Labs, Inc. and its wholly owned subsidiary, GeoVax, Inc., a Georgia corporation, are collectively referred to herein as â€œGeoVaxâ€ or â€œthe Companyâ€. Â The Company is focused on developing human vaccines for many of the worldâ€™s most threatening infectious diseases and therapies for solid tumor cancers using novel proprietary platforms. GeoVaxâ€™s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which it was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. The lead oncological clinical program is GedeptinÂ®, a novel oncolytic solid tumor gene-directed therapy, which is currently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. Additional preclinical research and development programs include preventive vaccines against Mpox (formerly known as monkeypox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), and Zika virus, as well as immunotherapies for solid tumors. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI <https://asc.fasb.org/275/tableOfContent> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-1> + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Significant Accounting Policies [Text Block] 2. Summary of Significant Accounting Policies Â We disclosed in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 those accounting policies that we consider significant in determining our results of operations and financial position. During the nine months ended September 30, 2024, there have been no material changes to, or in the application of, the accounting policies previously identified and described in the Form 10-K. Â Basis of Presentation Â The accompanying financial statements include the accounts of GeoVax Labs, Inc. and GeoVax, Inc. All intercompany transactions have been eliminated in consolidation. The financial statements are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of interim periods presented. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods. Â We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates and will require additional funding to continue our research and development activities. We believe that our existing cash resources will be sufficient to continue our planned operations into the first quarter of 2025. We plan to pursue additional capital resources through public or private equity or debt financings, government grants/contracts, arrangements with strategic partners, or from other sources. There can be no assurance that additional funding will be available on favorable terms or at all. These factors collectively raise substantial doubt about the Companyâ€™s ability to continue as a going concern. Management believes that we will be successful in securing the additional capital required to continue the Companyâ€™s planned operations, but that our plans do not fully alleviate the substantial doubt about the Companyâ€™s ability to operate as a going concern. Â The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Â The accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock split described in Note 6. Â Recent Accounting Pronouncements Â During the nine months ended September 30, 2024, there have been no new accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements. Â Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483426/235-10-50-1> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/235/tableOfContent> + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Balance Sheet Components 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Supplemental Balance Sheet Disclosures [Text Block] 3. Balance Sheet Components Â Prepaid Expenses â€“ Prepaid expenses consist of the following: Â Â September 30, 2024 Â Â December 31, 2023 Â Prepaid clinical trial costs (current portion) Â \$ 1,706,281 Â Â \$ 1,282,746 Â Prepaid insurance premiums Â Â - Â Â \$ 110,695 Â Prepaid rent Â Â 13,045 Â Â 13,045 Â Other prepaid expenses Â Â 10,000 Â Â 26,667 Â Total prepaid expenses Â \$ 1,729,326 Â Â \$ 1,433,153 Â Property and Equipment â€“ Property and equipment consist of the following: Â Â September 30, 2024 Â Â December 31, 2023 Â Equipment and furnishings Â \$ 795,411 Â Â \$ 774,758 Â Leasehold improvements Â Â 115,605 Â Â 115,605 Â Total property and equipment Â Â 911,016 Â Â 890,363 Â Accumulated depreciation and amortization Â Â (739,401) Â Â (680,674) Total property and equipment, net Â \$ 171,615 Â Â \$ 209,689 Â Other Assets â€“ Other assets consist of the following: Â Â September 30, 2024 Â Â December 31, 2023 Â Prepaid clinical trial costs (noncurrent portion) Â \$ - Â Â \$ 1,106,778 Â Prepaid technology license fees Â Â 60,000 Â Â 70,000 Â Deposits Â Â 11,010 Â Â 11,010 Â Total other assets Â \$ 71,010 Â Â \$ 1,187,788 Â Accrued Expenses â€“ Accrued expenses consist of the following: Â Â September 30, 2024 Â Â December 31, 2023 Â Payroll-related liabilities Â \$ 169,719 Â Â \$ 114,337 Â Accrued clinical trial costs Â Â 220,501 Â Â 490,635 Â Other accrued expenses

Â Ä 70,000 Ä Ä 111,959 Ä Total accrued expenses Ä \$ 460,220 Ä Ä \$ 716,931 Ä Ä Ä Ä X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/210/tableOfContent> + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Notes Payable - Related Parties 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Ä Debt Disclosure [Text Block] 4. Notes Payable â€“ Related Parties Ä On May 10, 2024, we issued 10% Original Issue Discount Promissory Notes (the â€“Notesâ€“) with an aggregate principal amount of \$150,000 to members of our Board of Directors and senior management, in exchange for gross cash proceeds to us of \$135,000. The Notes are unsecured, bear interest at a rate of 15% per annum, and mature upon the earlier of (i) six months from the issue date or (ii) three days following the date the Company completes an offering of its common stock with gross proceeds of not less than \$5 million (a â€“Qualified Financing Eventâ€“). On August 22, 2024, following the successful completion of a Qualified Financing Event, we repaid the aggregate principal amount of the Notes in full, together with accrued interest. Total interest expense recorded during the nine months ended September 30, 2024 was \$21,375, consisting of \$15,000 of debt discount amortization and \$6,375 of accrued interest. Ä Ä Ä Ä X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481544/470-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481544/470-10-50-6>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477092/405-40-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477092/405-40-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477092/405-40-50-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477092/405-40-50-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477092/405-40-50-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/470/tableOfContent>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-2>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1> + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 -Commitments 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Ä Commitments Disclosure [Text Block] 5. Commitments Ä Operating Lease. We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on December 31, 2025. Rent expense for the three-month and nine-month periods ended September 30, 2024 was \$46,764 and \$140,292, respectively, as compared to \$45,414 and \$136,242, respectively, for the same periods of 2023. Future minimum lease payments total \$46,764 in 2024, and \$192,708 in 2025 although the lease may be terminated at any time by either party with one hundred eighty days written notice. Ä License Agreements. We have entered into license agreements for various technologies and patent rights associated with our product development activities. These agreements may contain provisions for upfront payments, milestone fees due upon the achievement of selected development and regulatory events, minimum annual royalties or other fees, and royalties based on future net sales. Due to the uncertainty of the achievement and timing of the contingent events requiring payment under these agreements, the amounts to be paid by us in the future are not determinable. Ä Other Commitments. In the normal course of business, we enter into various contracts and purchase commitments including those with contract research organizations (â€“cROsâ€“) for clinical trial services, contract manufacturing organizations (â€“CMOsâ€“) for production of materials for use in our clinical trials, and other independent contractors or academic institutions for preclinical research activities and other services and products. Most contracts are generally cancellable, with notice, at the Companyâ€™s option. Payments due upon cancellation may consist of payments for services provided or expenses incurred to date, or cancellation penalties depending on the time of cancellation. Ä Ä Ä Ä X - DefinitionThe entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/440/tableOfContent> + Details Name: us-gaap_CommitmentsDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 -Stockholders' Equity 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Ä Equity [Text Block] 6. Stockholdersâ€™ Equity Ä Reverse Stock Split and Reduction of Authorized Shares of Common Stock Ä At a special meeting of our stockholders held on January 16,

2024, our stockholders approved an amendment to our certificate of incorporation to (i) reduce our authorized shares of common stock from 600,000,000 to 150,000,000 and (ii) effect a one-for-fifteen reverse split of our common stock. The amendment to our certificate of incorporation was filed with the Delaware Secretary of State on January 30, 2024 and our common stock began trading on the split-adjusted basis on January 31, 2024. The accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock split. **Common Stock and Warrant Offerings** On May 21, 2024, we closed a registered direct offering of 220,000 shares of common stock and pre-funded warrants to purchase an aggregate of 582,844 shares of common stock (the "May 2024 Pre-Funded Warrants"). In a concurrent private placement, we issued common warrants to the purchaser to purchase up to 1,605,688 shares of common stock at an exercise price of \$1.68 per share. Net proceeds after deducting placement agent commissions and other offering expenses were approximately \$1.2 million. On July 12, 2024, we closed a registered direct offering of 458,632 shares of common stock and pre-funded warrants to purchase an aggregate of 626,368 shares of common stock (the "July 2024 Pre-Funded Warrants"). In a concurrent private placement, we issued common warrants to the purchaser to purchase up to 2,170,000 shares of common stock at an exercise price of \$2.86 per share. Net proceeds after deducting placement agent commissions and other offering expenses were approximately \$2.8 million. On August 21, 2024, we closed a registered direct offering of 1,360,731 shares of common stock and pre-funded warrants to purchase an aggregate of 339,269 shares of common stock (the "August 21, 2024 Pre-Funded Warrants"). In a concurrent private placement, we issued common warrants to the purchaser to purchase up to 1,700,000 shares of common stock at an exercise price of \$5.00 per share. Net proceeds after deducting placement agent commissions and other offering expenses were approximately \$7.9 million. On August 30, 2024, we closed a registered direct offering of 837,500 shares of common stock and pre-funded warrants to purchase an aggregate of 138,110 shares of common stock (the "August 30, 2024 Pre-Funded Warrants"). In a concurrent private placement, we issued common warrants to the purchaser to purchase up to 975,610 shares of common stock at an exercise price of \$5.00 per share. Net proceeds after deducting placement agent commissions and other offering expenses were approximately \$4.6 million. On September 25, 2024, we entered into a Sales Agreement and established an "At-the-Market" continuous offering program (the "ATM Program"), pursuant to which the Company may offer and sell, from time to time through its sales agent, shares of its common stock. During the third quarter of 2024 we sold 84,600 shares of our common stock through the ATM Program at a weighted-average price of \$2.51 per share, raising \$206,003 of net proceeds, after deducting commissions to the sales agent and other related expenses. As of September 30, 2024, we had \$4,274,260 available under the ATM Program. **Warrant Exercises** During the first quarter of 2024, we issued 269,032 shares of our common stock upon the exercise of prefunded warrants issued in December 2023 (the "December 2023 Pre-Funded Warrants"). During the second quarter of 2024, we issued (i) 238,000 and 582,844 shares of our common stock upon the exercise of the December 2023 Pre-Funded Warrants and the May 2024 Pre-Funded Warrants, respectively; (ii) 2,549 shares of our common stock upon the cashless exercise of 4,000 warrants issued in June 2020, and (iii) 826,998 shares of our common stock upon the exercise of common warrants issued in December 2023 (the "December 2023 Common Warrants"), with net cash proceeds to us of \$1,389,363. During the third quarter of 2024, we issued (i) 626,368, 339,269 and 138,110 shares of our common stock upon the exercise of the July 2024 Pre-Funded Warrants, the August 21, 2024 Pre-Funded Warrants, and the August 30, 2024 Pre-Funded Warrants respectively; (ii) 3,398 shares of our common stock upon the cashless exercise of 4,000 warrants issued in June 2020, and (iii) 582,000 shares of our common stock upon the exercise of the December 2023 Common Warrants, with net cash proceeds to us of \$977,770. **Other Common Stock Transactions** During the first quarter of 2024, we issued 6,703 shares of our common stock pursuant to a professional relations and consulting agreement and we issued 55,422 shares of our common stock for the roundup of fractional shares associated with the reverse stock split. **Stock Options** We have stock-based incentive plans (the "Plans") pursuant to which our Board of Directors may grant stock options and other stock-based awards to our employees, directors and consultants. During the nine months ended September 30, 2024, we granted 200,000 new stock options with a weighted-average exercise price of \$2.23 per share and 961 stock options were cancelled. As of September 30, 2024, there are 333,648 stock options outstanding, with a weighted-average exercise price of \$12.71 per share and a weighted-average remaining contractual term of 7.2 years. Including the outstanding stock options, a total of 333,648 shares of our common stock are reserved for future issuance pursuant to the Plans. **Stock Purchase Warrants** The table below summarizes information concerning warrants outstanding as of September 30, 2024. **Issue Date** Number of Shares **Exercise Price** **Expiration** September 2020 **159,781** **\$ 75.00** September 2025 September 2021 **6,668** **\$ 195.00** September 2026 May 2024 **1,605,688** **\$ 1.68** May 2029 July 2024 **2,170,000** **\$ 2.86** November 2029 August 2024 **2,675,610** **\$ 5.00** August 2029 Outstanding at September 30, 2024 **6,617,747** **X** **References** No definition available. **Details** Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-14> Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477968/946-235-50-2> Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477968/946-235-50-2> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480237/815-40-50-6> Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480237/815-40-50-6> Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1> Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/505/tableOfContent> Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13> Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13> Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-14> Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-14> Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-16> Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-18> Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-18> Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-18> + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Stock-Based Compensation Expense 9 Months Ended Sep. 30, 2024 Notes to Financial Statements **Share-Based Payment Arrangement** [Text Block] 7. Stock-Based Compensation Expense **Stock-based compensation expense related to stock options is recognized on a straight-line basis over the requisite service period for the award**

and is allocated to research and development expense or general and administrative expense based upon the classification of the individual to whom the award is granted. Stock-based compensation expense related to stock option grants was \$129,923 and \$335,132 during the three-month and nine-month periods ended September 30, 2024, respectively, as compared to \$227,114 and \$681,166, respectively, during the same periods of 2023. As of September 30, 2024, there is \$655,314 of unrecognized compensation expense that we expect to recognize over a weighted-average period of 1.9 years. A We have also issued shares of our restricted common stock to consultants and recognize the related expense over the terms of the related agreements. During the three-month and nine-month periods ended September 30, 2024 we recorded stock-based compensation expense of \$-0- and \$54,167, respectively, associated with common stock issued for consulting services, as compared to \$70,833 and \$132,333, respectively, for the same periods of 2023. A X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(l\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbri:stringItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Revenue From Government Contract 9 Months Ended Sep. 30, 2024 Notes to Financial Statements A Government Grants and Contracts [Text Block] 8. Revenue from Government Contract A On June 12, 2024, GeoVax was awarded a contract (the â€œBARDA Contractâ€) through the Rapid Response Partnership Vehicle (RRPV) to advance the clinical development of GEO-CM04S1, the Companyâ€™s next-generation COVID-19 vaccine. The RRPV is a consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS). A Under the BARDA Contract, GeoVax will sponsor a 10,000-participant, randomized, Phase 2b double-blinded clinical trial to assess the efficacy, safety, and immunogenicity of GEO-CM04S1 compared with a U.S. Food and Drug Administration (FDA)-approved mRNA COVID-19 vaccine. The direct award to GeoVax, currently approximately \$26.2 million and which may increase to as much as \$45 million, is funding the manufacturing of clinical materials and support for the Phase 2b clinical trial, including regulatory activities. BARDA has made a separate award through its Clinical Studies Network to fully fund the execution of the study by Allcent, a global clinical research organization; the funding provided directly to Allcent will not be recognized in GeoVaxâ€™s financial statements. A GeoVaxâ€™s role in the project is being funded in whole or in part with federal funds from BARDA under Other Transaction 75A50123D00005. Allcentâ€™s role in the project is being funded in whole or in part with federal funds from BARDA under contract 75A50120D00016/75A50123F33005. A During the three-month and nine-month periods ending September 30, 2024, GeoVax recognized revenue of \$2,789,484 and \$3,090,161, respectively, associated with the BARDA contract. We record revenue associated with this contract as the reimbursable costs are incurred. A X - DefinitionDisclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction. + ReferencesNo definition available. + Details Name: govx_GovernmentGrantsandContractsTextBlock Namespace Prefix: govx_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbri:stringItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Net Loss Per Share 9 Months Ended Sep. 30, 2024 Notes to Financial Statements A Earnings Per Share [Text Block] 9. Net Loss Per Share A Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. The Companyâ€™s potentially dilutive securities, which include stock options and stock purchase warrants, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. The securities that could potentially dilute basic earnings per share in the future and that have been excluded from the computation of diluted net loss per share totaled 6,951,395 and 1,026,862 shares at September 30, 2024 and 2023, respectively. A X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbri:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3> + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Income Taxes 9 Months Ended Sep. 30, 2024 Notes to Financial Statements A Income Tax Disclosure [Text Block] 10. Income Taxes A No provision for income taxes was recorded in either of the nine-month periods ended September 30, 2024 and 2023. The Company remains in a cumulative loss position with a full valuation allowance recorded against its net deferred income tax assets as of September 30, 2024. A X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbri:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SAB Topic 6.I.5.Q1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17)Reference 13:

http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14:
http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Subsequent Events 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Subsequent Events [Text Block] 11. Subsequent Events Â During October 2024 we issued 826,761 shares of our common stock through the ATM Program at a weighted-average price of \$2.20 per share, raising \$1,761,309 of net proceeds, after deducting commissions to the sales agent and other related expenses. On October 15, 2024, we increased the maximum aggregate offering price of the shares issuable under the ATM Program from \$4,486,846 to \$30,000,000. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2:
http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 9 Months Ended Sep. 30, 2024 Insider Trading Arr Line Items Â Material Terms of Trading Arrangement [Text Block] Item 5 Other Information Â During the period covered by this report, none of our directors or executive officers adopted or terminatedÂ any â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangementâ€ (as each term is defined in Item 408(a) of Regulation S-K). Â During the period covered by this report, there was no information required to be disclosed by us in a Current Report on Form 8-K that was not so reported, nor were there any material changes to the procedures by which our security holders may recommend nominees to our board of directors. Rule 10b5-1 Arrangement Adopted [Flag] false Non-Rule 10b5-1 Arrangement Adopted [Flag] false Rule 10b5-1 Arrangement Terminated [Flag] false Non-Rule 10b5-1 Arrangement Terminated [Flag] false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name:
ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1:
http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type:
xbrli:booleanItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Â The accompanying financial statements include the accounts of GeoVax Labs, Inc. and GeoVax, Inc. All intercompany transactions have been eliminated in consolidation. The financial statements are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of interim periods presented. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods. Â We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates and will require additional funding to continue our research and development activities. We believe that our existing cash resources will be sufficient to continue our planned operations into the first quarter of 2025. We plan to pursue additional capital resources through public or private equity or debt financings, government grants/contracts, arrangements with strategic partners, or from other sources. There can be no assurance that additional funding will be available on favorable terms or at all. These factors collectively raise substantial doubt about the Companyâ€™s ability to continue as a going concern. Management believes that we will be successful in securing the additional capital required to continue the Companyâ€™s planned operations, but that our plans do not fully alleviate the substantial doubt about the Companyâ€™s ability to operate as a going concern. Â The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Â The accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock split described in Note 6. New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Â During the nine months ended September 30, 2024, there have been no new accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Balance Sheet Components (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Â Â September 30, 2024 Â Â December 31, 2023 Â Prepaid clinical trial costs (current portion) Â \$ 1,706,281 Â Â \$ 1,282,746 Â Prepaid insurance premiums Â Â - Â Â 110,695 Â Prepaid rent Â Â 13,045 Â Â 13,045 Â Other prepaid expenses Â Â 10,000 Â Â 26,667 Â Total prepaid expenses Â \$ 1,729,326 Â Â \$ 1,433,153 Â Property, Plant and Equipment [Table Text Block] Â Â September 30, 2024 Â Â December 31, 2023 Â Equipment and furnishings Â \$ 795,411 Â Â \$ 774,758 Â Leasehold improvements Â Â 115,605 Â Â 115,605 Â Total property and equipment Â Â 911,016 Â Â 890,363 Â Accumulated depreciation and amortization Â Â (739,401) Â Â (680,674) Total property and equipment, net Â \$ 171,615 Â Â \$ 209,689 Â Schedule of Other Assets [Table Text Block] Â Â September 30, 2024 Â Â December 31, 2023 Â Prepaid clinical trial costs (noncurrent portion) Â \$ - Â Â \$ 1,106,778 Â Prepaid technology license fees Â Â 60,000 Â Â 70,000 Â Deposits Â Â 11,010 Â Â 11,010 Â Total other assets Â \$ 71,010 Â Â \$ 1,187,788 Â Schedule of Accrued Liabilities [Table Text Block] Â Â September 30, 2024 Â Â December 31, 2023 Â Payroll-related liabilities Â \$ 169,719 Â Â \$ 114,337 Â Accrued clinical trial costs Â Â 220,501 Â Â 490,635 Â Other accrued expenses Â Â 70,000 Â Â 111,959 Â Total accrued expenses Â \$ 460,220 Â Â \$ 716,931 Â X - DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. + ReferencesNo definition available. + Details Name: us-gaap_DeferedCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal

conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfOtherAssetsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables A Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Issue Date A Number of Shares A Exercise Price A Expiration September 2020 A A 159,781 A A \$ 75.00 A September 2025 September 2021 A A 6,668 A A 195.00 A September 2026 May 2024 A A 1,605,688 A A 1.68 A May 2029 July 2024 A A 2,170,000 A A 2.86 A November 2029 August 2024 A A 2,675,610 A A 5.00 A August 2029 Outstanding at September 30, 2024 A A 6,617,747 A A A A X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-1> + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Balance Sheet Components - Prepaid Expenses (Details) - USD (\$) Sep. 30, 2024 Dec. 31, 2023 Prepaid clinical trial costs (current portion) \$ 1,706,281 \$ 1,282,746 Prepaid insurance premiums 0 110,695 Prepaid rent 13,045 13,045 Other prepaid expenses 10,000 26,667 Total prepaid expenses \$ 1,729,326 \$ 1,433,153 X - DefinitionAmount of prepaid clinical trial expenses in the next 12 months + ReferencesNo definition available. + Details Name: govx_PrepaidClinicalTrialExpensesCurrent Namespace Prefix: govx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483032/340-10-45-1> + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1> Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483032/340-10-45-1> Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482955/340-10-05-5> + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1> Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483032/340-10-45-1> Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482955/340-10-05-5> + Details Name: us-gaap_PrepaidRent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Balance Sheet Components - Schedule of Property and Equipment (Details) - USD (\$) Sep. 30, 2024 Dec. 31, 2023 Total property and equipment \$ 911,016 \$ 890,363 Accumulated depreciation and amortization (739,401) (680,674) Total property and equipment, net 171,615 209,689 Equipment and Furnishings [Member] A A Total property and equipment 795,411 774,758 Leasehold Improvements [Member] A A Total property and equipment \$ 115,605 \$ 115,605 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -

Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-7A>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478451/942-360-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_EquipmentAndFurnishingsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Balance SHeet Components - Schedule of Other Assets (Details) - USD (\$) Sep. 30, 2024 Dec. 31, 2023 Prepaid clinical trial costs (noncurrent portion) \$ 0 \$ 1,106,778 Prepaid technology license fees 60,000 70,000 Deposits 11,010 11,010 Total other assets \$ 71,010 \$ 1,187,788 X - DefinitionAmount of prepaid clinical trial expenses after the next 12 months + ReferencesNo definition available. + Details Name: govx_PrepaidClinicalTrialExpensesNoncurrent Namespace Prefix: govx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents prepaid technology license fees. + ReferencesNo definition available. + Details Name: govx_PrepaidTechnologyLicenseFees Namespace Prefix: govx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_SecurityDeposit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Balance Sheet Components - Schedule of Accrued Expenses (Details) - USD (\$) Sep. 30, 2024 Dec. 31, 2023 Payroll-related liabilities \$ 169,719 \$ 114,337 Accrued clinical trial costs 220,501 490,635 Other accrued expenses 70,000 111,959 Total accrued expenses \$ 460,220 \$ 716,931 X - DefinitionAmount of accrued clinical trial costs. + ReferencesNo definition available. + Details Name: govx_AccruedClinicalTrialCosts Namespace Prefix: govx_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap_AccruedSalariesCurrentAndNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Notes Payable - Related Parties (Details Textual) - The Notes [Member] - USD (\$) 9 Months Ended May 10, 2024 Sep. 30, 2024 Debt Instrument, Original Issue Discount Rate 10.00% Å Debt Instrument, Face Amount \$ 150,000 Å Proceeds from Issuance of Debt \$ 135,000 Å Debt Instrument, Interest Rate, Stated Percentage 15.00% Å Debt Instrument, Maturity Requirement, Minimum Gross Proceeds From Common Stock Issuance \$ 5,000,000 Å Interest Expense, Debt Å \$ 21,375 Amortization of Debt Discount (Premium) Å 15,000 Interest Payable Å \$ 6,375 X - DefinitionMinimum amount of gross proceeds received from issuance of common stock for debt to mature under debt instrument. + ReferencesNo definition available. + Details Name: govx_DebtInstrumentMaturityRequirementMinimumGrossProceedsFromCommonStockIssuance Namespace Prefix: govx_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionOriginal issue discount rate under debt instrument. + ReferencesNo definition available. + Details Name: govx_DebtInstrumentOriginalIssueDiscountRate Namespace Prefix: govx_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1F>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-3> + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482900/835-30-50-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-2> + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B> + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69E>

20-55-69EReference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69F>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1F>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-6> + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=govx_TheNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 -Commitments (Details Textual) - Office and Laboratory Lease Agreement [Member] 3 Months Ended 9 Months Ended Sep. 30, 2024 USD (\$) ft² Sep. 30, 2024 USD (\$) ft² Sep. 30, 2023 USD (\$) Area of Real Estate Property | ft² 8,400 Å 8,400 Å Operating Lease, Expense \$ 46,764 \$ 45,414 \$ 140,292 \$ 136,242 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 46,764 Å 46,764 Å Lessee, Operating Lease, Liability, to be Paid, Year One \$ 192,708 Å \$ 192,708 Å X - DefinitionArea of a real estate property. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfRealEstateProperty Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-4> + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LeaseContractualTermAxis=govx_OfficeAndLaboratoryLeaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity (Details Textual) 1 Months Ended 3 Months Ended 9 Months Ended Aug. 30, 2024 USD (\$) \$ / shares shares Aug. 21, 2024 USD (\$) \$ / shares shares Jul. 12, 2024 USD (\$) \$ / shares shares May 21, 2024 USD (\$) \$ / shares shares Jan. 16, 2024 shares Jan. 31, 2024 shares Sep. 30, 2024 USD (\$) \$ / shares shares Jun. 30, 2024 USD (\$) shares Mar. 31, 2024 shares Sep. 30, 2024 USD (\$) \$ / shares shares Sep. 30, 2023 USD (\$) Dec. 31, 2023 shares Common Stock, Shares Authorized (in shares) Å Å Å Å 150,000,000 Å 150,000,000 Å 150,000,000 Å 600,000,000 Proceeds from Warrant Exercises | \$ Å Å Å Å Å Å Å \$ 2,367,133 \$ 0 Å Stock Issued During Period, Shares, Issued for Services (in shares) Å Å Å Å 6,703 Å Å Å Å Stock Issued During Period, Shares, Reverse Stock Splits (in shares) Å Å Å Å 55,422 Å Å Å Å Stock Incentive Plan 2020 [Member] Å Å Å Å Å Å Å Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Å Å Å Å Å Å Å 200,000 Å Å Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | \$ / shares Å Å Å Å Å Å Å \$ 2.23 Å Å Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Å Å Å Å Å Å Å 961 Å Å Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Å Å Å Å Å 333,648 Å Å 333,648 Å Å Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | \$ / shares Å Å Å Å Å Å \$ 12.71 Å Å \$ 12.71 Å Å Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Å Å Å Å Å Å 7 years 2 months 12 days Å Common Stock, Capital Shares Reserved for Future Issuance Å Å Å Å Å 333,648 Å Å 333,648 Å Å May 2024 Pre-funded Warrants [Member] Å Å Å Å Å Å Å Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Å Å Å 582,844 Å Å Å Å Å Å Stock Issued During Period, Shares, Warrant Exercise (in shares) Å Å Å Å Å 582,844 Å Å Å May 2024 Common Warrants [Member] Å Å Å Å Å Å Å Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | \$ / shares Å Å \$ 1.68 Å Å Å Å Å May 2024 Common Warrants [Member] | Maximum [Member] Å Å Å Å Å Å Å Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Å Å Å 1,605,688 Å Å Å Å Å July 2024 Pre-funded Warrants [Member] Å Å Å Å Å Å Å Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Å Å Å 626,368 Å Å Å Å Å Stock Issued During Period, Shares, Warrant Exercise (in shares) Å Å Å Å Å 626,368 Å Å Å July 2024 Common Warrants [Member] Å Å Å Å Å Å Å Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | \$ / shares Å Å \$ 2.86 Å Å Å Å Å July 2024 Common Warrants [Member] | Maximum [Member] Å Å Å Å Å Å Å Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Å Å Å 2,170,000 Å Å Å Å Å August 21, 2024 Prefunded Warrants [Member] Å Å Å Å Å Å Å Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Å 339,269 Å Å Å Å Å Stock Issued During Period, Shares, Warrant Exercise (in shares) Å Å Å Å Å 339,269 Å Å Å August 21 2024 Common Warrants [Member] Å Å Å Å Å Å Å Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | \$ / shares Å \$ 5 Å Å Å Å Å August 21 2024 Common Warrants [Member] | Maximum [Member] Å Å Å Å Å Å Å Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Å 1,700,000 Å Å Å Å Å August 30 2024 Prefunded Warrants [Member] Å Å Å Å Å Å Å Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Å 138,110 Å Å Å Å Å Stock Issued During Period, Shares, Warrant Exercise (in shares) Å Å Å Å Å 138,110 Å Å Å August 30 2024 Common Warrants [Member] Å Å Å Å Å Å Å Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | \$ / shares \$ 5 Å Å Å Å Å August 30 2024 Common Warrants [Member] | Maximum [Member] Å Å Å Å Å Å Å Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 975,610 Å Å Å Å Å December 2023 Pre-funded Warrants [Member] Å Å Å Å Å Å Å Stock Issued During Period, Shares, Warrant Exercise (in shares) Å Å Å Å Å 238,000 269,032 Å Å Warrants Issued in June 2020 [Member] Å Å Å Å Å Å Å Stock Issued During Period, Shares, Warrant Cashless Exercise (in shares) Å Å Å Å Å 3,398 2,549 Å Å Å Class of Warrant or Right, Warrants Exercised (in shares) Å Å Å Å Å 4,000 4,000 Å Å Å Warrants Issued in December 2023 [Member] Å Å Å Å Å Å Å Stock Issued During Period, Shares, Warrant Exercise (in shares) Å Å Å Å Å 582,000 826,998 Å Å Å Proceeds from Warrant Exercises | \$ Å Å Å Å \$ 977,770 \$ 1,389,363,000,000 Å Å Å Registered Direct Offering [Member] Å Å Å Å Å Å Å Stock Issued During Period, Shares, New Issues (in shares) 837,500 1,360,731 458,632 220,000 Å Å Å Å Å May 2024 Offering [Member] Å Å Å Å Å Å Å Proceeds from Issuance or Sale of Equity | \$ Å Å Å \$ 1,200,000 Å Å Å Å Å July 2024 Offering [Member] Å Å Å Å Å Å Å Proceeds from Issuance or Sale of Equity | \$ Å Å Å \$ 2,800,000 Å Å Å Å Å August 21 2024 Offering [Member] Å Å Å Å Å Å Å Proceeds from Issuance or Sale of Equity | \$ Å Å Å \$ 7,900,000 Å Å Å Å Å August 30 2024 Offering [Member] Å Å Å Å Å Å Å Proceeds from Issuance or Sale of Equity | \$ \$ 4,600,000 Å Å Å Å Å Å Å

At-the-Market Program [Member] Stock Issued During Period, Shares, New Issues (in shares) \$ 84,600 Proceeds from Issuance of Common Stock | \$ \$ 206,003 Stock Offering, Shares Available for Issuance, Value | \$ \$ 4,274,260 \$ 4,274,260 At-the-Market Program [Member] | Weighted Average [Member] Shares Issued, Price Per Share | \$ / shares \$ \$ 2.51 \$ 2.51 Reverse Stock Split [Member] Shares Issued, Price Per Share | \$ / shares \$ \$ 2.51 \$ 2.51 Reverse Stock Split [Member] Stockholders' Equity Note, Stock Split, Conversion Ratio 15 15 Stockholders' Equity Note, Stock Split, Conversion Ratio 15 15 X - DefinitionNumber of warrants exercised during the period. + ReferencesNo definition available. + Details Name: govx_ClassOfWarrantOrRightWarrantsExercised Namespace Prefix: govx_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during period from warrants cashless exercised. + ReferencesNo definition available. + Details Name: govx_StockIssuedDuringPeriodSharesWarrantCashlessExercise Namespace Prefix: govx_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of warrant exercise. + ReferencesNo definition available. + Details Name: govx_StockIssuedDuringPeriodSharesWarrantExercise Namespace Prefix: govx_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity available for future issuance. + ReferencesNo definition available. + Details Name: govx_StockOfferingSharesAvailableForIssuanceValue Namespace Prefix: govx_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3> + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -

Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2> + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-4> + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=govx_StockIncentivePlan2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_May2024PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_May2024CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_July2024PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_July2024CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_August212024PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_August212024CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_December2023PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_WarrantsIssuedInJune2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_WarrantsIssuedInDecember2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=govx_RegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=govx_May2024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=govx_July2024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=govx_August212024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=govx_August302024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=govx_August2024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=govx_AttheMarketProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_WeightedAverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_NonmonetaryTransactionTypeAxis=govx_ReverseStockSplitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity - Schedule of Stock Warrants (Details) Sep. 30, 2024 \$ / shares shares Number of Shares (in shares) 6,617,747 Warrants Expiration 1[Member] Å Number of Shares (in shares) 159,781 Exercise Price (in dollars per share) | \$ / shares \$ 75 Warrants Expiration 2 [Member] Å Number of Shares (in shares) 6,668 Exercise Price (in dollars per share) | \$ / shares \$ 195 Warrants Expiration 3 [Member] Å Number of Shares (in shares) 1,605,688 Exercise Price (in dollars per share) | \$ / shares \$ 1.68 Warrants Expiration 4 [Member] Å Number of Shares (in shares) 2,170,000 Exercise Price (in dollars per share) | \$ / shares \$ 2.86 Warrants Expiration 5 [Member] Å Number of Shares (in shares) 2,675,610 Exercise Price (in dollars per share) | \$ / shares \$ 5 X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_WarrantsExpiration1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_WarrantsExpiration2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_WarrantsExpiration3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_WarrantsExpiration4Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=govx_WarrantsExpiration5Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Stock-Based Compensation Expense (Details Textual) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount \$ 655,314 Å \$ 655,314 Å Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Å Å 1 year 10 months 24 days Å Expense Related To Consulting And Investment Banking Agreements [Member] Å Å Å Share-Based Payment Arrangement, Expense 0 \$ 70,833 \$ 54,167 \$ 132,333 Share-Based Payment Arrangement, Option [Member] Å Å Å Share-Based Payment Arrangement, Expense \$ 129,923 \$ 227,114 \$ 335,132 \$ 681,166 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479830/718-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-

gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_NatureOfExpenseAxis=govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R31.htm IDE: XBRL DOCUMENT v3.24.3 Note 8 - Revenue From Government Contract (Details Textual) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jun. 12, 2024 Revenue from Contract with Customer, Including Assessed Tax \$ 2,789,484 \$ 0 \$ 3,090,161 \$ 0 BARDA Contract [Member] Government Assistance, Award Amount \$ 26,200,000 BARDA Contract [Member] | Grant [Member] Maximum [Member] Revenue from Contract with Customer, Including Assessed Tax \$ 2,789,484 \$ 3,090,161 BARDA Contract [Member] | Maximum [Member] Government Assistance, Award Amount \$ 45,000,000 X - DefinitionAmount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483507/832-10-50-3> + Details Name: us-gaap_GovernmentAssistanceAwardAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-41> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32> Reference 4: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32> Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479941/924-10-S99-1> Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-5> Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30> Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-42> Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22> Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-40> Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22> Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-4> + Details Name: us-gaap_RevenueFromContractIncludingAssessedTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_GovernmentAssistanceTypeAxis=govx_BARDAContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_GrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R32.htm IDE: XBRL DOCUMENT v3.24.3 Note 9 - Net Loss Per Share (Details Textual) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6,951,395 1,026,862 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1> + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 44 R33.htm IDE: XBRL DOCUMENT v3.24.3 Note 10 - Income Taxes (Details Textual) - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Income Tax Expense (Benefit) \$ 0 \$ 0 X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-12> Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482663/740-10-55-231> Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SAB Topic 6.1.7) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479360/740-10-S99-1> Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8> Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-10> Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22> Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1> Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482659/740-20-45-2> Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1> + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 45 R34.htm IDE: XBRL DOCUMENT v3.24.3 Note 11 - Subsequent Events (Details Textual) - At-the-Market Program [Member] - USD (\$) 1 Months Ended 3 Months Ended Oct. 31, 2024 Sep. 30, 2024 Oct. 15, 2024 Oct. 14, 2024 Stock Issued During Period, Shares, New Issues (in shares) \$ 84,600 \$ Proceeds from Issuance of Common Stock \$ 206,003 \$ Weighted Average [Member] \$ 2.51 \$ Subsequent Event [Member] \$ 206,003 \$ Stock Issued During Period, Shares, New Issues (in shares) 826,761 \$ Proceeds from Issuance of Common Stock \$ 1,761,309 \$ Weighted Average [Member] \$ 2.2 \$ X - DefinitionMaximum aggregate offering price for

stock offering. + ReferencesNo definition available. + Details Name: govx_StockOfferingMaximumAggregateOfferingPrice Namespace Prefix: govx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=govx_AttheMarketProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_WeightedAverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4\$L#!0 (#.%;D'04UB@0 +\$ 0 9&[C4')O< ,087!P+GAM M;\$/V./0L",1!\$ _I{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x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

CZO@U9]?WRTZT=^*OL7ZW*IWIU;AP5;M=O6Y MLN" _[GN,V_!\\L[3_4131#KF9? A+S9ST?YEBOZ=X"NK*#?N2=&'\B
M1EG>5\$7UW-JP,CO60VK1%K780G3@I1?Q1?Q\$8<.X+S+R[Q:^"5\+#=Y@UO M7P=Y%ZSX^DU T-"\&(.,<)(E1U1^RGEZP.*&8LB>K
X>AUF,^WJ7:/VV>=K M?C3DU7+FZ]J]O"7/Z\$H_#L47I]@F2KD\$G4R*NIC(GU"BM1(1UJ8 :.0 MIBDC(5(M5Z;E/\$Y(&H>8J):9:8FC* Q#
(OM8<9Y>G*=6YW)MVV1>SS_ K\$ # MM3T.5[%X!7VDB[68,.X2\$HH*-?(QOE2/BK4=4Y//)UCF"4R)/[O\$C_ UX *&8
M,R,A8BW@S.P5D85:8JU,JU!+/0"!B\$%N M1J[F+4T+C).0IJ?J3#,".0X&E.7.92@GD? (L6A%.D1X"^.U3YPV?8)DG,"7J
MZ27JZ=A%RQGI%BT(FT>6*F=X0,IPDA^HQALX33 E-]3&7F99B1\$4,L1A.
M.11*NAO*(4SI#.NF2O,ZIZ:=5[3,%YH:^RNI@,SQI3.4@S="K=3D@QD38#I\$
MF0!3.V="DJKVHA/[>ND5;>45+4.F[IBCA,24L*\$2TZ.QI%R;8 _MKU(N!XKO#J@,3J/\$R#EK_9,#ZQ,M|X6FQEY* F371%
<#W!UO@"SP1% # MD:D0Q,J2\$E*]=4,)VG41PC\$L?Z #=-4X120@<8#9*D'-E9^:VU02:S'^(V@.D0N0%,>Q&2@9DUPQC
MQ1%RRH,E8)(Q%"#<2=4YH92W94" MD5A'4U39P:"9E*0A=)@,F5>@&/TPMCXGV& M?:)EOM#4;KC:XK=+AYLW_,ZX:EKJ<0>>!
@^GNBS/6"3X0P M%!O:].[2V6,[LQ^N&&3R>L3'F"!<8P0U=UU0F5N*5=2::QG4S;%C=LDF#? M19/CZHL;8#):)@D*-=&'&INBD9,
[Z],3OU X88,Z37/[5/GE*,F9?:&KL M)6/&HQFS.JX08S,T;&@89,ZC7 -,A00-8604:EH09VPGSB.U_.!HFI46I:#O# M>D"J4_./I]HF2[T?:2O>-
Q_ ^CXXFVR^3[>K"!1P,H1)@ADUH!=!V%E\$0D M3IB>?J8M[\$(R.D*)3S)[;&?V?JB52?.C.#1HIU>[Q4M(X6F/L67) 8.?-
MSJ8A%]/26+R@I-E,-\$D051%)+TG-+{PUZ?;F,JZP=XLRY: M[D&N NV=IR1YT5[HZ:FHU>TS!>VB&2Z),B3[8(6 GF(Q=(+> \FO&&U M
JR,Q+29#&X.EECY_H_-GZ?"&KF&Q!4Q^JS6\$0AF19UB%]1PT_>MO1\$*V M^+[+HG&EILG3*&#;RTNO>OE>TS!>VB-2CA[")G:(V
OF+*%,T+*FA&ZT M(R,K;29#*16(7: M,E:\$N?9F"5@@D+S/G/F,CAE+E?* V.6!38\$24PX8 M+C1/SJP DSE+6(CT)2;8ZFZ?34
N4D#7#]#H& (@&UM\$B8D-&9:KQK *UKF M"TV-O=0 9+0&<,:U !)O/5@@QH 1T*\$ZKL[@.FVMT4DU3?(,L!6K!Q&T@& MJO#
(370[3D%\$@+U]4(#:ZY^\$5;>47+* V"\$4Q3B,ZL+I0R>;I M34?SK ?;P-F.FJPZB<+4G/#L]4.K->#/K[0U-A+4%]"!WQJL*- 6P\W
M<\$H(IV)MB5)]=0%,YP@CT85BW='N&DKN U)XH\$-3GIU2G ?W /Y?0!2KE AWW:&-4O,UC^0"YH0#5'R W@.D@N0%L->2&2@%! M[0+
[]82!9XM1*&4I\$B/DK55DU/2)UKF"TWMS:EUJ%WK /C>C7O'HA>,+H M>#XBIK,883U-W<>'8*R41 /GAZA4'2N/L;J>H]*+0\$3 3QBZBN>-
U0F1M* M=5=J#6K7&E:R9Y[U-UPT)8?A'7#&GX6BZ537V,LU7M1DM8S.ZU_S\$LSO_-J M|SVJV^.^_C1OMZX9AYF&^/P^@K3*3+V!DV=
<+RB9;[0U,ZO H/9!;<XS@ [MP+P%/@63=TL&"W"@F,IIQAG@*%O90W&8D-*BTD=P&[2 =>'RD!BP\$P=0%&<
MQ&82>M4!7\$M7R7VAJ*4.8*U@#O>I@X0)=99+P-T .KU(F,Z\$0,-11% C.(Y3 MXQ0?
9"MH8(KQ@!!@4@@PNQ#PR48<"X_2E\$]>U>ZLF9Z57> +>V1JPN\ M=GGPXUR,F:)!((N&IC)[M,X"A.=B@%VQO0(08E_ J2\$2:7 -
SJ9>YK08") M&)F?ILMKY8;*W%"JNY*&L)OO[C+WY5[FOMT+F,Q9@AB-]+8RQ5-R6_9@Y^ M[8^)F9P8QQ11XW2UO463YQNOUWY]H:F
(>D_L/ _Z1BID 0/_;_6# 8PG& M4(*_@@7L#2&PB&PR0>N@328T0W70-V+E+&)F*-Z5M=<_0^JHF6^T-38 M2TD0C;X&[(ZW*0" 75G
:FA7% C=W)6%*@=W91=70J_4 [S6^[QY+JHV*/F3 M*!F^B46^-*=?K#J]Z>K]2>9/M==5^ .+[<W "F-Q#?/]5U]_U- RM/E\>
M>_@ 4\$L#!!0 (#, ;%E?XND)I04 /H6 8 >&PO=VJR:W-H965T M&ULK5AM]LV\$/XKA#L4*3#7(O6>.@829(7VH5O0K-MG6J)M MKI*HDK2=[-
?O*#F2+5%*@/F+3=%WI^=>,>^9[X.0W]66,8V>JQ0-Y.MUN7U M;*:2+S8CC!+.<F*RF%=[#W(Q%SN= M(8)(2*1V>4[EQQW+Q.%F@B7!F115;BNQOGNKM\$22:H)2M2[37/7A5W9T MR#?V\$!&IZA,=:MDPF*!DI[3(CJ (.=% 4V?CH\$X40
[=@5R5!-=!6 P3TJ MN)6C-+*K7NJZ6(NQ0%)(PW6S***3:4-WO#"/%12 B5@YY>+\$610E)8BF"E M1,93JN'A4<,79\$LK)-9H2=46?8;,*W3UK:
[E/!,S1%WQ[OT=5/^8S#5", MP5ER?.U=_5HR-H8?1&%WBKT"[P^/=>?@0N-^3%CSLR:O"1E1^1Z R,B\$,) M"Y[EV]7=\$3AN\$U:WLN<.A=5%;%U;"U%CN#82:YL:GKEFO.U+4M;+59SV[6 MG.EK5=*W4S@T"HF]VRR>/.!XGF\7,G86 :^)@#=F??
[\$M*!,&5SLM8, M*DW39_+*0Y\$@<>F< VIQ[8],W%\$S?:R3/X/D-/T0;?W/X@Z[K 2I2
M(HJ\$9PP51)QFUPZ3D[F=2"]>L: _4NF4+&SN(4-*'1M-XS!HPFG=#1?MTDB=N8@04QOJ>KS)JBN!?!J>^%?NAU MT%M
MD0N=T(D&AT^H7@)BOZ/"N@(0-R+,,0D<."H]\$B&4>!%T<#&F+D;RM!DKZ M; J@[C5)(G>L#;L5/+% PCATND?7(DAQ;L04QP'.
N>INH%T%CX?J MN*5L/[,9W:&%WNFWL+&^*)T?"EKYU%H"1F/, +#3B9;X#8SF+,?UZ:DK-Z MW2?
7*7\$"W^VFS"87QW\$XD^*6AO\$X#_?JS98P_*(>S=J1V^1&D+=C%\AY\$ZE MK7E!83Q[0Z5=E)0O9>TV"BTMXW%>-ODKI4@82U).G%
(["\$15>X70K&W7[J]%" M!.-0.9%0>RI'(PNWV"QJ[O.#T^?#.1DY;(R3B1?P4>?S8'YQ]Y0/I,<7 &M@ZX+&L\$A%UHV)^-
LWL^*HEF5\$9AU)WY>))9VKA*6,WZ8%IRY9&I ME61A^&0(U314,WUR)B-8[<[@EL\$80J("4P! J.6:< ,LJO=6^V(494HQ7; M)*P^8#S -,
%ZG5%;^+!_!XD?=87S4#V;^7XQZ M\$1N1B?(DQZ1Z\$OB\$D0A7#0.Q[3FX16J0M5<7E_-;O!->YM=6W9 MV; #U/OZ&K8U4)*?Z\$2J-
0QM9@TOD80F!E?=%/VA15G>5*Z&UR*OEEM&4 M22, OZ%].SC@WE!<JV> J02P,\$% @ X!L6=Q[?Z+!0 LPL !@ J!W;W)K D;:=
TP9)MPMTL0^T-+8(2Z1*4G:V[7[G%*EQ4SE97+MQTS-:A5P;OG'DZJ)0;GO!N=V=<:T=:W=<*M7F9!%@:3LU(M^8[# M7^6-
P]N@J+9@HW7UI#CQ7EG-GI[.9]<_,WS1N_JTR2R=S:E;Q3,[0P\$ M.2=!=!"C\K?F2/UP< <:Q/F>G#2F&^\\[[^]C[LAEKCQ?
VOQOG8;LO/.Z0RDO M5)6'6[OYDYM(7HB Q.8^_M^*FWGLRZ5!2^6"++Q@("FWJ?W7?+!G'KX&X-Q M8S".N.M \$>65"FIYZNR&G.R-&
WF(J49K@-&BG(7'+YJV(719QN81M2CSR\4 MCLDNZ*+RV.3JV2 @@@P)(VS)B99#?.WM"U-2'S],ZDG/YL/P%MUXA^YB
M_*3#.R[=#[+LTG@XGCSA[Z3-]B3Z.WDB6T_!TGMM\$FTRNDNJ,1063B8;^UN MCE/3)!..6K"3I[Q/RKRI62G1,2>_OG* M]X\$ND
M#86,:19R98+JBH%;D4%!V=+F^N@T@08%W2GA0E *,3E?=0+?37*,6269L
M;I=2FQ1*%T2ZTB);1*B@(A>#Y&KC!9TQX+RQ5C&0'ZOV(E90 P->ID M-L^W9#<& GPU]SK5F#W=QF27F6K1[*#
[*Z@QT(>)B:X0<3@YTD#PEE8 \$< M\$* /G/T>CX>GMO#VO"SL*BU>\$68R1E1+*E-DO* M]@(4KE622\$FPR:'S8= 0@7&71^>Q),K44V%P#&X#FS\$6IM%G'R5IU1[QN3R MD1:8.E7JQ%H;16%7.A!+T!+L/(D\$EF0L@%)6C K- :11F:L@QX#?,=X&SZ&,
MML!BLW2JD,0^O/02N[P3Y&0K%!=GM+&HV:Z?+&MX]7O:&78X1T2,328;B MT0;4.D[0FF!>HV9 B<7LJNK66!AXD!,S!N'R2X%>24!: X4C8;=X7#8*R%5 MG6B0'.@F P+TGC @#[#:'W:5GDEFA2),' UR22_>UN"E\$OY(E4AAC=" MP?>A5)IJFOM[!F#AZ2";&(BL6T<\P[1(T 0)R%_AVJ5!1V#I&6BB\$')P_ ML:6+HC)6VL?90HN&2G KXPQR!X[P#I\E%(%MH%WQO!.DK,J2. II*VUJ, *M'/8^J+1EE3>3IZX- 3(6F)A2% ;P[=_!GQL'VTD,*J W5TZ&DL>.,J9DB; M!RAI06]TR"C)G 4GE&^+,K)-L@S5RLNT*^'EY^>4>L1R?B#74/.
<+,M8JK#24:SRD&WWPF46M/):VB3V=):BBLY%K>?9VTR=F"QX!JGB MMJ&E)Y!3K:#1X+&&8JE4NI:RIG%J1[H,)ZM=K?
LT:Y0:L7/K0\$X%Y40XL&AF M41&E4"?H943G5 "KJ [2J94D?OYC97%V!E2[5+W=5JF0B J6U9\$ M[3U]^C]02P,\$% @ ,X!L66YVA 4(!P LQ\$!@ !X;"JW;W)K=7=.%5/D\$ "5*R(I&L(4X=ME*L43' M/J1R& SV8L>:G5G-!T#FU^?US.X"=E7+Y0N!'/=2/KUZ)[9G&U< Y3:):DC M/7&ANM9& /9K,5]:\6-Y<6K#/#QS V=J| MW"TG+[7NV M+'ENFK>WVY_N+F5]7O"CYETXN";9.W<)[GYMKZ>G0D@-EQ%
M\:#P;OOV!AQ!!B!Y^S*:08'EZ/WK_.N2.7M0K(SIF=?W;ZJGK=&7# @P>WV^P:KP6"5 M<9=&>5%=-7-E7<)[K:(WN0BIYJM 4Y;*T\$.I"KF& M'03&ZD97RD:ZK2J7;-1V0_?Z\$ISN%I&!!;S934N\$2M!5K2Y* TP=G8!O; MK;E^&K\$X GU:D1]MSKI\([!5V]B8N\$B^+[LXP4*@Z.AK;96M MM#+T\$%5DJ" >S;>XNNSN3AKI>A5Q=WL"[4.6*O4 MJYO?_ JZP=^C1G7/7IW>PG_1^/MJ9??KP_ZB:G6H3(N<W:TJ QT.N2 M\K9@)4UZ*VIF@_\$.PJ4RJBZU8W%J:L.(C)Y'0BM/+I+YV80O%" .)8LOT MQ,H3B[KH/5?
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

(;H:16&[%2C/L=*\$Y!5ZR6XV]- 69(99B[QLD--7 MD' B&Z/]QM\$GG7/^7'X(*SM3TX.IR_0HX#U7 QHG?4J3='(;]RY/HYXXR.N
M._*&/DLM=";%HGL/GU%R_D5 &[C]RW"A>RY<)3*>]]>CNC[T]Q;OWHS.DLLC MQDXZ8R?'T?7O/T+5VFC*LMTY_>.=I]4SVV-
=+MAY%>JG6R>"YT7PGQ* @ MKYINQ)Y;&0KZM&62SM5@&25OZ:N5!2*IZ\$N@16-K3W=6E."S=A]6V2G?L/T
M[LUYFB:7D1+/H\OWJ'V_(8%>+0K+19139254P%5E!-K.ED-\$WZ29\$W<5 < MKMBZ0#:U;JG1@~7:VG1]P800N?
D6\$MCT3<:@R;DMT]2\$^RC=%\$V8%;=8X M1YEP&^@T&7,>:Z-VC<:Q-&@8WG@AD(5:\.V0CKQ/*Q86H)X13T"V2# M Y
>3=]2Q1:6Z+KL1X,P3D(6ZPJ#*40#PDJ!=RG/CTYN:RZ9XUHA=98J0I MCY@67#S&|N!M>,49BO4A>1-W%PT=35D+O*
<-7<31;0F:;6%"NE=>(0R MPJS)'IH4-'HX@^;3PI!M\$C9'0RQ2Q2*HS54W%(Y:^U4'(M40UM0T#IT<\$ M^Y#>0:B@J[K
5*,T/131<|M=G650LZ[5P:>@! 8(>A4_&J+E2L@8AR0'M]E M\$4/:J//<,LFWK+|MLJ.E#,I%TXP'1)9=W6(DNJ,R,Q6RC0+8^S4Z[9 Z
M#H./,+9(+)-N=M%6.#I)1_WQAVD?;F+.=F[4=2QO'+1?N@B.(N _LT MNPPE='(6Y&H_F?P2P-G^&1)E&R+N I#H'>
[(N.FVW;JV),_O>K.H;8='I M#@6QAF@R^##MD6W67W/QIHHK9V4%\E@;O"+@6U@P/O:('M)2CH?H,L_@%0 M2P,\$% @_X!L6;J8A,V @_
0!D!X;]JW;W)K&UL?53+;MLP\$+SW*Q8LT%-KR;*=M*XM(\$X:-\$#2!\$AZ('6E+M1/A0R76<_GU)2E%5P/%X((PQEEREXN)JL0^N1B1X4E*
|:)N)FCG2N*)&Q=W(M-*CJRM98Q&?[93B]L* MI=DOV9@]3J]R+JJ8PD>2+AE>X1OK6W%D?3U+*11J)XP&BJLE.QO/5].Q'.^
M"R]P1B"DXTQ#R&X*IP8E;OE.TKW9?;SRSP%4:Z^(5)FSLY59#L!G5@;T M]73[YT_>=0P 1^,7 %D'R+N=J.H(H(3SQ?
6[,&:>_6!M%J1MQ0H=+69U M]_C*/B"!&[Z-4H+_9;.)2)PW)=2^KEB1[@>#W!A-M8-/NL3R?WSB M!_?6JLF=5J^PHX1J;\$4S2MY"EV?
0(WZ1W.8EDR,N"!2Z&Y+@27L"9.^*+? MEFYZF"XTRMPUO EYW@T#XBR|^V^D'X^((G?9BI?8\%5P(5PA31N9Q% ^ M?
L4G@I4TQ<.O0Y*/DAZ6/!N]&FYVZ#E)'0%U@+?037HO#MAW!666S:@2W M5*.%(>R0Y610D0IM%?O.06%VFMKB[&?UCYK* I?
>OLNW!;"U XM9#T]I MC(%M>ZT-R#2QOC>+?+?+\$8>V?)@AP:JOC;_+@;@;]>_A=02P,\$% @ M,X!L6=BVXU9." +QL !D!X;]JW;W)K&UL
MS5E=;]NX\$GW/KR"\Q=XNH-B69,MVFP1(FA:W!=H&37?<'\$?(&FVB\$JB2E)Q MLK ^G%6D79L-
UD4R'WPAR1RQLS,F>&0.EDJ_=VD0EAEV>%>VEUI:O@_3 MIR+GJ]#*4>#7.F<6USJQ<"460#\$3FS\$U793!;B M2C-3Y3G7]Q#5DHB#?
@+RF6IO.?D24W2GVGB ?]:6](@\$0F8DL2.'YNQ1N1920(M,XT,GNM2IK8_>2 L[9#EMNN!%O5/9)C8]@4U[+!%S7F7VBUK^6S3VC\$E>
MK#+COMFR'AL.>RRNC%5Y, QD(9Z8#G"PH*-=6XZG\$/OV25G!(G,KJV^OZB[+P M%+@%&@(P.R
M;>T,G+SQ@KV%6L7>RX\$4L>0+N17@F36[*W%C7+HY1Y94H>MB],>6760(T)W03PH9#?S MJ_4#7@3;_9%W.)*U&1@UV4F+>-
%@OM)56>1FK/SRJ9*R[J%PYJ3#%TXW* MS13_H0>-Y17G(EK5J1_RRTG*&.N8,U33PIJ/1/I\$O;2K8[[)-MH?FUOPW\$[
HZWM4Z&O.,&^* _J/_WD,!9!1QI34%J]3REG25=&A(X7,&2V,J M3&J]T=9&2PA5:O0&*EU O@XJ]+I=^7B+U,W D=2\R" _MA9^L+O1U-
60JB; MV&>?!%3L1)F(X:51V1WEXNX4+=]WJ0!H4,LX/RO@U.O@B#LLF 9HEHA= M3=L[B>5#9/D.\$ 5SS),
[E/X/U2XZP=/C_JH//6B,/B58^"R NCO<[LQM_!M?GX")X_9P&^P@0]*?1LQ BC<(<%XML,C_HQ+@(_UI#;Q+ZOY(\$83CS@FCV
M&)L07_N6C_9_CJC/N8]!Q4F/1GNZBP:G:>0H51./&OW8U_.IY M[1>X@ MP@KX(Q)A-L&2L!_W_Q\1OUH@P;H-&.WF!^,.XP 61<]&4!
(SF[YAGDG2-@ M#0YH%<RFTQB,^"ZI%5T[#'0^ D^KNP31PH #D4159HP2JA>Y9FB ?D0X MW?
U5#"WRN*EXW7TM4QFG+BCH=TI>W-&SK&KL\N*P>4M-E4ZH3]0=H=KYL%!/OTBFX[0&G0Y
MX)K\$+@]6^DE6QTC#XBA09Q(CCG:8#:>#6#C_&IHF'M-<&L+T(AA#A#2HZ MU/><*+E8;/=0=TZ*-!%HHD+7OZ[-S9LB;(1JE(>0(R-<\$GP@=ZBV7&>B MO\$ FZFU#^V^T^K):=U[UQJ9/26>[N93B7"V[T'P]<7]74?>8FVT8A3*T M784;B;)@ER)NF#,P@T>;CXY6&
Z5A@!GC]@2=<,VA@J2KGOYA#_PXL^CZ MIQB!=AIYJ'T&I01MG>BP(KM_>R F\FC*5,Q-"C#9#70C9\].AW^H%D(% MP*-F1P-
E4 2!LJGTR3[8+M9/CVNS9=J,*0(F;>K2BLQ;EV6DCRM@Z*N]<#I# M/Q3^O\$ALA[J]>[VV]2%//%S]L^#:@V05R?BSULGKV7+
(Y;779P)O?"10?P% MG*&&1ZNN(_FRT./+V\G\$FTR&6#Q=V=S8=W%\$,=T<73ZEN\$?C(9\$YW M\$>0\$:RY<4>=97;C;7@
ER%29_ U\8[E*>QN/O5%PL);.55W!L6@5"1H=C)GK MVBXH;"9R8U0LW9KAG.8F-?RQKD-UH[;ILAQW3\$27&. 1-T
MHE8[HY>T5W5KFYHQD@!>*_. \V(UJTH;UQJ7N@ XF%=' MF<2O,S4O1"[@0]*[#B7F+*1^84\$2?/Z%*X5-FS:CI\$M)XUNX="++?P.5?N
MZ EV[B!X+8Y< !GD;]MCWK F,/162:20XLZ.052/ G#T(M&TRU)JK+H^(H\$ M1GM/@>D' 8F_A7/3"WH4+JN60I+,*O ->1+3E(F_8#="ZX-M?
1Q5B4KUW=0 M,>)%O4 +6X2?69CT7[.[\$3FP#)Q"3"O;*7K"1W;5/-#MBKMAJM=H6M#7R M^ZT(KB.ZH7<1S7L(^3?
4RZ)^O4"A;0W\$=K9W5_ KDU\3[5Z1]_IF]DE\$O#H M4^6>T4!GX-&JRT+U1AAP6/*HT^CJ#) //,F4Y^8!/:DFP^F]>^BA3
M431E NSAT.BH[3+6YV1T[K6Z/SM:+U3K@Q0Z_&#GZI&Y;,:CU65#XR: 973 MN'XT. K<9=2 Z"Z-4CR9LU]GXH/2(Q=ZX5[5T
Z@*FS\J.JVIX-J? M@JR'UZ^2L=92"1(N:8.NQ/QCVFZ]&ULK59-CJLV\$+WW5Q]J9-MR9_>K>V@?4F
M07M(L(C3YE#T0\$MCB5B)5\$C*VNVO[PPI*4[B.##1BRV*,V_>S+PAM6Z5?C(% M@&7/52G-)BBLK>_T*0%5-
Q,50T2=XY*5]SB4N>AJ37PS#E591A'T3*LN#! M=NW>/>KM6C6V%(!>-3-57]LH-2M9M@%O0OWHNL/0BW*YKGL,>[_UH\95
M.!DH@)IA)),PW\$3W_,N=G.R=P9_ FC-V3.C3 Y/*'B]VP31\$0(2D@M(7#\ M.\\$#E"4!(8U/68PA"3"\^>_8W+7,Y< ,JOPH,EML@IN
97#D36G?J_8W MZ)/9%ZJ2N-^6>MMYXN I8VQJN81U:#\$=.8=I[SQT_!WH6_9625L8]E1FD'W!R+@60<<JW%
M5P'W4\$J9\$HU9',7S*WC)D'OB)(KN1MF%7LC))>IX"56@5M S5ES*5V_, M1^S-9VJ>PB; ^3"@"3Q!L?_EYMHQ^O4)V/I"=7T/?
[@NNH>O/(WACNQ>:RYS MQY?)0&>+=N5V,6_+W_&BGZ9^VZKZTX]4T+9=?^YQ P M,"R
(2;6"D,D4W;OGBV%1Q-5#+1C*]+J7K7+71'TI2] M^E\Z2_4A1IJVS8DB1+DVCBV^R88YM7WTK#*#P^B6TKD, 7Y>AJ1U/E852 MZ&?8
*NK532^23%HYK'29)\^:^?>N:NG38AFW["?5UWRENZN]048/L"V_P]02P,\$% @_X1L6=06V7V@!0 %@P !D!X M;]JW;W)K&ULO5??
4JLX\$'Z OV(G93HPDQ^.WX5 MR\$R KV9EDS2TH;>U#L3:RK+;F23\$C ^M5N_,JX%>B&5KO_UVO]V5.-UH M\>FB
X>BES9LT[F7/EA,+!)AH6P?5VBHB\K;0KA:&G6 UL:%*DW*O!)\$4' M@T) (\U9F<^G0:_9*GU#U\Y2\Z\Z\$1/" M!"/()^O\$"\YR!B,;/&K/3NF3#I\-\
^I6/G6)9"HL7.0\N4Y>==8XZD.)* M5+F;Z/T-UO'L,UZB<^O_PB;L>]W(*FLTT5M3 P*J<^O*>CS,3@*K%(*X- M8L[./L+X43DU.C-V!X-
Z'Q@P_56Q,YJ5B4A3/T59*>FWS1#N\$(>C#)>U05 MPI71!5SK>S2*G T?NV&B0U#-G 3I^!>H8/I-M9N&C2C%];C@
MFBW7N.%Z'K)N,"R#Z.H" W\$4C_&[6QCSS>Z(W8+3@-5U)E4B1P()AQRW M?2G> #=&^8[;YX,M18)G'>H/B^8>.Y/W[X8'TQ>?
H.%BV/7+[G11"K5EY/#\$PN*LMA;(SD1?F1 M) DEK0?]F1!Y!&E#8%8;ZL"5A77.2RW'OA/DX4)@D])=B\$V
MK5RFC71/V;5V>M"2:\$R8<:IM3YTKJ:\$XUB*E1:X%HF,->S%5\$:-M-G: MG2YF\SV0R\H-ZR_ZY)1QFV3*HA([D(FDQ-).*M94%_ (7IEV8931
(5Y"JJMECKTE MJ<0Y:5JRAKN0M,26XV7N%K1MV3;2M6Z,B7"V9M*1X*7- M_#B#\$/N5UFG(O\$G60^=T]XJRW-A-
E:>C(4RCF7Z;O:)*0R=J&UF&C+1I6% M#_4UWX)>9!T9" M=N#?DRC _J*43^>U2X&0WQ+4F3T\$E**?=\$10U%Q;5C8
M&>W!ETN,ZXL=8^&R13M2(*L-O*.PV=^R/TQ>JP%9E287IBX7MVM0 SW67 M,>25AS>XKG+AM-F&PU(ZB;9?2Y/Q/Y\$B9=-
R\$9&S)@=UOTJ:0A<-, (1)A72 M%W1+' JRJG= L0=8'3"J?^K*+9ELN7\VF>5XER+4C8)WK)<&UI\$W30G0/
M\$4K^N]J=>/LF2RRAY*H*2I%/IE2:6JR0T&S>AHIQ0OR4USOK'&_G8=926&PO=V]R:W-H965T*Z= (B)ZLLX=EF)E71#4Z/FF+82A!O[39VM461U'E MXC1)IG\$E1(Z6\W!V9Y=STY"2&NVLN*JA'U:H3+M(AI%^X//M@\$UBZP[6X"/9&O-
^S19X M0:@P@(^@^/ & UZB4V(90W:<4>_2 P_7>_ ;#\$O'LA\$.KXWZ+G,J%>/%!#D6 MHE' TV;3O?
+C'+A'JK,=IQ&D#6.3+4#LX)*ZNXI'G=Y. !<)_I#M&G1WCH+*MX+\$K2O;I5>I)P MC?40QLD TB2=G. ;]J&.
J_X1+0.R,"MU\$)G4BA8DR#DMXS#PN=S9\?I726H2V S5<7M(Y(*= %!4Q=\^=3 M=U0BM\$?>">T)[@VZJ#<->0>#
YX4CM@3ASJ\$+XR\9CZAGY>7J2CUV 8 M1*-=J=*>75JN(W!8=9821+=-I29B5(G:DFYQOB(["I?=[\$W4C0,G:8.H 1\#].
(?FBKH[Z(2872PYGT:->J34N!RX L"AXTO 0 M:A2G@H\9UYN%]BS9@8(8A?>^ PT>2LX_ ^C^>[DEUNBX8:[YAC"T3_)PXR M)!1?
30>S]@/#L/#D:#)T.+J;IOE[LC]N2>|97<^>P907XP%:E=CF+7J M:0C^B ^%<5VFT8RLZG0U,WN?K3?NY?=>NV;S[:P'4=BNYS
H+AB;#U^<1 MV&X0=QLR=1A^&T,2L.RY&76F_JX7A].\VWD' -5S!E+ P04 " S M@&Q9#"\#>PR "#,! &0 'AL+W=OR39 M<<-
,ZHNMCWT?O60M.FV5WID*D!>0"VFRH")JYF%HB@IK9B;J06EW-DK7C.Q4 M;T/3:&2E%4B3*+H,JP9ET&>^K6ESE.U)\$.E+C68?
5T S_7>10K59\$?'A4> MK=<@MA'G:L"VND+XW2VUGX4 I>8W2<5!XR8+KN+Y8N;B?< /CJTY&8/+9*W4 MSDWNRBR(G"\$46)
C,/_M\ZQFL4PH&LC3\]Q,B,=,+3%9^>Z.W.WN:R9P6LE?O*2 MJBSX%"&[87]*C;]CG<^%XA1+&/Z'M8J<7 11[0ZKNQ=9!S67W9H?^ YP(
MDO@50=+\$N^>[\B{O'&E2K%K2+MC0W*EZM37I;N46F[RZV.\@=%"\$ M'!%.JI&>&(-
&E(ENTBPJ+G#I@KG,]PK296!K+[&G]:#T-QI*CL44R M'EQA,X%I!Z*2)F->9#HE/FFXD:H 4W'+9,&9@!4Q0EM@=#=;?#C<[CW.] M,C<-
*S +#_8U,8Y_>QI?1EQ&SL\L; (R>O)P%W'3" &7V&N'7\$QX(%D(5 MN)_G\(\RSSN.H\{TXN\}!P7G(_Z M_)[I+9<&ZL-]\|M) VAN]
[I]J0:7Z]K1;;Z_>ROQO4+L#N;Y2JRG[B#AA^ M8/D_4L#!!0 (#,.&FR4JZL_ (%L& 9 >&PO=V]R:W-H965T MTQXH&4;0Z<
MQ5[;&BS)2^*2 ONNY.#2 7*(J=K]OM6VLUJL_2CJ\ M[\$0MS3RHK&W.P]!D M%0IFAJI22>%TH)96NHR-(U&EGLG48=)%U" P;@,TIG?
6^ITIEI;/+ M^3/ZC==.6M;X*6J?_<5O-@&D".16MK>Z^V7W"OY/3A9:HV @_O;SG9\$/;6
M6"7VSK067'8CV^WS_,A&KWC'D.P=\$L^["^197C'+TIE66#].FM#J%<[\GBC VH-6 4W M7#*9<5;#RC*+XCV]'=SX;3A7,.>F81G.
ZH(@W#0?K18SR/A@.^.JC@^A MIZN\!XJX,[HE;9X^>WV![\$>YMM' _O YTU6HN2[C+K%JC]MF+0(WIL4< MILED<#]P52,<\$ 5H%H-
F1*RHQ/;8(2MM*J+2L:2X>F&I5:F9 &:!9(K M9\!J5'Q2M05?K ; M=Z+K\F\^,^:[BWB3]=,U5B0:S0V0E
=ZVL6UC5^/Q51:D9]6U/1.P,Z M+Q05U7[A O3_]>E?4\$L#!!0 (#,.&DW&O97@, +\$ (9 >&PO M=V]R:W-H965T@*2%0L?:211M
M&MK8#+M >M C-W: C- >A- /+ (?0 [J\$K(BE8!X:7S.W?]=,UJG(WKH,T<-> MKHV;1IGWQ7ZF>8K[M@X;]> /DB8!A&S" L=3=\$M'8<>
MM0>=VH, ^]FY&B5T"-G = RVW!#?> JAKBF] ,M@WZ,D#B,WOSP&?E MS#1M'OKE8VD#^>#P21(0DIW.%"8LV[RG%/%F3]#ACB
K[C'70KML\$??8:OL!G.YG=UVOLQWY.XU&G>A5 M-0PMIHSHE@/ 9S<2=Q _HRODAF/_R3.N_,-9*C7=7#TG\$?E\8W\$Z7;[>Q
M23.&_KLWP_QBGHH+L-?3T M[XVG&TQ6:E-1RX:[U2@YG?]KJYISGRX2#> \WBWK/B2->?^7=7_7E; F MR%*5V(+&SY;>D+5L" #
^#S9GDTM>N\6O]68D_F#JUE[.7.U53 MH[-_SN>QKB\$8"5MU^>JEV9>X]58]=>B.(B,[_Z;N!A;'+Y1,+5L." ME> NC@3E6YWTU47P.Q5X-
JSQ@X0JJP'..\$[*QQ3PU6!=NOIH-LXTIM(NJ>N J M\MDExS,JUEM3&8KJ^/3/R"6"?YXU:(:-

4VZLG;"^MWGN7VJB^<375C]V13\|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l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l16BT"C"BMV21VDKJBS6WY=Y MEL>+V^GB_I7RV1((A)9(J1IU+M%D)J: A;IV;CFH)I:&N%H^NZ,1RW8@#H M]#ZJ!4<^AQ =-:T9OUK=? UK_S_U [V^&+I[MTE2,U-\$0O5.%1S4.VMM-TE MN^J]E;/38(UX+BG\$**#1I36![%UG\$^5Y_E>KD=\\$6;(\JKH%)(D_C M29F25OXATGEGBT"3@JAFHJ?;C:J;CFHJ?;CZJ!0>[DSY]N(T4S1EO@< M]JYIR&W K# NC.Q916K/U%659JU;J6'K^+;5[T@"I% &JX#H(92_+\$Q*K M^\$2F(C.%D'&S:Y0S40U"5L5'-0S;VTP<:Y@^@J@5/H<0'36BM&9EUS% M59YS7+V_I7PGQ'6Q3+A;EF@VN23,VGH0>[VFK(TRXAJ%JK9J.:@FHMJJKY MJ!:@6HAJ\$4.U.T(=?U3E^<>K69QE2G*W? 9M" .:NOWNR\,7]8 MN-F"S3:3XM

MIO^K>#8KF9OK+'M&YLM#F8BY;O2NXF@J4A4L]2.1.%&P^'S95VJ'WZZ*@!JH6H%E%:LPW4.4E5'I3<'C=4IP:..V9
 I^4\$Y]8S;!PIHGA'57%3S4.U'M0#50E2+**UY6Z\$Z M_JCIXX'5PU%R4?Q>U^E.9HR7..!8%#GPN6 03..U9:UX<8Z-]I(#>WO'5%1S
 M4'C9<.P52S3BB&HFJEFH9J:@VHNJGFH MYJ-:@&HAJD64UNP0=1?2DP+N^765Y AMAU*GI=MD0CCJAFHI%:C:
 M..CFHI':CZJ!:@6HEI\$:N M=C3PB&H6MFHYJ]:BVH>JOFH%J!:B&H1135[PLXG,3[V@CKUW*1ZIW/UEK MNO_.6H?/I ?
 [T0U%14/5-1+4"U\$-4B2FLV3KVJ\$OS5,BD?K?MDYJ]:A:JV:CFH]J+AZJ^:@6H%J:(A&E-=M\$'804Y.'(%ST+B88I M)?
 U/"G>U<*&G=\$-005;%1S4,U%-0_52%0+4"U\$M8C2FFVACD7]ECDBRX; M]F_JI^IC56W\U?R7>
 [=!'M!.)*K9J..@:FHMJ'JKYJ!:@6HAJ\$.4UVT.=B=0/ M?(KVC[AXB68?422XW7LEWO&^30#4+U6O4O)0/UG<#W2M^:@
 W:L0U2*;Q9XG6DI8V&Y^T9'OTEHEJ:(A&E-:N#B4. MGOU*W"X)-D5]>[JT?LUHIJ: A:JV:CFH)H[W\$^2#O=6X-Y1C +1/0M0+42U MB-
 *:55UG"8?R+&":KYY8D^ZHD=#@ZAFHIJ%:C:J:CFHI':CZJ!:@6HEI\$:M:I^KC<|W0!QWO" ?1G0Q0+42UB-:I5RG M^4:R-'
 <3_ZO.AZG MZL:@3%=:IPOI-!P-:#;5V'MCL=IVOX8|M_&WKW\$6_W>F^N M&|13BW[T\$XAJ]I9J&:CFH-JKK'_S^&-QO'17/IO^L
 KY5 O_>F>+'R\$G6%:B:J M6.AFYHJ#:FZE-
 <[G:&#=S=B:LEA?50+CGT2(3IL1&G-TJY#?88"U< K^*M^ J1WA6G6.A??
 A9?:"DA OHY@ 53%2S4.U-&0?57%3S4.U'M0#50E2+**W9 M)NK.GW@IGCK&7]S/J^M"=XIA_O10X^DZ,SY#F^#Z*8Q3-1':?/.ZFN7O"
 M1S-J&:BFH5-JHYJ:BFH=J/H%J!:B6D11S4909 B,(SYU)R&9W1:MX&^:MR_6-7EQ^+>[3+UX15FB!C39%*:B/ITMDDT#P?
 JIFH9J&:71[HFWK@P8= M=\$07U3Q4U\$M0+40U2)*6Y?^:8@1&[&>7SQ=B[2>W\$E9K..F23+1<&? 6W MWU52<5>T!O7-
 I79RNO=I5WWCJOW#]0WX>K1S5_?8QOA=1G-Y/%YDR\$W%? M4/79(60+MA)D2>[T4\$^5CDN?)?/77!Q\$7/=:0\O= TG1<:HOR@&^
 M).FGU=,Y^!02P,\$% @ XIL603&3L\$@ P LPP !D IX;"JW;W)K M&UL05==;JHP%/TK5C9MK;21.)/.D!NT[.0R=4 MM/5AVH,)EV(UB5/?:
 %3:CY MI(&O!((E0=B.[GGGN/!>L,UHP B 6 1)LL MS<7064A97+BN2!0\$=%A!>3JS9SOC\$C5Y?>N*#B0F3*4M?WO #-."V=T<, MC?
 EHP)8R3F..1+++"/Z1)2MAXZV'D>N*7W"ZD'W-&@/(

#Q6H\$[M4OONMI 10YK@53!3(N"!T=7TA=#)W;0#.9DF_2D6'Y MA4@R&G"V1ES/5FBZ84(UUHH%BR= 1?O MT?7CDLHG:/R6P6R9
 F+S<@JZ(YR37 IT]@4DH:DX'[A2,=%X;E)Y02R1^BU> M)U!T4-?[@'S/Z&WR\$5B03B(ZO\$2T%4AU7Y=5R^!=KBVN938\$:UB7R&GB8<5
 M3F_1"U&0!:(.VH.^ J\$=* MB;WM&>V=5.P*[L7.#+T@C%\$LQ3O5 K^"D63>=?IVVUX>V1C^UG?L:NL M=L!C==T6!VRO#@?
 KVMW3U<>1IWXMJ=N> -A^)I(U)Z>KGXG#EO;0L"ME>\$ M)ET#NZY6P&-UW58*,\5!^L:[NL:1D&(VW3=5@%L+P, GTC7: X/ X'=G2NH
 MOL?S'Y&ULM5=::;]LV%/XKA#84+9!&-UMV4MN ;:EH'[9 M<,L#^M@I&-9B\$1Z)&TG ?4[I&3-3%UE(%NW%YN6<|UR^HT-RL./B4.X%'G*
 M.R:UDJI:UMRV@%.977? T.=Y90(9WPTMU]HOW?*)2ND%>S18TP06H'ZLYP)G=H42 MISDPF7)&"R'UMB]G?6UO!X/86=!=@3'6HYV#"
 (E\$:@^+>% M*629!D(W_BXQK+H:+^*9+1D5HZ%HDV4O&15\$8/I05_2IS..! N+4*WBE@G>JT+F@X)<* M_HF="E"IU3HO-
 1"MU0PH=M%"9Q(55T-!!1X261C01..DWVIBOE.DZ62B! MNRGJ|=S\$WKH#TR\$>R4#OZ #C!G,=DRG.L0TD-E; G/0;R@1%TTR2["D-C3[
 M@\$H %B%Y ^N@:W0%0UH1Z7926'6NV#6W>&S?KL/UL 2H9?%85O#]7%94 M0%D+< J,4&1L1"4):#^5^0.9UN0"K?.RKB* +:6M?
 *%5.5+:BKR%V.N(M,>2GX"YQOOF*HKE,*5P+BBN]IV^?2'OHMV! [FO%CW4UOY9I&+2P74H0 M6!&[WYQ
 ^=3'1LOLSEKR>81!YV@T!+%"S_1Q\$RF."AI^69-5QT6C2Z] M[K1-L+ Y62&[3 5'Q(9(7;<KD)@^R[J/26WCDCM5J1V& W<])][R*AF[CM'
 MUIC\$0RUE'1FSF'PUI]JVY0IFN5@% =2W8X:I\$XZU[4F MZWO^ =A1 +T1_ML:XB^@<8R;:3PVC)M\$RQL\$VS6\$M@132V*IO[5J; \W+Q
 M;FZDRJNJB29DD&2S1E'/=PP]9 M%&^08J+XVERR'[C"*[L9KO#9!D(+X/Z2XT6[G@#@U4-P]102P,\$% @ M,X!L6<'Y;P.' P #1(!D
 IX;"JW;W)K&UL MO9AK;JHP%, B15-TR9US840+@,D,(DN4]>JW>7#M]NOF"/M1]X2L @7992OC86 FO'IFCU:087Y)UT#D
 MDP5E&1;REBU-OF: XT*4I:9C69Z9X808DU%1=LTF(YJ+.%PS1#/LPRS;S-(MZ79LV.9]P4VR7 E58\$Y:<
 [R\$60#OU!=,WIDU)4XR(#RA!#%8C(VI/O/P)JY1 MX4,"6[YWC=2.W%Z1=V\CL]&&I1H\$*41":#;VL OT"YQ*X/PJ
 M)?*W?)*C+M8X\$G(T:WB*G:DJ8N"KL*M4Q0P0E3'NA5,/DVD3DS>4@&HCYCYC M&@ R0&%C;&H)=T ([+ "#2G1#/#I/WKJ@!)RM\$[V(D)-
 M!5Y*[XB@,<0>K]=/VC1FS%0=1Z<^SS,G%:@+;PO M4<>Z0([EN WMF9[N|S2]SM)% _XN>M@N?Y.32V0[3=\$/X5U33R]#>44P-
 4]N)DZO M/W#[LJF;?>.ZUF?-SC&AUK8-F?>5@O^"TI;S6@R&?TC!&MRMN? -F!,
 MGCCR/>M%2WK=KUN:WIGTQM ^C.OGZX@NP/VN2EUK:#3FUGF5R?,UPD+=,)" M3; #: [NUM=U6: ?F73DJ\$BXPB>
 "3:>8Q6B:T9R)IM:H>?:K!FZX0%F%A M]WA6>2O..E7#_4#" [W:ON]1B?ZCEXR3:J:ROY!_IUPGR=L\$ G+-0\$. "Z
 M5WO=^Y+7> \$A:ZU4>ORT>4W4&334!#LPK5^;UO # 7J% =TF69ZU#M)5] M[A#5"? UP@*=L%
 3I,#M0>WVX% ^LJ*W0SNV&!N71O\$]!>5!RA=DR M(1REL)"AK,N> !G RL.'D;0=;%90J."SM %Y0IP#\$O5D,\75&Z8JOL5H#X! MFOP
 4\$L#!!0 (#, .;%D%>&PO=VIR:W-H965T M\$82-(&L60/+/LVK3 ML5!=/\$E.TK^?)#M>UC7%7BQ1XCD\I\$EE>Z6?3(UHX2"X-/HMK:Y)LO4-0IJ
 M+E6#TMU42@MJG:FWO#0:1E @LDCJ=\$4":C MG:YUGJK6<25OK,*T05#O MD:O!%IOX.'MJVIM/RIYUM M;M!^:1:661@*9E
 :9B2H+&:1XO1]2KU L'A M\,L.=F#S^11J2=O?"GG4>P%:@JEAVND-/Y&3ZCFC(0'GNZJ)!" M[BZ71VIPI?A/5MIZ'EU%4%)&6VX?
 U/XSJOE,%^AN E?V>^<01%:ZP2=:@I M\$%QV?SWT=3@!])7 4D/2%X"OF< :0(E2.=LI#6#;4TS3:@ ;>CLUO0FT"
 MVF7#I/^+&ZO=+7,XF]KBS"##W#O.N:K,@:6J&%34XWP@[8M9=S -SS8E0+W MSLWX&Y,1ZV]I+E+T<99=G.1,G!G<*6EK
 [>RO/JO/!&:1^)4?@R>9-P@(TE MI/\$%)"R?D7/DZ_O AZ1MRTJ:&.: G^%:2,M*QEO?E+#!'HM7, G3!@K>NHRA MTDK
 2HFFM30TL*K@EFK)Y:DY>P\$*J5]K4"=P(F08 ?SET^G4U&Z6R2D=U1 MXO ZC>)D>C5-!K\N0W+2-0+U-&R3@<+'I [#
 <#K,ZR*TZ8OSI9OC,NS^T2/ MP!W56R8-<*P<97SYT:G2W6!UAE5-Z,U'95VGAVWMWB+4WL'=5\KU9V X /K MEO&4\$L#!!0 (#,
 :%GO83UD'@(+4\$ 9 >&PO=V]R:W-H965T MH#R!M."2,,56(5#3^M%);HJF^1" MK#IV9CO _OUL)Z2LHF@OB>]WW?
 7>Z2*1ZT26B@6%A9X%I3'U+2\$Z*[&B M>B1K%/:FD*JBOIIJ1W2MD.8>5'\$2A>&45)2)(\$V:Z721#:,&X\$K!J*JK^
 MS)+PRP8!R?>IN5OCE(FM1TAVLTS_5*68OT+&#F4@&F2@L9L'=^81NW@? M)A09^=P56RE?+%&0 Y+ B=(.28&=<
 [6N/"^3<5D9DOS0.H\$ I@,.G\$ LW M7[NM94LU+B3 Q7)3SH(O>18T(:JWGXCT[GQO!]KGV3SBTL=-1%FCC:PZ ML%50,=&^Z;KPOQ
 [EP!&1T@>@N80 .(X#O'&F5^,*6U- T4? (RD5-:G?P MO?%H6PT3[BNNC;*WS.),^D,:A\$('^%!+)"V-C:A@LT5#-&6SP!:K!AS:@
 M>V\$P7Y3\$1RV/= D:[71L+IT6Z;1AC, M46#!S/[2MUJV6=S2=[/PX3LS_5?BV@EDK,)J%#M_&)HR&0C3-O(WMOOWIT? MN3?
 ^N=W)=H5>:=J%?J1OX0&CH6E#>?42K=DE.P\ C:S]E6&CNU EC: PHJ M%V#O"VEGK3-<@OY/E?X%4\$L#!!0 (#,.%F.KI@)P, \$P4 9
 M>&PO=V]R:W-H965T H^9?:=+L/51\B+TA>T!.I-DXS-C#WGAR?39/X>4LSNR0\$R(20D-5<-&EDL@,%'A0FIB. M98W-
 %,>9.9 *O@V=3TG.DSB##44L3U- WJ&A)QFAF< S[T9X7>9>L 1 M;(% .6RH:)DU2O"GD+&89(A#.6)I-G,P5
 6OP>PXDU[E\$QE1TA+T7C0S S MK&)\$D#/"PHL_HZPA"0IF,0XOE6D1NVS #:OS^R R,F+R>PP@R5)OL8!W^> MB8\$""&>_D]"M4\$OH5?
 #Y)F+RB4V5K&OE1 -@.I M!C@5P+D5 *P PTN >P7@#>W5L"HLBIF^7?WZ,A4".Y=A MXU#MW 0<,L?2#-WMT%>[=G>
 [X"TOAG6#"6?>VTVG@/OZ -C.01HE=,X MB] &:\$R" =KN,0V40!%66 9(G7B#/#W9W9D2E%:7OB!>S\$S!%#CP\$]@C' MZ0=
 [L/W<%8.2;"3)BKIXG\$ V5H>I27](@W\$ M2A2+ET!41+(:=05%R=00TD;7?J?C%?E+?,\$W4": MDJIOSCK5CK\$/UDK7A,ZGA, L?5>/+]
 NJ,\87V;O4#JEO?>22>9(K6!X MK\$>^!MOX ?K:"V'UH/5[HKO3?5W>=9)XFLI;NMO7VY6+=!)D,H\G> MUO@U3O,4+:
 (0H3%=\WY6,DZ='Z2%*WT+59:V5856S-!AE,Y>(UV'IN1.O MV;7AFV-&U^]K[K_AOU&M'1/36VB=";NM;)XNMG,\$G+>(.9KW115AD42-
 MS8QS4874:GM+KI/T562FXV3E-2H)\$QF+0WGW&RX.5NK<^*EO(R+SS:P\ M9UMC&L490PF\$ FK=/XA%EI9'5V6#DX,]F1D1SDDJ: >
 Z%"@>L+/C<) M?8 X P=02P,% @ X!L6:\$ZU;4G P 9A(T!X;"S='EL97.N M>ULW5AM;JHP\$/XK4;LK30U0\$9*5D#:D"!VJ9*
 [8=]JPOQ@B7'SAS3P7]1M?8(+4AU@]61"-8 ON<-WESIB6.L5I =S2G6P++FH1^%+MS64M^"=S]I-W96>?O\F;??F&!RS#RDO:/
 M(+WJ='!B #'RY#CR0]P8!4NM5U^;HBYE)LZA: MSF BDY(&3X2/P@GA,*H8>.6D9'SES#TPS"27*M"88R4+EC]7P[NNAGT4L-3
 M,B&5C>TBN+ 39OD>L)Z!0.9Y^L 7.L-X6!&M]1*W9F(76^S,*C&#Z0**P4
 M675[7#C8&FR%2JC*HV3#=>MU.ROS7W#M!S7/WSP45!&^+=K FO,HL5 MO)? 2K+J[K(OV*NQ.3U?N|C^*8A,3D'D2?3DX%6*C)JS<>L
 WCE^6V LKSF C M\N4% /T& "Z8%PST*8&WI-IN8E>H?P, JH3A9)\$ZC-?9R7#YG8#Q,[Y,R] 3 M-(WC), \$R.IEX%4RPO"4)?/ULF#,PP.)
 I#_+5YMO\$.IP%6TT,=@NT4[T1L MIWBN ?G#3S2U%]M+ YX8%7 >@?B^&- 3_EJXABJBFG#GF <25..@5[T]V2 M(-E)X..O#_4O'&:A'
 KB&\$/@:<013 %HP) XMN?@WGD4K<^I://+TO@W M4\$L#!!0 (#,%F7BKL

-8?20\$3.8T.P6BP^0"X99K> M9!:GJX#X%&C-&^S]#CX]G. TOJ> 2X+96?)OKGMZ6!@LPV4 MPG[46U!X9*U-*1SNFKN!W1H0N=T N+
 (8).%P.BB%5,GG3 NU%F80[F@F9: MX; ?^"GAT?X[G?93EJYDH5T3LDWBX@8:54LJ3/D, ^28<+L1C] ^TT8^;^5\$ MLBTSN-!958)R M31P-
 %!Y0V8W.JYWERU0]P@AN94 MX@\$SSVOP_B :6#L1 SW+*ZD#ERY.O<%\$)EP) (3D#R=X3/O0/(\$0\$Y>A? (MIT*. L@1 3GM% (:JR+V2&
 [%]JXR2/5:G=6 M*K V #PB (B ('7%9F*LZWO=R M]M4K:4X(R, (D& JW#LH5X\$GA^W+ OLR\$LY\$JD@/C8\$[8(0:OE,Y/#I \$
 ME)1.SY:IT: ^670ZN] H(@=C/[#&APJE&]\$2DDE[MDP->2#/P7304J<4F+MLT_2C-ISYZI.8 KIV\]@)V973)ONH=&-7V3\$])NW9-
 #7FB4/;.%W,3%O MP&?Z!I*&S: <^>:4KX\$!GG*M,EL%OO&UHY0 DEC2*8" P4
 [!@*PL/E6]E+WKL%JD48E(6&L6PT*LV^&^RAYCDY(48%GJ\W'X93P,)Z)(EL8YG^]I]QO> %ZZHHON#8# 5=BWS -7G_M)?SS'U!+ P04 "
 S@&O9C-?K6X! #=% &@ 'AL+U]R96QS+W=O M]Q]N]R M3>9676 ;4G1#4WFQ^50ZC[+UEI-<=QHH?&>IX>)T9G1^] < _KBBNN?
 WL M\N &MOZ/P]JG&VZNLM:KZ)P-I?6ITO=ZONWT=*5.%E%ITNJA.M% E X=Q!#\$ MX8,,!)GP06L(6HC-J#
 <+T)7/L"]&4FP7HS:@W"]>CWBO T:168#>C'JS M +T916!>AO4VPC0VZ#>1H#>O4V O0VB\2 7H:U-N\4V G'[5U<\JSC?N_
 MDVH_OFOGI:>E^&BZYUPUG":>P%4\$L#!!0 (#,%D&5T)WCP\$ '5 M 3 6T-O;G1E;G1?5'EP97=-+GAM; V8S6["!\$7R7%*1%CI74_BYM
 MKRV'OH":(A%\$ENVH?#V=<*/U(I&("IU+K\$2[V,Z,O=)WR,1]:A%F[IW#0N MO3>/C+FLI]Z1]MJPDZA;2U]>+4+9F2VE
 MB8C0:LTPWGAAJ^*U&/)L4R%7 ME8]>-N&S4[J9Q18]T= /N+6:OI+8RJ521_VV;K)?@,JPY)Z.QJ7*F, &X2" MF)UT:='^>CJW0:W)6I53-)?

60\HZ5+%_Q9S?5N22?HD3&751J(QRG:WJT)(X M8TGFB3R=97L1 ?]SCI<..V>_&K_3J:/.%3.K38N3,S2Y7:'D;3=0Q,\$R'K5 M?
\2C8Y"~^GS43CNG \$SO<+V?VBZ>3C6+=??<9' 40S%" &UL4\$! A0#% M @_X!L6:K@\$O_N *P(!\$ (!KP &1O8U!R:WIS M+V-
O&UL4\$! A0#% @_X!L69E&PO=VJR:W-H965T&UL4\$! A0#% @_X!L67[7^2R0! N1 !@ M ("!K0X 'AL+W=OCATE@(%'0' 8" @903
IX;"JW;WK% & M @(%@% @>&PO=VJR:W-H965T&UL4\$! A0# M% @_X!L66LG[>R*">@ 0TP !@ ("!E1L 'AL+W=O M&PO=VJR:W-
H965T&UL4\$! A0#% @_X!L66YVA 4(M!P LO\$!@ ("!3\$ 'AL+W=O&PO=VJR:W-H965T&UL4\$! A0#% M @_X!L6=BXU9." +QL ID ("!_4.
'AL+W=OPR "#! &0 M@('U60 >&PO=VJR:W-H965T&UL4\$! A0#% @_X!L63<:IE<> P L0@ !D M ("!U\ 'AL+W=O&PO=VJR:W-
H965T&UL M4\$! A0#% @_X!L65EE)!W\$ @ "P8 !D ("!%VX M 'AL+W=OA M;(D" #%"!@ &0 @(\$2<0 >&PO=VJR:W-H965T&UL4\$! A0#%
@ M,X!L6>/!J05T @ (P8 !D ("!^'8 'AL+W=O&PO=VJR:W-H965T&UL4\$! A0#% @_X!L60>&PO=VJR:W-H965T&UL4\$! M A0#% @_
X!L6?%A/60> @ M00 !D ("!J('AL M+W=O&PO=VJR:W-H965TS !:0V|N=&5N=%)4>?E&UL4\$!%@ J "H 70L ,>T \$! end XML 47 Show.js
IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content
created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var
Show={} .Show.LastAR=null .Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE')var ref=((window)?
w.document:document).getElementById(r);if(ref){e.ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}
if(e.style.display='block')Show.LastAR=e;Show.hideAR=function(){ Show.LastAR.style.display='none';Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'
}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}} XML 48 report.css IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497;
font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-
top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report
table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width:
400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a,.pl a:visited { color: black; text-decoration: none; } /*
table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight:
bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-
align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-
word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report
td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /*
Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re,.report .reu { background-color: #def; } .report .reu td
{ border-bottom: 1px solid black; } /* Odd rows... */ .report .ro,.report .rou { background-color: white; } .report .rou td { border-bottom: 1px
solid black; } .report .rou table td,.report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-
space: nowrap; } /* styles for numeric types */ .report .num,.report .nump { text-align: right; white-space: nowrap; } .report .nump {
padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space:
normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic;
font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 50
FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 133 159 1 false 40 0 false 7 false false R1.htm 000 - Document - Document And
Entity Information Sheet http://geovax.com/20240930/role/statement-document-and-entity-information Document And Entity Information
Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet
http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated
Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets
(Current Period Unaudited) (Parentheticals) Sheet http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-
current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3
false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet
http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements
of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Changes in
Stockholders' Equity (Deficit) (Unaudited) Sheet http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-
in-stockholders-equity-deficit-unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)
Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet
http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements
of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Nature of Business Sheet
http://geovax.com/20240930/role/statement-note-1-nature-of-business Note 1 - Nature of Business Notes 7 false false R8.htm 007 - Disclosure
- Note 2 - Summary of Significant Accounting Policies Sheet http://geovax.com/20240930/role/statement-note-2-summary-of-significant-
accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Balance Sheet
Components Sheet http://geovax.com/20240930/role/statement-note-3-balance-sheet-components Note 3 - Balance Sheet Components Notes
9 false false R10.htm 009 - Disclosure - Note 4 - Notes Payable - Related Parties Notes http://geovax.com/20240930/role/statement-note-4-
notes-payable-related-parties Note 4 - Notes Payable - Related Parties Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Commitments
Sheet http://geovax.com/20240930/role/statement-note-5-commitments Note 5 - Commitments Notes 11 false false R12.htm 011 - Disclosure -
Note 6 - Stockholders' Equity Sheet http://geovax.com/20240930/role/statement-note-6-stockholders-equity Note 6 - Stockholders' Equity
Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Stock-Based Compensation Expense Sheet
http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense Note 7 - Stock-Based Compensation Expense Notes 13
false false R14.htm 013 - Disclosure - Note 8 - Revenue From Government Contract Sheet http://geovax.com/20240930/role/statement-note-8-
revenue-from-government-contract Note 8 - Revenue From Government Contract Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Net
Loss Per Share Sheet http://geovax.com/20240930/role/statement-note-9-net-loss-per-share Note 9 - Net Loss Per Share Notes 15 false false
R16.htm 015 - Disclosure - Note 10 - Income Taxes Sheet http://geovax.com/20240930/role/statement-note-10-income-taxes Note 10 - Income
Taxes Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Subsequent Events Sheet http://geovax.com/20240930/role/statement-note-
11-subsequent-events Note 11 - Subsequent Events Notes 17 false false R18.htm 995445 - Disclosure - Insider Trading Arrangements Sheet
http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 18 false false R19.htm 995462 - Disclosure -
Significant Accounting Policies (Policies) Sheet http://geovax.com/20240930/role/statement-significant-accounting-policies-policies
Significant Accounting Policies (Policies) Policies http://geovax.com/20240930/role/statement-note-2-summary-of-significant-accounting-
policies 19 false false R20.htm 995463 - Disclosure - Note 3 - Balance Sheet Components (Tables) Sheet
http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-tables Note 3 - Balance Sheet Components (Tables) Tables
http://geovax.com/20240930/role/statement-note-3-balance-sheet-components 20 false false R21.htm 995464 - Disclosure - Note 6 -
Stockholders' Equity (Tables) Sheet http://geovax.com/20240930/role/statement-note-6-stockholders-equity-tables Note 6 - Stockholders'
Equity (Tables) Tables http://geovax.com/20240930/role/statement-note-6-stockholders-equity 21 false false R22.htm 995465 - Disclosure -
Note 3 - Balance Sheet Components - Prepaid Expenses (Details) Sheet http://geovax.com/20240930/role/statement-note-3-balance-sheet-
components-prepaid-expenses-details Note 3 - Balance Sheet Components - Prepaid Expenses (Details) Details 22 false false R23.htm 995466
- Disclosure - Note 3 - Balance Sheet Components - Schedule of Property and Equipment (Details) Sheet
http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-property-and-equipment-details Note 3 - Balance
Sheet Components - Schedule of Property and Equipment (Details) Details 23 false false R24.htm 995467 - Disclosure - Note 3 - Balance
Sheet Components - Schedule of Other Assets (Details) Sheet http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-
schedule-of-other-assets-details Note 3 - Balance Sheet Components - Schedule of Other Assets (Details) Details 24 false false R25.htm
995468 - Disclosure - Note 3 - Balance Sheet Components - Schedule of Accrued Expenses (Details) Sheet
http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-accrued-expenses-details Note 3 - Balance Sheet
Components - Schedule of Accrued Expenses (Details) Details 25 false false R26.htm 995469 - Disclosure - Note 4 - Notes Payable - Related
Parties (Details Textual) Notes http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties-details-textual Note 4 - Notes
Payable - Related Parties (Details Textual) Details http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties 26 false
false R27.htm 995470 - Disclosure - Note 5 - Commitments (Details Textual) Sheet http://geovax.com/20240930/role/statement-note-5-

"Notes", "order": "7", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R8": { "role": "http://geovax.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "007 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R9": { "role": "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components", "longName": "008 - Disclosure - Note 3 - Balance Sheet Components", "shortName": "Note 3 - Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R10": { "role": "http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties", "longName": "009 - Disclosure - Note 4 - Notes Payable - Related Parties", "shortName": "Note 4 - Notes Payable - Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R11": { "role": "http://geovax.com/20240930/role/statement-note-5-commitments", "longName": "010 - Disclosure - Note 5 - Commitments", "shortName": "Note 5 - Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R12": { "role": "http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "longName": "011 - Disclosure - Note 6 - Stockholders' Equity", "shortName": "Note 6 - Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R13": { "role": "http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense", "longName": "012 - Disclosure - Note 7 - Stock-Based Compensation Expense", "shortName": "Note 7 - Stock-Based Compensation Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R14": { "role": "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract", "longName": "013 - Disclosure - Note 8 - Revenue From Government Contract", "shortName": "Note 8 - Revenue From Government Contract", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "govx:GovernmentGrantsandContractsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "govx:GovernmentGrantsandContractsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R15": { "role": "http://geovax.com/20240930/role/statement-note-9-net-loss-per-share", "longName": "014 - Disclosure - Note 9 - Net Loss Per Share", "shortName": "Note 9 - Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R16": { "role": "http://geovax.com/20240930/role/statement-note-10-income-taxes", "longName": "015 - Disclosure - Note 10 - Income Taxes", "shortName": "Note 10 - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R17": { "role": "http://geovax.com/20240930/role/statement-note-11-subsequent-events", "longName": "016 - Disclosure - Note 11 - Subsequent Events", "shortName": "Note 11 - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R19": { "role": "http://geovax.com/20240930/role/statement-significant-accounting-policies-policies", "longName": "995462 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R20": { "role": "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-tables", "longName": "995463 -

[Disclosure - Note 3 - Balance Sheet Components \(Tables\)](#), "shortName": "Note 3 - Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "d 2024-01-01 2024-09-30", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d 2024-01-01 2024-09-30", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R21": { "role": "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-tables", "longName": "995464 - Disclosure - Note 6 - Stockholders' Equity (Tables)", "shortName": "Note 6 - Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "d 2024-01-01 2024-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d 2024-01-01 2024-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R22": { "role": "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-prepaid-expenses-details", "longName": "995465 - Disclosure - Note 3 - Balance Sheet Components - Prepaid Expenses (Details)", "shortName": "Note 3 - Balance Sheet Components - Prepaid Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "i 2024-09-30", "name": "govx:PrepaidClinicalTrialExpensesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i 2024-09-30", "name": "govx:PrepaidClinicalTrialExpensesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R23": { "role": "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-property-and-equipment-details", "longName": "995466 - Disclosure - Note 3 - Balance Sheet Components - Schedule of Property and Equipment (Details)", "shortName": "Note 3 - Balance Sheet Components - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "i 2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i 2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R24": { "role": "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-other-assets-details", "longName": "995467 - Disclosure - Note 3 - Balance Sheet Components - Schedule of Other Assets (Details)", "shortName": "Note 3 - Balance Sheet Components - Schedule of Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "i 2024-09-30", "name": "govx:PrepaidClinicalTrialExpensesNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i 2024-09-30", "name": "govx:PrepaidClinicalTrialExpensesNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R25": { "role": "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-accrued-expenses-details", "longName": "995468 - Disclosure - Note 3 - Balance Sheet Components - Schedule of Accrued Expenses (Details)", "shortName": "Note 3 - Balance Sheet Components - Schedule of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "i 2024-09-30", "name": "us-gaap:AccruedSalariesCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i 2024-09-30", "name": "us-gaap:AccruedSalariesCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R26": { "role": "http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties-details-textual", "longName": "995469 - Disclosure - Note 4 - Notes Payable - Related Parties (Details Textual)", "shortName": "Note 4 - Notes Payable - Related Parties (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "i 2024-05-10 DebtInstrumentAxis-TheNotesMember", "name": "govx:DebtInstrumentOriginalIssueDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": ["p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i 2024-05-10 DebtInstrumentAxis-TheNotesMember", "name": "govx:DebtInstrumentOriginalIssueDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": ["p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R27": { "role": "http://geovax.com/20240930/role/statement-note-5-committments-details-textual", "longName": "995470 - Disclosure - Note 5 - Commitments (Details Textual)", "shortName": "Note 5 - Commitments (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "i 2024-09-30 LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember", "name": "govx:DebtInstrumentOriginalIssueDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": ["p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i 2024-09-30 LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember", "name": "govx:DebtInstrumentOriginalIssueDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": ["p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R28": { "role": "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "longName": "995471 - Disclosure - Note 6 - Stockholders' Equity (Details Textual)", "shortName": "Note 6 - Stockholders' Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "i 2024-01-16", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i 2024-01-16", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "R29": { "role": "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-stock-warrants-details", "longName": "995472 - Disclosure - Note 6 - Stockholders' Equity - Schedule of Stock Warrants (Details)", "shortName": "Note 6 - Stockholders' Equity - Schedule of Stock Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "i 2024-09-30", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i 2024-09-30", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "govx20240930_10q.htm", "first": true, "unique": true } }] }

"August212024OfferingMember", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "August 21 2024 Offering [Member]", "documentation": "Represents August 21 2024 Offering." } } }, "auth_ref": [] }, "govx_August212024PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "August212024PrefundedWarrantsMember", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "August 21, 2024 Prefunded Warrants [Member]", "documentation": "Represents August 21, 2024 Prefunded Warrants." } } }, "auth_ref": [] }, "govx_August302024CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "August302024CommonWarrantsMember", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "August 30 2024 Common Warrants [Member]", "documentation": "Represents August 30 2024 Common Warrants." } } }, "auth_ref": [] }, "govx_August302024OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "August302024OfferingMember", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "August 30 2024 Offering [Member]", "documentation": "Represents August 30 2024 Offering." } } }, "auth_ref": [] }, "govx_August302024PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "August302024PrefundedWarrantsMember", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "August 30 2024 Prefunded Warrants [Member]", "documentation": "Represents August 30 2024 Prefunded Warrants." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense", "http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense-details-textual"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229"] }, "govx_BARDAContractMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "BARDAContractMember", "presentation": ["http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract"], "lang": { "en-us": { "role": { "label": "BARDA Contract [Member]", "documentation": "Represents BARDA Contract." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r8", "r63", "r413"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashAndCashEquivalents", "weight": null, "order": null, "root": true } } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r8", "r32", "r79"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r32"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbri.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_CityAreaCode", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r58", "r68", "r69", "r70", "r83", "r102", "r103", "r105", "r107", "r114", "r115", "r130", "r145", "r147", "r148", "r149", "r152", "r153", "r182", "r183", "r185", "r188", "r194", "r275", "r329", "r330", "r331", "r332", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r355", "r376", "r393", "r403", "r404", "r405", "r406", "r407", "r471", "r481", "r488"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r11"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas call options are issued by the company and are not guaranteed by the company." } } }] }

options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-stock-warrants-details"], "lang": { "en-us": { "role": { "label": "Exercise Price (in dollars per share)", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r195"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r195"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-stock-warrants-details"], "lang": { "en-us": { "role": { "label": "Number of Shares (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "govx_ClassOfWarrantOrRightWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://geovax.com/20240930", "localname": "ClassOfWarrantOrRightWarrantsExercised", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "govx_ClassOfWarrantOrRightWarrantsExercised", "terseLabel": "Class of Warrant or Right, Warrants Exercised (in shares)", "documentation": "Number of warrants exercised during the period." } } }, "auth_ref": [] }, "us-gaap_CommitmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsDisclosureTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-note-5-commitments"], "lang": { "en-us": { "role": { "label": "Commitments Disclosure [Text Block]", "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights." } } }, "auth_ref": ["r38"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r20"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r452", "r453", "r454", "r456", "r457", "r458", "r459", "r484", "r485", "r487", "r535", "r583", "r584"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r20"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r20", "r355"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r20"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r5", "r20", "r355", "r373", "r584", "r585"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Issued and outstanding shares \u2013 8,609,308 and 1,977,152 at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r20", "r304", "r446"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r39", "r81", "r134", "r135", "r136", "r137", "r138", "r143", "r144", "r154", "r160", "r161", "r162", "r163", "r164", "r165", "r170", "r177", "r178", "r179", "r284"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r6", "r15", "r16", "r45", "r47", "r85", "r155", "r156", "r157", "r158", "r159", "r161", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r176", "r423", "r424", "r425", "r426", "r427", "r437", "r482", "r497", "r498", "r499", "r539", "r541"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r155", "r284", "r285", "r424"] }

"r425", "r437"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r18", "r156"] }, "govx_DebtInstrumentMaturityRequirementMinimumGrossProceedsFromCommonStockIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://geovax.com/20240930", "localname": "DebtInstrumentMaturityRequirementMinimumGrossProceedsFromCommonStockIssuance", "crdr": "credit", "presentation": ["http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties-details-textual"], "lang": { "en-us": { "role": { "label": "govx_DebtInstrumentMaturityRequirementMinimumGrossProceedsFromCommonStockIssuance", "terseLabel": "Debt Instrument, Maturity Requirement, Minimum Gross Proceeds From Common Stock Issuance", "documentation": "Minimum amount of gross proceeds received from issuance of common stock for debt to mature under debt instrument." } } }, "auth_ref": [], "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties", "http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r6", "r85", "r155", "r156", "r157", "r158", "r159", "r161", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r176", "r423", "r424", "r425", "r426", "r427", "r437", "r482", "r497", "r498", "r499", "r539", "r541"] }, "govx_DebtInstrumentOriginalIssueDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://geovax.com/20240930", "localname": "DebtInstrumentOriginalIssueDiscountRate", "presentation": ["http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties-details-textual"], "lang": { "en-us": { "role": { "label": "govx_DebtInstrumentOriginalIssueDiscountRate", "terseLabel": "Debt Instrument, Original Issue Discount Rate", "documentation": "Original issue discount rate under debt instrument." } } }, "auth_ref": [], "govx_December2023PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "December2023PrefundedWarrantsMember", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "December2023PrefundedWarrantsMember", "documentation": "Represents December 2023 Pre-funded Warrants [Member].", "auth_ref": [] } } }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-tables"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [], "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization expense", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r3", "r112", "r121", "r125", "r418", "r419"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r201", "r203", "r231", "r232", "r234", "r431"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://geovax.com/20240930/role/statement-note-1-nature-of-business", "http://geovax.com/20240930/role/statement-note-10-income-taxes", "http://geovax.com/20240930/role/statement-note-11-subsequent-events", "http://geovax.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components", "http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties", "http://geovax.com/20240930/role/statement-note-5-commitments", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract", "http://geovax.com/20240930/role/statement-note-9-net-loss-per-share"], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [], "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-OT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [], "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [], "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [], "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [], "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_DocumentPeriodEndDate", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [], "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r466"], "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r467"], "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_DocumentType", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.' " } } }, "auth_ref": [], "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-earnings-per-share"] }] }

and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r464"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityFileNumber", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r464"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityInteractiveDataCurrent", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)" } } }, "auth_ref": ["r470"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityRegistrantName", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r464"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityShellCompany", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r464"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r464"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r464"] }, "govx_EquipmentAndFurnishingsMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "EquipmentAndFurnishingsMember", "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Equipment and Furnishings [Member]", "documentation": "Represents equipment and furnishings." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_EquityAbstract", "terseLabel": "Stockholders\u2019 equity", "documentation": "Stockholders\u2019 equity" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r5", "r59", "r74", "r75", "r76", "r86", "r87", "r88", "r90", "r95", "r97", "r99", "r113", "r131", "r132", "r133", "r196", "r246", "r247", "r253", "r254", "r255", "r257", "r258", "r259", "r264", "r265", "r266", "r267", "r268", "r269", "r271", "r276", "r277", "r278", "r279", "r280", "r281", "r286", "r287", "r293", "r310", "r322", "r323", "r324", "r335", "r393"] }, "govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember", "presentation": ["http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense", "http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense-details-textual"], "lang": { "en-us": { "role": { "label": "Expense Related To Consulting And Investment Banking Agreements [Member]", "documentation": "Disclosure of expense related to consulting and investment banking agreements." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r27", "r378"] }, "us-gaap_GovernmentAssistanceAwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentAssistanceAwardAmount", "crdr": "debit", "presentation": ["http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_GovernmentAssistanceAwardAmount", "terseLabel": "Government Assistance, Award Amount", "documentation": "Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan." } } }, "auth_ref": ["r538"] }, "us-gaap_GovernmentAssistanceTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentAssistanceTypeAxis", "presentation": ["http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract"], "lang": { "en-us": { "role": { "label": "Government Assistance, Type [Axis]", "documentation": "Information by type of government assistance." } } }, "auth_ref": ["r283"] }, "us-gaap_GovernmentAssistanceTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentAssistanceTypeDomain", "presentation": ["http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract-details-textual"], "lang": { "en-us": { "role": { "label": "Government Assistance, Type [Domain]", "documentation": "Type of government assistance." } } }, "auth_ref": ["r283"] }, "govx_GovernmentGrantsandContractsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://geovax.com/20240930", "localname": "GovernmentGrantsandContractsTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract"], "lang": { "en-us": { "role": { "label": "Government Grants and Contracts [Text Block]", "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction." } } }, "auth_ref": [] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantMember", "presentation": ["http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract-details-textual"], "lang": { "en-us": { "role": { "label": "GrantMember", "documentation": "GrantMember" } } } } }

"role": { "label": "Grant [Member]", "documentation": "Award of money not required to be repaid." } }, "auth_ref": ["r507"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-note-10-income-taxes"] }, "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r84", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r250", "r251", "r252", "r334", "r432"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://geovax.com/20240930/role/statement-note-10-income-taxes-details-textual"] }, "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "terseLabel": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r54", "r56", "r98", "r99", "r112", "r122", "r125", "r239", "r240", "r249", "r312", "r432"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"] }, "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"] }, "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"] }, "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:", "auth_ref": [] } } }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"] }, "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherOperatingAssets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"] }, "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r2"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": ["r468"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties-details-textual"] }, "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseDebt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r29", "r174", "r180", "r426", "r427"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"] }, "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseNonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r120", "r478"] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties-details-textual"] }, "lang": { "en-us": { "role": { "label": "us-gaap_InterestPayableCurrentAndNoncurrent", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": ["r46", "r553"] }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterimPeriodCostsNotAllocableDomain", "presentation": ["http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense"] }, "lang": { "en-us": { "role": { "label": "Interim Period Costs Not Allocable [Domain]", "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred." } } }, "auth_ref": ["r9"] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"] }, "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r112", "r119", "r125", "r418", "r477"] }, "govx_July2024CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "July2024CommonWarrantsMember", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity"] }, "lang": { "en-us": { "role": { "label": "July 2024 Common Warrants [Member]", "documentation": "Represents July 2024 Common Warrants." } } }, "auth_ref": [] }, "govx_July2024OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "July2024OfferingMember", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity"] }, "lang": { "en-us": { "role": { "label": "July 2024 Offering [Member]", "documentation": "Represents July 2024 Offering." } } }, "auth_ref": [] }, "govx_July2024PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "July2024PrefundedWarrantsMember", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity"] }, "lang": { "en-us": { "role": { "label": "July 2024 Pre-funded Warrants [Member]", "documentation": "Represents July 2024 Pre-funded Warrants." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": ["http://geovax.com/20240930/role/statement-note-5-commitments"] }, "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r290", "r472"] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": ["http://geovax.com/20240930/role/statement-note-5-commitments"] }, "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r290", "r472"] }, "us-

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://geovax.com/20240930/role/statement-note-1-nature-of-business"], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r55", "r57"], "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r78"], "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "auth_ref": [], "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r78"], "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "auth_ref": [], "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r32", "r33", "r34"], "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "auth_ref": [], "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r26", "r34", "r49", "r60", "r72", "r73", "r76", "r83", "r89", "r91", "r92", "r93", "r94", "r95", "r98", "r99", "r104", "r130", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r256", "r259", "r273", "r275", "r309", "r375", "r391", "r392", "r460", "r503"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." }, "auth_ref": [], "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r469"], "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r469"], "us-gaap_NonmonetaryTransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonmonetaryTransactionTypeAxis", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Axis]" } } }, "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." }, "auth_ref": ["r291", "r292", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445"], "us-gaap_NonmonetaryTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonmonetaryTransactionTypeDomain", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Domain]" } } }, "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." }, "auth_ref": ["r291", "r292", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445"], "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income (expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r28"], "govx_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://geovax.com/20240930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [], "govx_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://geovax.com/20240930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [], "govx_OfficeAndLaboratoryLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "OfficeAndLaboratoryLeaseAgreementMember", "presentation": ["http://geovax.com/20240930/role/statement-note-5-commitments", "http://geovax.com/20240930/role/statement-note-5-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "Office and Laboratory Lease Agreement [Member]" } } }, "documentation": "Information" }}

pertaining to office and laboratory lease agreement." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r52", "r417", "r489", "r490", "r491", "r492", "r493"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://geovax.com/20240930/role/statement-note-5-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r542"] }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-accrued-expenses-details"], "lang": { "en-us": { "role": { "label": "Other accrued expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other." } } }, "auth_ref": ["r46"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-other-assets-details": { "parentTag": "null", "weight": null, "order": null, "root": true } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-other-assets-details": { "lang": { "en-us": { "role": { "label": "Other assets", "totalLabel": "Total other assets", "documentation": "Amount of noncurrent assets classified as other." } } } }, "auth_ref": ["r66"] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-prepaid-expenses-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-prepaid-expenses-details"], "lang": { "en-us": { "role": { "label": "Other prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r475", "r496"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r30"] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533"] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://geovax.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "govx_PrepaidClinicalTrialExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://geovax.com/20240930", "localname": "PrepaidClinicalTrialExpensesCurrent", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-prepaid-expenses-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-prepaid-expenses-details"], "lang": { "en-us": { "role": { "label": "Prepaid clinical trial costs (current portion)", "documentation": "Amount of prepaid clinical trial expenses in the next 12 months" } } }, "auth_ref": [] }, "govx_PrepaidClinicalTrialExpensesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://geovax.com/20240930", "localname": "PrepaidClinicalTrialExpensesNoncurrent", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-other-assets-details": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-other-assets-details"], "lang": { "en-us": { "role": { "label": "Prepaid clinical trial costs (noncurrent portion)", "documentation": "Amount of prepaid clinical trial expenses after the next 12 months" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-prepaid-expenses-details": { "parentTag": "null", "weight": null, "order": null, "root": true } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "totalLabel": "Total prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r476"] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-prepaid-expenses-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-prepaid-expenses-details"], "lang": { "en-us": { "role": { "label": "Prepaid insurance premiums", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future" } } } }

period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r414", "r421", "r496"] }, "us-gaap_PrepaidRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidRent", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-prepaid-expenses-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-prepaid-expenses-details"], "lang": { "en-us": { "role": { "label": "Prepaid rent", "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r415", "r422", "r496"] }, "govx_PrepaidTechnologyLicenseFees": { "xbrltype": "monetaryItemType", "nsuri": "http://geovax.com/20240930", "localname": "PrepaidTechnologyLicenseFees", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-other-assets-details": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-other-assets-details"], "lang": { "en-us": { "role": { "label": "Prepaid technology license fees", "documentation": "Represents prepaid technology license fees." } } }, "auth_ref": [], "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://geovax.com/20240930/role/statement-note-11-subsequent-events-details-textual"], "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfCommonStock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "govx_ProceedsFromIssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://geovax.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Net proceeds from sale of common stock and warrants", "documentation": "The cash inflow from issuance of common stock and warrants." } } }, "auth_ref": [], "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": ["http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfDebt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r480"] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "documentation": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r1", "r329"], "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Net proceeds from issuance of notes payable \u2013 related parties", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": ["r7"], "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual": { "lang": { "en-us": { "role": { "label": "Net proceeds from warrant exercise", "documentation": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r479"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract-details-textual"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r126", "r300", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r412", "r429", "r447", "r448", "r449", "r450", "r451", "r501", "r502", "r506", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract-details-textual"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r126", "r300", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r412", "r429", "r447", "r448", "r449", "r450", "r451", "r501", "r502", "r506", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]" } } }, "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "auth_ref": ["r4", "r289"], "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Total property and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r37", "r64", "r308"], "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-property-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Total property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r4", "r289", "r302", "r308", "r446"], "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-tables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r4"], "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-property-and-equipment-details"] } }

"lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r37", "r289"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://geovax.com/20240930/role/statement-note-11-subsequent-events", "http://geovax.com/20240930/role/statement-note-11-subsequent-events-details-textual", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract-details-textual"] }, "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r139", "r140", "r141", "r142", "r199", "r200", "r226", "r227", "r228", "r236", "r274", "r297", "r298", "r299", "r320", "r321", "r327", "r347", "r348", "r398", "r399", "r400", "r401", "r402", "r409", "r410", "r420", "r428", "r430", "r433", "r434", "r435", "r436", "r448", "r454", "r500", "r505", "r536", "r547", "r548", "r549", "r550", "r551"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://geovax.com/20240930/role/statement-note-11-subsequent-events", "http://geovax.com/20240930/role/statement-note-11-subsequent-events-details-textual", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract-details-textual"] }, "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r139", "r140", "r141", "r142", "r199", "r200", "r226", "r227", "r228", "r236", "r274", "r297", "r298", "r299", "r320", "r321", "r327", "r347", "r348", "r398", "r399", "r400", "r401", "r402", "r409", "r410", "r420", "r428", "r430", "r433", "r434", "r435", "r436", "r448", "r454", "r500", "r505", "r536", "r547", "r548", "r549", "r550", "r551"] }, "govx_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "RegisteredDirectOfferingMember", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract-details-textual"] }, "lang": { "en-us": { "role": { "label": "Registered Direct Offering [Member]" } } }, "documentation": "Represents registered direct offering." } }], "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap RepaymentsOfNotesPayable", "negatedLabel": "Repayment of notes payable \u2013 related parties" } } }, "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } }, "auth_ref": ["r31"], "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r237", "r411", "r418", "r552"], "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r22", "r41", "r305", "r325", "r326", "r333", "r356", "r446"], "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"] }, "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r59", "r86", "r87", "r88", "r90", "r95", "r97", "r99", "r131", "r132", "r133", "r246", "r247", "r253", "r254", "r255", "r257", "r258", "r259", "r264", "r266", "r267", "r269", "r271", "r286", "r287", "r322", "r324", "r335", "r584"] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Revenue from government contract", "terseLabel": "Revenue from Contract with Customer Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r50", "r51", "r112", "r117", "r118", "r123", "r125", "r126", "r127", "r128", "r197", "r198", "r300"], "govx_ReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "ReverseStockSplitMember", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity"] }, "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual": { "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Member]", "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding." } } } }, "auth_ref": [], "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r469"], "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r469"], "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://geovax.com/20240930/role/statement-note-11-subsequent-events"] }, "http://geovax.com/20240930/role/statement-note-11-subsequent-events-details-textual": { "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } } }, "auth_ref": [], "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-tables"] }, "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [], "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-tables"] }, "lang": { "en-us": { "role": { "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [], "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-tables"] }, "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return." } } }

potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r11"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r463"] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "calculation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-other-assets-details"], "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 }, }, "presentation": ["http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-other-assets-details"], "lang": { "en-us": { "role": { "label": "Deposits", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": ["r474"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r465"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r213"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r211"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r207", "r208"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r207", "r208"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": ["http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense", "http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense-details-textual"], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r211"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r43"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://geovax.com/20240930/role/statement-note-11-subsequent-events-details-textual", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "terseLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [] }

"http://geovax.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r35", "r80"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://geovax.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r58", "r68", "r69", "r70", "r83", "r102", "r103", "r105", "r107", "r114", "r115", "r130", "r145", "r147", "r148", "r149", "r152", "r153", "r182", "r183", "r185", "r188", "r194", "r275", "r329", "r330", "r331", "r332", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r355", "r376", "r393", "r403", "r404", "r405", "r406", "r407", "r471", "r481", "r488"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r5", "r20", "r23", "r24", "r59", "r74", "r75", "r76", "r86", "r87", "r88", "r90", "r95", "r97", "r99", "r113", "r131", "r132", "r133", "r196", "r246", "r247", "r253", "r254", "r255", "r257", "r258", "r259", "r264", "r265", "r266", "r267", "r268", "r269", "r271", "r276", "r277", "r278", "r279", "r280", "r281", "r286", "r287", "r293", "r310", "r322", "r323", "r324", "r335", "r393"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://geovax.com/20240930/role/statement-note-1-nature-of-business", "http://geovax.com/20240930/role/statement-note-10-income-taxes", "http://geovax.com/20240930/role/statement-note-10-income-taxes-details-textual", "http://geovax.com/20240930/role/statement-note-11-subsequent-events", "http://geovax.com/20240930/role/statement-note-11-subsequent-events-details-textual", "http://geovax.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-prepaid-expenses-details", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-accrued-expenses-details", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-other-assets-details", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-property-and-equipment-details", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-tables", "http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties", "http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties-details-textual", "http://geovax.com/20240930/role/statement-note-5-commitments", "http://geovax.com/20240930/role/statement-note-5-commitments-details-textual", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-tables", "http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense", "http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense-details-textual", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract-details-textual", "http://geovax.com/20240930/role/statement-note-9-net-loss-per-share", "http://geovax.com/20240930/role/statement-note-9-net-loss-per-share-details-textual", "http://geovax.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r86", "r87", "r88", "r113", "r287", "r300", "r328", "r346", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r374", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r393", "r455"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://geovax.com/20240930/role/statement-note-1-nature-of-business", "http://geovax.com/20240930/role/statement-note-10-income-taxes", "http://geovax.com/20240930/role/statement-note-10-income-taxes-details-textual", "http://geovax.com/20240930/role/statement-note-11-subsequent-events", "http://geovax.com/20240930/role/statement-note-11-subsequent-events-details-textual", "http://geovax.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-prepaid-expenses-details", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-accrued-expenses-details", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-other-assets-details", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-schedule-of-property-and-equipment-details", "http://geovax.com/20240930/role/statement-note-3-balance-sheet-components-tables", "http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties", "http://geovax.com/20240930/role/statement-note-4-notes-payable-related-parties-details-textual", "http://geovax.com/20240930/role/statement-note-5-commitments", "http://geovax.com/20240930/role/statement-note-5-commitments-details-textual", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-tables", "http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense", "http://geovax.com/20240930/role/statement-note-7-stockbased-compensation-expense-details-textual", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract", "http://geovax.com/20240930/role/statement-note-8-revenue-from-government-contract-details-textual", "http://geovax.com/20240930/role/statement-note-9-net-loss-per-share", "http://geovax.com/20240930/role/statement-note-9-net-loss-per-share-details-textual", "http://geovax.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r86", "r87", "r88", "r113", "r129", "r287", "r300", "r328", "r346", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r374", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r393", "r455"] }, "govx_StockIncentivePlan2020Member": { "xbrltype": "domainItemType", "nsuri": "http://geovax.com/20240930", "localname": "StockIncentivePlan2020Member", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Stock Incentive Plan 2020 [Member]", "documentation": "Represents information related to 2020 stock incentive plan." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services (in shares)", "terseLabel": "Stock Issued During Period, Shares Issued for Services (in shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } } }

}, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of common stock and warrants for cash (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r5", "r19", "r20", "r41", "r329", "r393", "r404"] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited", "http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Fractional share roundup following reverse split (in shares)", "terseLabel": "Stock Issued During Period, Shares, Reverse Stock Splits (in shares)", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": ["r5"] }, "govx_StockIssuedDuringPeriodSharesWarrantCashlessExercise": { "xbrltype": "sharesItemType", "nsuri": "http://geovax.com/20240930", "localname": "StockIssuedDuringPeriodSharesWarrantCashlessExercise", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "govx StockIssuedDuringPeriodSharesWarrantCashlessExercise", "terseLabel": "Stock Issued During Period, Shares, Warrant Cashless Exercise (in shares)", "documentation": "Number of shares issued during period from warrants cashless exercised." } } }, "auth_ref": [] }, "govx_StockIssuedDuringPeriodSharesWarrantExercise": { "xbrltype": "sharesItemType", "nsuri": "http://geovax.com/20240930", "localname": "StockIssuedDuringPeriodSharesWarrantExercise", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "govx StockIssuedDuringPeriodSharesWarrantExercise", "terseLabel": "Stock Issued During Period, Shares, Warrant Exercise (in shares)", "documentation": "Number of shares issued during the period as a result of warrant exercise." } } }, "auth_ref": [] }, "govx_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://geovax.com/20240930", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon warrant exercise (in shares)", "terseLabel": "Stock Issued During Period, Shares, Warrants Exercised", "documentation": "Number of new shares of common stock issued during the period upon exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services", "terseLabel": "Stock Issued During Period, Value Issued in Lieu of Cash for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Sale of common stock and warrants for cash", "terseLabel": "Stock Issued During Period, Value of New Stock Issued During the Period. Includes shares issued in an initial public offering or a secondary public offering.", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r5", "r19", "r20", "r41", "r335", "r393", "r404", "r461"] }, "govx_StockIssuedDuringPeriodValueReverseStockSplits": { "xbrltype": "monetaryItemType", "nsuri": "http://geovax.com/20240930", "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "crdr": "credit", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Fractional share roundup following reverse split", "terseLabel": "Stock Issued During Period, Value Reverse Stock Splits", "documentation": "Reduction in value of shares as a result of reverse stock split." } } }, "auth_ref": [] }, "govx_StockIssuedDuringPeriodValueWarrantExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://geovax.com/20240930", "localname": "StockIssuedDuringPeriodValueWarrantExercise", "crdr": "credit", "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon warrant exercise", "terseLabel": "Stock Issued During Period, Value Warrant Exercise", "documentation": "The gross value of stock issued during the period upon the exercise of warrants." } } }, "auth_ref": [] }, "govx_StockOfferingMaximumAggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://geovax.com/20240930", "localname": "StockOfferingMaximumAggregateOfferingPrice", "crdr": "credit", "presentation": ["http://geovax.com/20240930/role/statement-note-11-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "govx StockOfferingMaximumAggregateOfferingPrice", "terseLabel": "Stock Offering, Maximum Aggregate Offering Price", "documentation": "Maximum aggregate offering price for stock offering." } } }, "auth_ref": [] }, "govx_StockOfferingSharesAvailableForIssuanceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://geovax.com/20240930", "localname": "StockOfferingSharesAvailableForIssuanceValue", "crdr": "credit", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "govx_StockOfferingSharesAvailableForIssuanceValue", "terseLabel": "Stock Offering, Shares Available for Issuance, Value", "documentation": "Amount of equity available for future issuance." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "presentation": ["http://geovax.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://geovax.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "terseLabel": "Stockholders' Equity", "documentation": "Total stockholders' equity for the period." } } }, "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." }, "auth_ref": ["r20", "r23", "r24", "r36", "r357", "r373", "r394", "r395", "r446", "r462", "r483", "r495", "r537", "r584"] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity Note Disclosure Text Block", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r40", "r82", "r181", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r196", "r270", "r396", "r397", "r408"] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": ["http://geovax.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": ["r42"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://geovax.com/20240930/role/statement-note-11-subsequent-events"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event Member", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r282", "r295"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://geovax.com/20240930/role/statement-note-11-subsequent-events", "http://geovax.com/20240930/role/statement-note-11-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type Axis", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r282", "r295"] }, "us-gaap_SubsequentEventDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventDomain", "presentation": ["http://geovax.com/20240930/role/statement-note-11-subsequent-events", "http://geovax.com/20240930/role/statement-note-11-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type Domain", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r282", "r295"] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://geovax.com/20240930/role/statement-note-11-subsequent-events"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events Text Block", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were" } } } }

"https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 54 0001437749-24-034530-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-034530-xbrl.zip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|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|FM41VOP0'IRG2Z(+ M)9+K8 %BM,IT@RXY)4WT?\$.P\LO)-8KC#P|T&+R M0LA3F=UNP2X!E.VD.55YX9>/(;"UH ._)!)">DU^H, #7AEJPIO2XSM&U MCE(ZI"LR?>SD0J|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|O^=:=:=?7LW&Q]: "/5? UJO>=\$OEPJGYG0)4OO90ZH ML4Z-X Y;^)GO?N!T@>(+EGD)R MOZ:)6ESVXOK![!N+S#FZWO2)T.KN!#M MLX67,3TL)E7%=&R&E=NU9M2TM,! C)&FS&7I?>CH'+?N>E6W0:[G7_0IU@+ MO?@ [N:VX?/LRUH01]3[!A!ZTXI> +\$WN0[G_5!+ M P04 "S@&Q94:E/GG,(#L@ #0 &5X7SY _?WP<'JO M?P=[&[MYX[N?L/JOE0I<<,4-ES\$65XU+1]EC"3TJ1-@ESE9 I'CB A M50D"K1O7*.VXY&FL%31NM1UJC-C6[T=#@ZX;2#U>N8L7_> VJ>ZFK@V^ (M6"+DL ;OOV3:U;LBX1:N^ Z.F\$J;ZO#RL)0J+L:[

D%>SM5H>H09.9J4P.6 M.5TGG>F,HF+>N0GK\$R.\#?ZRSXQ@RM44K4_6'7|P%2.%G:H9<1>[>L+,G5 U MDL<-Z37;#
[!H"0<U9W]QFZOV=A-F^>T?_KG & KF+!C.+WJF?3^M=T?L: M [R\W"PL\K3=Z5Z>7YZVN?75T^M\B^OX.\V_ FV==6%[C5T;C^VH7K
M#7 M_+8-VD#U,PO7L2VZW/H M&%&?J\N7UZV\GL7K8 0 L IW^TKB\T#KM MI4 M _0!X2M%Y(R&RS)8N8> KT#'3Y46H:V#*>QX!&
<"54-774"1+@!'; MT_ JB# "115#N4@4@[!U.1\$-P.7.U\@-[CO4DAYXVZ/A'2GOH(KF4A?L:7JN4 M_:/KPJ2!%"U.CG\OESIX#
CTW:@1|M(P<FE<&WE.%R(Z+ZOM\ _MOX9N)OX24C:P7\$18[J|+#PBV!\$V"5#N=%-Z(EQX\LY@.M,AAHU*NUD,(A%\$(-Z+_) ^ \$WO)B\$
M%61(*\$-&1\$C"0+@%VA3S#Q).\V:HFDZQ&4BZ/*\$=VH:-L1|G<0>&W\$XO"- M,Y(O,E(O,A3':C/5+U1>0F'MA"\. @MO3J3+&%
[+2#5!\$29%M!-1BV!\$W\@3UAE<-3!JS_U& M*M3%+,C8O:LW:#L=:+L<U9UV!Y/N?C >KO]=MP_.BI:=PH(O4G\!Z"(C-%K:0 M#B%?
N68.S\$.5-W%H8?Sj91 E?C1YMN6T_U>C=)5?"JK<5.Y+FA\H2\$W1 M:-ATZHQ_3@)8KS#\3O<).YM:+0B&P)1\P&ZT2=@_S#MK
A>/(GHFU\$=8V"7%Q3B36R'XY)?+ZPU/ M%QR(@!J!CT+H#G.X'VU&GR#> * "C" M=4+60ZF15#2 5N1M?N>IO YZ<+P
)\MSP;IV%|E8!NV\JCHIZ_(M6\$.0XII+XJ!P3K\|S5NT*L\|V1P_K= 1P)*..OO#HG#D&J3R\$!..)9 MB|CX2^7;R.?P+YE TIU_R91_<-
N:TX7WNI0DMB/8"!(*IUS..O8-8YZ& S; X?Y=4L% MK7MENE.Z=SG65=\$-YL+Z\$CIT/8)0ITY+N.*3TM'>+ -H*A9)R19,7D;\
M,VGSIE8:C9HY)*6A-.7J^ZF@N)5?07DC5T(\$#PO+3TKY;VF&3WMG[\$ M^W\$P!;W8|GJK^Z R?467F & C-PF*9?
43901[VT!BPYH\ C&ERASTMZ\;/M M^V6@UY**# + "U@ 7G_VI +ANMN] E2#G ?/VZBZ?![PO)%OUXJ\K=&73.
MOS"Y8<B_O#"\LXC>HW*!R 5#YR*OD&W" ^2%GQ8CJ^ M'1ALXT@B% M2IC<>%<FXOS;F>N+8XJ1@6&ZGV@YNN+J]M/\$VTH01^#+?
E!*W:IXS#\$H/ *[?10 M2P,\$% @_X!L6:YIXXL0!0 T!@T_E>%W-#0R_,N:1M[5EM M<^(V\$/Y\^15= ^YM!H--DGO!P(P#)\$U!%R@XG?
931\8RUM26?*<0'!5[8A M0')SO>OT2(X\7%A0^ZKY4:\$UM=226,V%EUL 1EQ[HJXFT%
M39>83+;@/6MNPI56_QD/5>YU6XA" ^@"F^@>@7H.\Y|EWWDY\$R(67SBDA&N.YP MD^S4,Y|LTE1\LD6BO8S(!,=HX 5\$?9'RX2%3.-
AN^EV6V& V\H :O YG@// M XT.P:747|<9PS70".J\PH<#= @IT M!9+FN.N#B/%8\$+^1);PCH6K_.9WX851M08BRPE?62!9SA%&
[@UVI_BSBs+ MJ70B*84.4D44#O+(OBYX!0.G0:8(P3G:L"07+\$_.8.110U(*&2XMDSIU*S M>-6 /?I D. +8KM ;:5&X#B
(2B=P<6!QJ:R6L(A..\$6A&9%\$@XPF:#>)G2 M%?CS.D"3TP9JD*@T0RI*GNR%?S%Q75*HP7M//24NTTU_](<5RDV)AC-E.&
M!C:U.(F@DF:X2I1!HP.V%0S+D\$1 A%)(#+L5#E6DSPVB(3)OZ!?)^WA MD0>1P=P7%. (.5FS%&@) & ,?B0W9QYP**3.M/*:50;)A%\$F:
DY T52* M>B!%6C'!S3OC557VM#1BA MT%ID&S.C.[?!,?O]O^+^N%:UGWV^6 4P[RZ^B/V Z,L,6"5#<^GLP(6X
MHEE(6!I5Q3A\XN)05D/!VIO_). C&[SOPHU/^@8NN*Y&RZ_Z@^Y2.*G6 M3G7LT*K!7%!:=O_S=_30AUR VO)!+@ALKR0ER.F:(*#PC6>[!
(&\$TOML+ MWFOTNZ(PCF.&5!8BVK1" AO/O7#!NXONL-]E%#YV>7L8T,VJ:H?E?"Z M_56M[03XZ=?LK<=KJ-
:+#E!"E1JF>|V>!/?'1O;)=.3 LGDLKWHG9Z?! M=\$^60+84U>%YD((D_+R=[IN|\H\U9.5/1A# ^%"5%ITD M9,;R0-8MF>,
<906L#4%GKYU#E9)^LFISMO.H=7\|23:V@6E(&S)0^*^T M|/[+//KM[NR>W8YWP,CNF).ONO6IKICGMTMF?W=WF\YN'4?:C5*X]0K\O|-M
M.***)J"!\$.< #@7(54'J%P+I4F'&OPW<:[1M-IH+.%"0X_60+G,I?9EM_SN@U MC&1"1"GT("5AR,2T!0X3X-1=)CR8Y]J3@4DU]
(S.M,U1=6^&QMZ-R*#_7K M%5&-.T2OC[N:3K3-N%L*E*36/M)41-F6B9^4A(T!W.8A8P#3O>K="+KM M1MK=ND? VPT .S\9K"-R+
(4J 2\$,*K>DT9)H\$A3!_,VI!2#2Q29KRN9.H MD84 Z;3J7@NM:WJR%J=8 @O^*Y.8\$V.8NC\$.;V7VG GVE+3+= V!R/ ^/"X MW ./AV? Y-
RO@N#\8C2^Z)WYX ! 0 717&17X?OH&@;NSY\ WP=4,0^@ M>X/#F 5X@+81^>;P)K>C\CP,8J\T;O!/V!^?C+X WI\W\ZD3B/G:
ME>5K&HZ%R711\KMP570,J9PF6-F4<7GH&B\Y"YSO("N _7,X(0\$60V:0.0. MVV;JU9)=2L3<>@>XPRJ\$P/8 @/78%5L16-*%20(),Z 8M4(X:=
<4-AO:F"**M!>Y5@U.B/L%O=1C1N9\1 4O510+S80JS:Y#5(E'.T K1<#=X*N G>&I_ M2\A34Z-61R\F82
9.PRH,5\$!\$NI>IVM8P6_P M1SO%E@@[E#!4LPT1RYPPIFF"9(.&]JW":= M@.NW;Y:DDNQ@C)M=AC,L.R+*5WPZW[=57+]RPE
MD\5![!DX?QD>I@'\$ J\C+=2QZ=^27)4:\$+&,>+ MS%O0,P.*^F.L:AP;6JE+J<1ME)X:F2=JSR;2W)"*36.EGRL;/W?/FXR JN M\UG:B\B[E?
#?RT<5M.O: "#C6<Z2 W-O;<*&90*)0+%^<-X^'94X'; M'XX_.!B-I?^C[P1,6?.4?^ B)YGD++R;S:>8XVLL4;H9K VDG:WT^X9Y]G
MN_OI1OQ+N+^\$^<_UW/LQHQ\$<+F@PRAB>!% B?HBW+?P;2X)S>L_>I/FY MDX7[KJXOVYNEJTUKI="ZKJ/JNV\WQ7/I%3\$=[_]?
GK_*# OTF6=:R3WMBW MSWM WM_-C1:[56!D/SKT1ONR.+*50+XM-/=_Y#)ZNSC=..?!.Z)HF)J M,)F*GYS+!E!+ P04 " S@&O9 JK.H0,
"JB0 \$0 =&O=G@M,C R M- Y,S N>^D[5U9<]LX\$G[?JOT/6+VLYX'692>Q*Z4CSCK*3MVV"1?48V>M M[F&GA0BS/8>R5GKVY-U G1Y<]-
"0F+F8=-CY*S%O-OG [YCX_LJPOA!& M.)7<0(\$&YYA%JY4X+^O'B11,J= [? .]I_&UPB7=WI5[5=CF5]C@7 MSJFP)V2*5C
Q"DDG+4F4L.Y_V^7EY?#E ZAO?M7?3?JY= ND95NAL.WY M3)/%7& ^Y.ZAU\AV'MNAYEIM3 NX_.N.+)*A+F)@ZAZ=^0D124W)*+&1\$)
M^W41A0"RVRI:E>E8G:[5ZT8EB>VDIX".A"K" &DO*1HT3J_3)G-F!#EUA* M3/D#?"FLGO)E6'ON3S(404Y"\$R3.8\$Q\9|O_-
#VIEJF<*/JW01^YZ.%SS6 M;ZOL(18D\$F>8V8B+=)V5L\$%0.UT4,I*7,:"(RR&6C\DK@NMN6=5.A%*I S MGJ?9JZ(TOON4?YKOJZ8
M;W@O|&W=DY.3MLY(2PEIT-?DFN/3Z ("LN6..SOWWLTA\$E#HP4+ID2)A," M*|D2/S&17 &4B!FV22ZM8\$!12(*= #KSN\$1LHU@>KF
HN?5L3?Z<(NJ7%96S M5)+5[5G][B&H;K4-K,CD;IH)(KM \&FISW*ZD).P MIT4%5!<[+H=

[9;0UPAS+ZZ_RCDZ_Q67=K>O8SH;BJ"+F**2^K:&X^BC)R+7@P(R0J_0%JHFO)6K_0T M%8Q0*17Z10PG)VVNN:3-R%BM/(Q&)?
S1"DU+)(VHF; [MT_S)@G=54Z+4J= MS2@;>6\$2)*H@Z30*L*)IR,SEHJ M#+>BX,_@O%P/(7*+1#84)\$,[S]6U\\$/QIG7&5L6V;;T5;"&,EG[?NIT
M_LA"5Z&NU<JSYJ#/6BVZ6.K!V%[3M6&+XASSI[I[4^\$18,)?(*)GEG7F[=MM^DEP]3(F68^MCWF0@ S-"
<^ECAZEAIC5ZS0Q(40**XACI04@B, L]:/0P65@%WKO=J^OD5V M_3E4S16#*OT"94&D7!\$JMU6 7PWVU,PP=/0,W5-
NW>&Q@+"D:6FW"Q M T-& -M=5&I;T:E6\$0@ X3N8X00P7Z< G2C<%L#*LURB#&LJ// -5K\$&IK2^HBVU\$9LET&UB*+&_&
II: 19VTN.K@*[UMST5S!F O ML4:N]_I_UB|MKHX=5R*4V 1NE86[4FCW,@2:RNO:#T.5\$N& J".B+*!4W9 MM=7E!'=JY46%7/H5,"/KZ
2J<#JU.J?P1*MUOK 8LX4^GF" ^4(P0=,PJC M)5;K9%N%U\$VMF:036Q**GA[*RUUL!>I!@MT6 *B%3ON) ^/I%"J0+K YL
M.%QN"5E3I^4<5U>?PDU> -X8= #X% ^/T86 IVH(= = ROZGY3*J?5^G2R MFJ2/75UV7QWN1'G?>=RZP,%*;&D" ^AR8L./> P SY3-A
M/K%&W)M:8^>9=5PNKUBNKR7'ZOHD*Q&ZT/C10^G:=C5U+^\$.!T9%*4@-9E=@Y MM:Z)Q\Z;H&.EZ/S;H?2!3M2U3; C"NOQ^WZ
M+G\Y\A0,M4.WRJ!=7'6-#\$B/O/*VP#10%NOZPO(70-7=GYNK37Z/3T:RUIC
M|WU>V#5!0Q3UH:"LA\$M.2]X5**ZN1(>D07N[8&P+!H=2[4L;JV, ^< M3&>J: ^J.[^HCSO >[B*X?@I];O;<2OV!7-I"?
8W12@X"JCU%)J#N0>0E, 1 M5C=F(U/W?-O.X9ZV4@.M<&[AFU MG7-AZ<)]DKSH\B&IFU 8'0&K. R/W\^6)N1,RU)YM+[@I: =Y05"-I
M2A\^ORO!@J"J6=+XARY/FID5UL?S]Z;G%COG6ZT-*[^6;5UTB"18ZY]W0P MM=J1#*SK1?.69UA+>E=9(FO23)DS2)*,+8+%^YJWCSU,
ISG4-VALKZI& M\J3O19K1(87^*HCR9&M== (C/3JX23L M"LY%_J\Y11772" ..P/KET#VOC>XR%\$C 4QJKY%\$Z9NMZ3='HH*]OK
MSP.%*25(F7HPAV" N(\$;?B7S@WICCZ1V9# @/F M067GE\$4O[JZZGA33-DZJE7S'3 X4_1^ VO+V2OJSJ@VJGQ6+266L-1+-
C\$11GXVPD&O*P # R4@->P4NR5.M\$&H^AT SIN7*-0Y/M,R)J\|P8AI M1.*0'5Q GAU'BW9DBC2LQ1A:6+A:@?
A4UZSQ_I>*C!O\X)JRF0KU%\$ O MEBX <^KEEJB,ZXH,Y0W,I%R_!G:G @=RL6CVFKD600,YONI/P5KA(YTB; \$ M\$6H!'G1^O8]S(X0?/X8-
B@(@(1.9NALW0-A2,D7C#YFHC\A'S\0/10:52/D29?@.WCES/NM7&Y6 MW_>+X>7+5.C#4DTZM6.*+R>I=P=

<^9U1.0,V:SXJ\$&C'JAKO!X>GTP%/-H BN MNB\$_.5M^*P9R+TT>4%9M]5VIB3X*V4: A5:VE\$6RPW/+ H?H69\$TV50JUN+UP8 M-
B/[IL+5FDHILK@_O#=15'H62#3"=-%J:G)FYC,*J+8+O%FL\$FCM<2*A\ MD2,A2*=35F+3+"@4Z%4(X&M>X*XA?
&VQ6!1E>XV3B(ME0#C;2C0LD M"VQ-/%*K9,B3>YSPL4HOK1;JQ^& DH#:IH.86#STH\ ^%+<& "O%"LO.9 MBS=B1 G_U".O QU=:PV?
B(V0F8G^P(6E0X,EUY5YUG_UF&V,-2=+@#8^8 MYWKQ2VP\$JR) D2L@9&M*-Q/UK9YH%_TUY2ZA,E?D9T(VZZR,9
M4R\$))X5Y<26Z3%.H50CAAYUX0+HIO :>92N0XB*IN1X4NPP<4(A%!)@ @ M:?? XBOA%<@TPB001B&0QU>D"1X(UO= 1-
A%U(NI+A'QIFL2W)9E? I^K8G= M9;"^8R;>^Y;EVHJSOJBUR<0XHHP)E=Z?LGU=N@.VXG%&DX=#CR0/[U7G(M^1@": 6?
0D71#YS:2>2F)11(9I) \$?3- V=8!BMKKST!>3S.GZG(B\LT%OM@ M0O2Z,CG3,J0V,F98#J S&A3O)F'D";P11+TB1+VWAJA?A*C_UA
=%2\$Z>FN(MCHL0'3<"T0:"8!^*8:N'0^E0D/GY" --5&A5*,9- >?&Y/L" K>PGI M /-%&XERY5FS&E[0"9JCYCH,MUU"TR, #
(T, #DS_%)C86PN>&UL5U?<JHXS^>F?L'/_L \$G[D\$S2 M#B5IAYFTS9#TVK<05Y 5R-ODDS@/OVMC" \$D8%LR058[G>DDP:_U6VC]:
MJ^=OYY.X,0,A*6<7S,-=3<]K8>AZ/Y08B/N!BU MCMOMD];*NIF1ZV/CM6ZP?RZM?OR3,K5!<-2MLY/3UMI=^N227=18B==EK? M/E?]
AF.8D(R+9%0R+R+IF4P?7O,0J2,11_N13Z4[B"2CH'ARUF*+23J9QM!L:4@()&8O*G\$K %S1JZQNA?&DDF8*#> MLGE:1GS(G(-&JRI:][
(N_3R4D,)DFO+9@ECU9-4NJEDLP= =\0(TS) M&[@S\TEKRM6(G)<0733/B)=^Q5EPN,ND>G. V!A!GFM/H,RX+VKB&H- (M(+JFY)
&5%&0I0"Z=UR'Z'6XGHA\0VA49, UR)0J\$O?X9,+9K>+AISPQ@W= MX1\$25V<>ST^&K&O\$LW81>4RQZ1XRZ+*^K?Q-
<7C%R(KNJ1X18H/W_B\0) MY!OU=8MJD>= + 200^:4UXUM 869,C/F,?I04@M5+7X-VU6%Y9BO? =D+ RL MOB"6B
39V\$ARX6T3KF^\$3%#?AJ/M5."V^!FO%8K=HZ1@11Z*+6[0X5+(MEE,AJ7,-T-+G0BEOXA3# !2A#*(K(AAN?A*M?C+1OBE\$ES"D(7.V=H?
@#NMVSTO MICNU?>JV"X!(>39A6X6COVA*(4@4 J9HS*)/+V::H^K"DW5O)FB@S/+Y
M!9IV" C.%MEZ>3SII'&MR\PC@QVM@_L_ZWW\$=IYZ#N\@/TC\FD \$!MK_ MIN/*%S@FPI13_ +>ECI>?OE85F,:M-
J11J31?_B\UIPO@!5T BPSQ0(MD\KC 5VA3,ALE(/"H(5C!#/D1NM(GZ&+P8J_7/+R9WRCK\SDHMK+O.2WSMI MW"Y,
<5+5HKUO)3>79PQ4K&1Z<<^GJX,94+PHH'6?,)*9U+F62Y\A-S_ H ML%#C-HX1C#&ELI!"AZG,&*J05U[B50H7(\$RCA-
=2:\$C1OP7W9%Y+K,* M?F9; J0&T;Q^>4(0ME4&5+FIXJL M?Y+EOBOO ^!0TB%-S>0>U?^Z,-1#*C*,9WBR(X)7V7B?=>+V*-.^5XUH>
M8@CG=4K#F31<52"AJALV8'MTP<,E#=IQ29%"4 D7,+R1J47W#,.6\$C*&!*2 M7PV\$.9E_IAPJF<+V\$J*3IOH% QY#:! 1)UH^E_Z/\$R_S9
M:9=F^KZ, ?_.>B7T'O_+LV_63 M9)Y=MT0/0X/N34W.1#L_W!=IVX3IQ!2M:FX>FA+PVWKP,PXVH,J3Y!PHF M31SGN*>9@GP>&LB_C-
OM>N8" B'5C#"D\$^>O2?MIC8SRS[06(_K>KT_1 MIT/+RSX,JF:Z= #2,5EAIO(X<9%CKF\YY85:IN)YJ7.*OSZ6,178ZY]38.5!
MKF+"O%TM2S3YN-MU(L37"! MJ0%AN%\$)T^>O @JPP92SM/QAN@Q& LCJWX)(O<3KWDMP9= X0#5X"\#M|
M%H"D0_20DB*H.T%)O*HWW'W?@6TSJY= /U9N?C6AO(&OZZ?> E\$?283D5WH M5L#^%ED=O Y*13PPE&9!?)I-.CO_ JI@.?
CDK%A"K;9 ^>175)S;XB56(6KQ M%.#VXO3#G=&76\$9#>JL, QWRTN*:A'NT] M;%57&=/_ NH*RO@*@

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|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|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|H"\$.C]7S I 1T @ N+V MXB@J^WJW\$S>X2(*+)+A(>C'4@:3%D;1% !+A2'TB78GQ(.69=/*#^/;& A") MO7M8RZLZ(DU+JZS3.SU890O@"5:5VBEG>3YDGXE ^R-FP?5CM;3]&OU6\$W7'D)R%"=2L Y G*1% B.M^?WM] ^>YM9 =204ND>%* MTZUEV2LY] ^>VSH*UZ 3:G93?1FE M=.V6'14)DY&T S!5O%>F N"2.ZJZBTN:JWI\$K.8*E0TOBT4*-P*<>O==+ MPJG83IH3(I:IU- W9XL>K/G+&C+R8. F? 6RR9W4,I51[C/CNP#>OY.T MT,-V-!UF4G78>9; TNMG&P5#Q#_ 6F34O.!@+=I,P7/[SR9]J]A5; ^ M(3? N>Q4W6H3M^WOOJ?Y(MJB[PI#V-S]H#U4/RL>1-W'GUB0 4Z5>D#CB3S@ MB &CDL;7 J]SAR MX1'ZK,&YOBC4>I.MX665:4FDJ8T/MX) ^W"O M3 ?:\$8ZI%"5DG.4DK&>F* M" LKO;"O%L]1%7G"JJ5W3^CE# <L5!8M(R7CRYPLSDD,+KOOP29*7.S<9X?3*L\$1(^C-LHM-DA)#+HN: "T:96U;+J4NX9D\$(SFJY!KB;#C M";L:W,P]W9"0O0=L- SPZJ)*K=&E7YK%W9J&P&SS.SB^&66>6L3OS'(92>6 ME;P.TKA)XPT/A9]A[V17(4J5@%5I(H5XDI:5]\$@QYM'DFTH MSN0;X?%TK0B%E/KF- %BGSC/*GNAKB/Z>I.H>NRWRL"V9'>):H=JYCA3:J ML6F1BYQD<9(M*EVKL [2OF>LO?7,G/5\$4>^ #R%OO6SPFE!]=&[W2/PW\W M]M]MESZSOJN!7?VSA((IIX>HG 'M^Z:IOES,C _[4+R;ZD%GG/L.N!YP& M3V[UO12GKBF DS- W^=.'H*SPOZK? RI\$7O&N/AZT681B,&I4 OS^DVR+Q2 MN56MP\$=44>Q!MT<=MA16(H,Y23N).MN-5,B@=O<.9 M# RZ0S>3(1>Y!# @7(*=R7[8MB%>QE;>P*1W[(*:Q00T@VFM6HTR*9-<8= MU3J#;LDC63-3GE XANZBBLNVX13 B2Z"BO..UL1_180L=JWID*2=%5E\$9 M3N<:4!N_17A[HMMB]GPD,K!Y-7?+0+N^P^I0D0'K;V!IRV]DD]ECO MJNDDM<#0:\$55 (C4QHD =V8) 50S=A.&R%IUEP"Y 1DEMRZIS1 9 MMB.DXYJ#[G>7I= ^I]P06,\$L/CHF'A#%2V@68>RE:6@H[LOU >.)'K/SR MP! <5WSF#>"0M0D#PZ<2PYEVC&/\$ISC!YF^7??X%*KF?>16@P=&:3%S:& M=\$UTAA#:@>H.%Z*3+=M< ZI-(4:G4@*N16U>D R? 7@EEMU'9."B[6,2HCHK\ M0=G(&ETU+K@+912,1 7/IH=RB\$V0/I; ^49F^#4*AT&RC0VF:GW")HOZ"4 MLH9(Q85V&:#!K? Z#=.P2+K>2H[#7%8\$)!ZTD .TL+!(EFG1U: =AD4EK M+I-JA(^LCW,G5%BMJ1OD=*(S:O?HV)D7IWU=(.ZMKI."OJ;IE@)NE7" & MRZ9>X653C_KF.N'E%GEDKV6N)>X%T <70!\\ (4H<2]P+H>Q= WWL 1.D% MT*?F@)\$1\% 4/!0%QU84? \$IT=F&PIEDHG>2 _=%

(H<]*.D4_J\$A*2>QM%@EI\$ M9%2!:B&OM&PUBH:Z(*VO'8)G899SHB4!U%"S5CL=:#@S1OR'Z]P"C M?YWT&'2GPP#AD7T[!7ZL3-VE5R:>[7E^>(GJO/M.=!3M22Z(@#S.;Z UH'_P/M;H"6V(+_Q7: ^JF7%4SF5XAMVPC(AN99[UR2+S][*O+264J/R/1W"TZK M4
Z|@:>_WJUJS2/D4TKO>P,SG26%
C<^&OOE2 FSG?]>PZ CL8KRC.Y;(- MI=O8N/INO&#ES%QB5?3.;?4\5T?Z6>3%D, N@ZPSU>%/H.
M: MCKUT(7KW>7R>ORMX5+R)T\$OD/W'8S=8CI@6!L08:3^38 JAN-9<[B M+BK3 : +'X/SM,L[^FOB*+J5X;1AL1Z,7BC70H>[_8&4K
N2.>U&MR1_7KJ MFIBB1^J4_."@B"IP9]>_ EBV ?E?XHKO:-902/51Y\$E"R/GRIJVRRRIEH?_ MYB PX/EM"RZX?
E^AZ _X6PZOVY!K+VAC+!STCF?SKL7NT-W9LP5EN M1_@1U25G<3'+[IMJ'C4C9R/SA5%(16-7L_S!?6+_.UKV4&JN
MRND.C7:E."17Q8!H4(?!.P^Y42(1\$7NR:5.VFA6K'A42YY9Y(&M!N?\$\$OT! M:8**!Z,3"19H[P,NTI4>*S MM%_ON;_KJ?
POOB'W&DY:/"FX.H.K4VM4P^O3& ^[!%!.FSG)NIA8!M9=JGB6D%WF WE GN]U(>_M1?^W+8 1QG-(JEK(I*
M3224<[JEH];ED1YOC)"W4M86/%S2=W:M%3>-JT: 6 M15[&4SG9X2K6L5B=^6-T:O1Z;.#+3380E:0H-D&R3,PY-L>]B[A#L)9
M\$.Z"1'.0+NO1W'K*!+%K:# _# *M17RER8MY.Y! [I0 _!RAA.DKT.6 MOCOY\$].17!^OA/I!TO.%IS4YQJ:#N_1^2>XZV+?;8<_E_3G?/?FD:1^@
M>^LO(O)Z0^0MRY=>J?%.*3S*K6#[T%_L@[WI N2P2U-X%\$^7>NC.HZ=BOT?-W+JFW@-.P/W8%_1;^9.^
MKUT: ^7K0:8^4R*U.2\$#LD:DM.E(5Z:_3FS=)&[TP^P(\$E42)X10]HXB MR POT@<_84F 65V'8BYKSP7)I7B^LN70[.N.UXRZ")I2[P0
O).**J*1 M3W/W0/G"0!#/?8N17J61S5Q&U[M!Q0SL(S[L|\$1CA4L!]!+5E;(@PD.Z>_0 MUK+D.F;::3H.T.+U?
IC#M'P602WWWFYJY;_77M_=3+_17 U.WYLEO_C]0 M2P.% @_X!L67V98+7]0 #14#_14!G;W9X+3(P.C0P.3.P7VQA M8BYX;6S=?
6MSY+B1X/>+N/_&T?8.Q&EZ5:WO_:_QO54FM6>ITMK:3QK* C MPD&1*14]+*),LO3PKU\2:KBB" O*MZ(W8!:@E\$/I!
(9"82F7 ZM^=5@1YQ M5>>D /-71)^_ @KA,B597C[\^N?;D FMV>7EU^ANDG*+"E(B?_54F^>K> M_ ._?_O'[SVY/3TY/3UR _#^YSZI,:)
(E#7 YY^_6C; ^H=7KYZ> MGKY]OJ^*;TGU\K-Z]=O7W6COVJ'L|F3?_!74IC?OV(C7I7X M@2W3A^>_O1G/L6RPHOO[XJJVOF.X?
\$]P^/T=PR/7XW-UKRLJ6S4^6I=X*]> M66-ZC:N<9.1+QRB/3^L%][LFJ1H?V!.!IC_](DA50,#Z=TC3-58=@QS@=3
M.L:Y\$W8L'_L3NL_7@&ASB*0F=@4;18'^U YD\$TXH50ZO5>_#B?%S@_^FYU&K- M?FZ2#A#Q0?Z3!C1/KMZAYFNPW?
S|GZ6%:RV9>4F71Y,W+9.D@U8KK]PX, M1U/H#5>H%6P4X)4+<\$_!O.>U(N.G%\$V/5[@FFRH5ARH%\$8Y]7)@/_O5 M7SK8B)'
CH:@_3JRVVA[3,JI/294]<^M'O\$H/5'7S2Y=BXJL3.A,C#DG M&S&1V%3/5%A^->=H.%(_ZGM,P:8^>4B2]2LF0Z]PT=3=[A4<8E]?_WJV:)
M|JTMJ7:TPP^IYC4I,S3P1J #/28R?8Y,1^J. HJMLDQ9A>_OL2 MHJ'T/(@/6)88%NB.HQP/UB* 6\$J2B\$EYO&2X"!L_!%WV =_0?
2=DL:XF6LYT,J/^@'8V+LRU^ MTS(>FO>_O+>8(A,_H9Z!#_X9Z#&>H(>@>H^LDSV;H,SBIT%6)HYPEUL), M7*^*Y?
E3=ZKG9/!3 E#FBSO-Z,)FI-R? [69,B3W-<]S^,G4HNYH_<539P M?6 YVRT:>:
[C@_Y.%/+2>+1)QSWH,HE 2@/_7E[PD78.>P,&ML4^*(OL*)*\$N@MT5R=EOC?XFD A>"^9 M0PRUN 0Q.X;]=MMBB\B"
[CV!+418O+W#]DO:@#)L-F3T.6.O\$L"O^?)-2[M:YR?<[IP8NS,(7S"\^- G]R'X)BSG'DG?_Y-J[VG/J!8V\TY(TK3:8GU5I M
BO&CI/A=&RGWUS@^<5:GD9RX&KWZ2UNV(C#/# ^IY.GI^J2\$GC0V0()\$*E0 M(O,UBK&WT?@0!.+X5%N,^LU!P9"3!?2P<5^/7;.
[I#U*.A% CCLX:0V51R M:Q/A4!S!7F+(LV#7/2(Y2YY/_KM#"UIL(L/^ =!3+GBB9? *15!^VK=0 M"=B(D=;Z,@S@X\X O\ RIVP%K<)A(7>5)
D,LLT=L2/_+G/&8LMBP91K60,P|GA9RT^QCC94* M9V:U;NKO<#XNV/93;IPB&,-74 -#<&[-2:[Y/S,4^"OHR0FBT L_.!O,P^VV MCNYK/[5X]*
[M|LKT>Z*&M+[B5C3B&W@DG1?6J)O7!SVN%N?XOF!1 M098P?UWA5;Y92:1)^SN@5"GG#V6 _!&F"!D>J -8(T,LF-IF*>_ .?1UBTK8
MNSMS^2)@MEJ&M[M;3K3JXK#/V(5 =XWTG0&PP)9DLG],TY^@>+61T^EG M5ASO?LG(V)?
Y(U&M*6=ZB=\$BK^H&M5>R|S3IZ%KSRBC@_ JT6&F#'_0N;R_M.9'W-SID 4T>7^#_H|F ZXP>8"!VY!* _S1RB1_EH')?V рLB\6]2/S;
M!+_UJ7\$@^F 2WRSS*MC%_A]F9\$+ _@#G0O;TT\$ K<^/_ZW03^MRX%_DR'
MA4U#_@LCUSB]X5+&O&C"0N)=^92/QW/B3^NW@2 YU+B0?386%+XY>X= E M1B[PHPR%_A^:WY9UQ0N;W)AV^H& M9QM_.
I+I,AP8;\$BSH\$:@?3 *_7UICF8;WOZ>1HXYT*\$+0<44).@&+>=1@TR MS\$4F/DO%V^)U1LJ\V/(-6^Y3V=44K\$&Q[G^_UA=_.
<:VKZ&3/?CHZ!WI /YPIV&SX\$"KKYML/.E,VXN."<4G6KR)I%?H/ TS_MZI M)Q'A46!K,T= _!6C.>*55/[M]8%_&B!HY%YNJS.LE];9K>?Q5ZP-
(H&ERXA 2 M)*H0,3_V!X>BW5_,S1P1.W9FK]J|O#LD+K8818@.Z0D1,>=D,!W|PL3C^Z2 MB1% /3N8R?<^X*
T9=Z3\$AWC&J%@1EA!T'!T=B<71P\W>W|UZ0V0HL^OE3 M4F57:S.POMHTO_>_&+4+J)BGN<+5Z,^7B MQ<\$OGD.BW%0MS0L:6"!])A7
I^G "WG&A!&1J0QMH8#L>UY%^.WL10"FD M/VOIG*& 2M22B7HZT8!0Q"!B-Y!4@+[H8"8U.&V(MDN37?G^_M? >'-Z>D?
T1!FOWO]_>SMZS_P@>SIW_ M^_GI=V]0TJ!.!K?_F\$907]X>U ^YARG[6]_>6 _?SMC=Y1JG3Z(B[5N95+ M173Y'R!E?UC4S?
<=X=N6'!HVE>X\$^X\$15E!/: OXLJ9?7%7G_,YR]>_F) M:KC+LG T,F>_ Y;]G%* MT8:=2WF2/2^P*NDQOC,TRJL8D)K&[D:R.%9^_.
<1=V\LSO:U:X1LP:,SNR-6L3.(Y/L/8X M/2548^R+(5#727551*6(MM7D>5D*6]H,D@A!4ZB@4BE2A8FB&,R#9GB,M@ M1HHBJ6KVX\$+
(8W1Q5*!-N&CJ,?QX _+I:81,QRZOZLA39[#Y_<8^/+OW%&Z M-#Z>_Y.^_>DQ,>]UZMUG3U!&XNL">J^4(_/P_8V?I(25"X)+GHIZ)=:E4Y
M'AK(ELWK/1K=N'!IRG7%2DKN4,617#5CU+UGF3%,* OL\$UKAYO=D&JBTVS MJ3"SI%F"7E.C;O1VK!R_4L6J,F&5.PA?
UII*&%K\$N8M&AAA;4VA?((T6 M^+?G#25VW+B+(3=J^K9K%#Z;^VVYO^X^W|D)P;3>J3 _5P^*_1-XK\X.SV
MZR9G%6L XH0E\$7/Z,Y81D5B=[/9!PD"K9X7?/R7.^VJRD2S[Z="!B[SC M]>E:8&R_.5<(T16A+0"64"FEJPKJL@2<& RW T8F#6#>
<:AH+<#,&OZF M^\$G,F.15/>PY,(%U,3.D,H"Y&Y ->BF;?XZ/F;92;Y1= #Q0?W;TD^>B2<%MWN#S\$^S\$0^!Q_).4|L@VZ09-&%KU'5,JLA*-
TR MBVW>,NL^_Y9928IZC>O;L2>>BT\$=\$3=J=50MPD_R,T.^_&GZ'X9Y22) M%7E3&^@Q_@2F*+B,A(MSWI-RIAA_AEN2#5
MJI\W+3O: GI3.9*_9*#@?^G,IPK%M*HG\$AO'A^1:Q/FK7%5XG>=9:\$M!_ M(&M0.?_A!#@[G!:_PV6!9.F;U+DZ4M?GTCQK%0Q&BA'
MDEE#!10EX%"A06>40+J1B1L7II,Y&K%Z&:MDA!BR*]Q6\$-OR1JY)1T9 17X[MDW]?1FA)=<5!7P(QPC6BP8] "1>:#0>0V7.L
MR62D8TO&S4-5)6%1,/E@313#;Z@'^=E=7!.F^79IF[("E>795ILV%43JX= M_R^>2YXE(F0Q\$U#* !]"V"+\$F+R@*@#B*N2*[>TQ0]B"
8A\$V DIM#:88:> M*&JHPV&>NO0AQZB^79E38"2APN1SC=+RZ/ZSLR3^EY5&I^24%8PG@)X7 MVH"!_7+:&(%_Q_T?B_H+?
\$#NPHRV07/=/+F-C=VIZE/DZ,UECM@S-MB> M/R^H@B3]#_ICGYQ-Z_,:UWXLIM!G%*6FGPEI@SS/*ZY,?>A^OZ^B7U)TS
MM*M4=6^Y61N9(^0?W= 56N# MLI6IR#V7,Y0;672Y0L2(F35)*E:1UF^6&^Y9M,(1_0?TU0Z;NNL:O"2G- M92UZ[-4S/MT
D(2)5K14Z,_DX) RSX=?(+R&CW@E)=4;Q0,)P0G"4\$E0G M!04V, YP7+&TA75!2[_095KY(7ZCUE.=P3F?QOG.=]0UF] MMRB4@B= <%_R_2 +\$13[0RB4#.%NK?R+G]> A1OMP=XH)9N;LU11;EJS6I M&A8Q<Q"X=0D:TKSFBY"0WE=F;83 _\$< Y3TG8X +:I%_ M'!LT0.
<(>HE FH>XX'G@:DT2\=SIHU5_ JK^>_F= F0*V8HK>@FE,9>X\$^YH M0KGT*5F-Y9U-
#8\$&@#93>0^2TWA!BO&WMDD[X@_0X)+P&AZZ00@2RD(E)"Z ME8,8:@#H[(@OO\$4P-I>\$_]#O*"
<9L%. YZYQ/AF=8XXP]U;JY;AW\ (W7S MB31 PV-L,3 A3->_J!TR,1L^P@:(,!_0W<08B"&P9%RV?+=8A><.OI
MSU!/_Q>XS0=;WNFY8/VST0FWT+04S-%_O#SN*\$@N[0TE4@0BFB^*2 \$^>??F6M*@R>4&JFVV8^S2T M23V)O+9UJ/(_O%&_BA51V5M.^)
[\$+-:FX+(OAEV"_,_UGF1_1N#F&'_XA* MT%*GN6C)I=1]7N\CBR*FLE#U.%OHO/NB^+?%6FRG, #X&Y2DQ7Z9SA|R\$M_ M27^4QSO?"&M
M\$HY3GU@61/B/O M48Z@+TPW&;A=3"3; M"7"V& FU;G8RKN8;ELH\$14>S@T12^C>_8?IN\$Y_ MG135ZA%2O+.7DR'L1)BFO^IK?
M>C'H@R'S6K0 A/HN2#>K=0>_0>19 D M4H%\$I%:W6MSG, #9&_I-&_O[69(BNURM*(X49C5X OHJS/YS+Z%K >-AK#C
ME+B^KS>K'BM3U=452C+<O(CNA5W2 M]LK, _/B!T>\$_P5,X0M#?W0W+A]W0XHP"2+<:_3Q1AWBZ\$+4=AVYM+L
MNG5TG/(Y41U7DC[F1#Y\^L^>X(Z^_K"98U3>HL<^&H&N/A(5AKTMXJW+ MCM, +_A&E^V^5[5CJC(6U*.AZ;5R>8-E;(@10"27>"0&O"!
M"!*_+7N8<_OJZ+7H9ISNX6FB,> BEWM]W<9AZ1*3 I>N":UL(WDUN4CZ< M?."Q!WI?F@/_&U!<+L3!CM
M.K#6IX8M_NX.")B\$N^\$D @_T>>8I33W5U8X_NP&,-(&?>ZG87L2!_I_0(OR&T !#CG12&>LB3U?_G1X D K7V[>E,=)609JWY
M@CH\$48#'_*."C.%GU\$S8Z!OJH9SA7R\$NK>(E= MX^PC6CRO%/_>S6 _YUU7"+DO, #, UVM2 M)6/%=FLZ1?
X3+KD_=^K9>H,PD=@P4H#6J J(*A\$^)T0+^JX>2X,JMLF MJ11#2Y55/67)HE@DCS=H,%%%&28(NJ9!ELQH8 V_.C_J:Q[7QKVM9QD*: MUV29KX)M,.09.88U#V=WV8RBD+AXX,_@E0?_9-Y,PZ-FMTMO\$BFIS@#_YKZ M>F8V,EXXE@LAS>XLMMG;?@M&_.H:M+S<21.
V^X^>_+VY57D M1C#N#22, %D;3(U>@J;V;(5\$5/R9#<+M4RAJH8#5:ML6M)I[8/30IB,HF*5 M+"6F? J7A8Y3 _OCY%_,(9)C&04/-=I=S; *_7<3S+!GGB"8!^>_ [S!M,1WU60 L"? O;F;W, Y,S;BLDSF PG@^H&*&@RN&=8L0NG!BPZ908N8]_>JP M-
R6%ZLYZ2E9/A; L2DTW\1,CX0X^,S^MXY#*JK9S&N*+IV\$0ZBN 8*^2\$ M&# M7*OD*UA0U&E3G^\$R.!<(&I05"U+0?>N^>6.6%1UZ@M?L4*;XNY;OW6BJV!.D60_>_I^H%>Z&9(RJV'?)9N[7U9HMR60O>5XX#DD MG=>
X:K=2:_^BjVJR&6DC[M9R&5B KPHW*];2U%GO\$WH M)48UQ6VLPEDY1?D.(S&O)^H!"5!^Z&9(RJV'?)9N[7U9HMR60O>5XX#DD MG=>
[^ZQJ2^OB=M81\WUL2,NTZP,6-";VVIM:_M=DVVZP!_E^"WDH(O@6P M10&U;0M
5HT, L#M&-9%&_DK2^XO,2^D!%I\$<:_>_33\$S@UJ<8 139IOC! MR%&X81>%SY%WB%RI#_E 2J?0HEFOWY% 8U034_L?
\$L(M4^W9K>3NN_J?* MH8!O'4_=45JW!P5P6O?3_AX07>LTU_WL-ZN!I93E7SPMHK=\$BVF2Z4S92M
MYX>^D'A>O=F6L3Z^\$6M=@@10O\$3(H^-/5B*F/8AL0Z+&^319B#SS< F.M;M:ZVBE3<@BXGAY:/L81&J\$.E'X0HZL"+SZ7O"J MQ
J|MEQ-T 790->Y,D T3@T?U_)/^4P M9"3Z?L/PF50T)^_16/K7 MNUT5JS-Z Y>E@/_/KY(5=RK5Y1_0D_>39,)DQ9_ EN&B=
\$D(DH7T#%8@5YX5#0#BQ+1/7(A*13^>_0\$!+EJ>3R+7M0OK), Y.K./SO4 MW* M?G]=Y:F;1/UY#32A]D(XX^NC
_.@YZH33<>K#&T.M1JA'_1N?/3Y M8>=U1V+2D]AU>J/(>_4#^+4B%:L7Z7B" W@/_N.6+(?#EQTK^CESO(I)>_!%CZY
M,YTS%9HXXJJC\$+J]UXA(C#_+3UMYIFB3FU2^XH5 ?F0UX60IQH(*F_6I_9WAQ'C2M5ZSN MPPJLJ-
IIWO\$404),1N[9W8.55"4J(XCUY3)RZ3&(AC(#21US6J-SVP*5T], M'Z0Z=4-0AT07YVUK)=F6L'9*G?4>AH0O.X(3@7!W-2/6,O:1\SV*UIK#46,
MV/SV+,[D3SBJF2Z<5[7>=TDE!&^>E13;2 :Y%7" C*68/M<4,\$"VEG/* M!& [+0YHB\0,B<_J1YVF"Z,D6 I'09!>>%+>KY8Y(7+
1_02K6(H! VM2 M;-10<,WOK2/A'CCA8^\$A.RBP/ZI=1 /%SBA'BD'.[0FJ%CIIF+(LMOJY& MBK1\ E.R0O-
@TK)O>WJ(6.R"NNP%0^)&">A=D3 F?, -C[OSS@<4&O,= WJ MI5K'!.PTM\$#XUOG=\$O!"HH*-FO^8^G'4E!38P:>+TIA.^]NB=\$#BY*C

M1X8%(UQ0G(N>2QG'\$S5TF&A@*UC!_MVO@7WS%"\\!%)%28KL@?C:FT WPG3GY MO<,M.0HGG#V@B9"K[>F(6K IT'8 _R@A@5-G&_05
U""/&H2ITJ+ &:(^, M3\$-IVO#FJDPQ-7([IF2&B6(CM@4S4 G17K]>'33#Y5*>-Q0A7B)W7X+() MO@%F@!9NUX?
D6Y6>M%\$9F"\")X8&KHT!/M4B05*^ZL\Z5=4'@*O>'-LD+
M:_HJX!+X+U9L%\$F%I%2+Z8=A4GU.ADPW2C'Z@M*9N>=7%6BM89XY2U.=+ M\$)YVI 0*EBJO@3XZ,LY?0 CKD-#M+
[8>I@5ZAK\$Z#H+]I=^*5@(^G/+AE'WV MCXUH2%?D1O,& 7!-NMBT[H= P.?(*#AT-4@MT.L09=#[\9E6?P6|PM MVG&.91]23T(LRQ&6
594"8)Y+TL<^A0PP=M" C4WMJCA7*C5.ZQV)Q015S M[4H ..;5>IT(.ZGRRD<6*SI4_L625:>UCRMR^B:1G4@_=LDB#GVG)2.0XH4<?5
>3WJ2F(EGA)K\7GDDA6^2YI.MH+O<(D7N;R&U^1H M^^Y-FNX6EVX&'UN1Q1 JK)Q6 C"ARUT-'7+7Q%&J2_LWU26(@AW*U FN2
MAG%8%3?Y=*NN217.E"2NWKY: MM/|<1.6.X|I|UO/K_IBWC3N5F7LVD40F|J H<
Q8&K|JZSZ|0X0WO=UA==GIW1D7F%='5GA2M_18I/I@3'M//\V-;WW|J%HX#2%@?4 M,"102FIV>K:/=:=>AI?
D3124VE8M6_3W%TNH%R/F"9%?3I&[0B9,, M>^5@+P\$RF^/ATKZ9 OPI>O=%?#JUN0&*WL\POQ&SI:[-D01V" H]IXR_9
MP(R;R9=116.BG+RP<36VGD,Y<&TV!Z[WG! ?TMEJ/[OO[D/2+&1511.4 MB7\$E3C#]:G+&Z780KXV3HF!)|LNJHE
FL_J4E[UH8>Z%K\$TUG,R"=GW\$:/ M|H|@O049-^BRR4=2: K 15(H\$NH,AREATC[BZLU:B.:3CH"4I|N<+M;L/M
\$V|P/LP>A20<^0 7M^"W10[XA!9VUL7L-C+&EQ|JW2%XN M2+7BGZ,NAE=#!
(UM(=>^C6=)%H11(5@\$/6/VAGNN4"!QZ+RXKNDQAE+B:*, ME-[IVGPV^QZC@\$\$+2+2/UK8@(KW>*(34I587#"46!M@\$5!!;,>.)ES.D
M1::OMOMF0D?L&OY3MW@1\9^OO%OUT7>R(\HO5#(Z229TO\|=PZV?:#! <./M)&OVC?RXY.R3+!."@J+^#4F+ JT R|9Y:3|T+>U=249A
M. .W &?L)KUZ.2/9OKUB^15;C1F1Y|NS% .SC,\$,>"7Z=FVFLO\$G'7A'A F#V6^R%/6 MO T -U49([.H<1M8X#VQML4"C4AB[VT'A6A
!/GLVL ^H7U SX@9*.ULV MU,+0W|RF*6!1S;U)9RE9BPRI.4G%\$C%;[A1&])5C T9(W#:70+P#X|DXB\$ M:/Z0M"OFUC.
(<6SWT24F*EX\$ U19.</Z;K&G35 _Z H5.:@/8>J'094MY M+&J07P"VC/QDO5X /DR89?Q.H_JPBWC8V:0@#8@J^ MJ4'AEA:
@=%#GL,\$,\$,:=C'5.HX*3/\$F'D! PO-M#8!N%B15QT'S0*NOV0\$ MS?<6N^+>+R>L&FLS5%5EVW6:\$&*@CPO_=IPO'K-V?
T&#D>^J/G+3&O E M!51RB;/U"?1.3KJ1X+2=<#-NC!P;27\@O6:/06B>JLD56.VIIXE2 O M;*LN7)'POC3, "34FP->EXHTT6.3)P.U?
8CU\OXY7*,14):BQR-34.8). M3><J3M"\1'U0Q*&-JP/L5 ZW52^188#83\$TS=?WW 3/04.V|QUODH5\$
MAR|1>Q|PCN+,KHYC:7^G|G|SGH:C \$Q%RMJH-134X>G;1S/00(K-LA/F8K MZV%\$S)T9)D5KLA.#FL6^+B9% C.%^%F4.578L*L8&KY-
|WEV7=5/Q607NO=D.1X@F&V36N MV N=Y\$ V|5|J|ZU@<42|O18P31X#|!43@&#IHB|J2|R&4IM;FV&=&GV
MI,T!TDCL61/[1B&KKB)WC!;9Z)6N?|XDC>\$NEDEPXC*,|""F^H| GZH7K? (M=C,OM?-* M-SULM
4^0PO|S+KA6MPF\$!8&44C.4M=31P;U/G*LB,+4F9]413\$KS60R7\$,.=>N4HZ^0KKO.4DF\$9W*>-%_M/PWI.C%X4(|)AJN-HZ3&UN?+|*
|[|V!%P" L_RM%)=RR.J;Y1-I1/ &^ M^V+;P#3Y%'R=IP;A6JY; 'KW|(P-1%/2)Q|4VC= =BO'VS\$7*JVY^TJ*8IW
MFSHO<3T6!|8;8S=V8+9%JRF@#&LFL'&2-7SE8XJ0N1UC@^2,.)@L M7+QF!"46L:#&OQSX7 C^T6C D#TN'\$D9N>V.JCYO';4+
<'4 .:='FNR M7" M> \$ P" 7);N/T#U=67#5Y-W2/#;P;F;F7?/.CPB,/^TS:3" F MG LG0? ,M,3GIV,A;@2'3QE':#CHHY"77;
I*966\$6<-.5;&ZFIQ@B/F?D=@1AX).C/6|)U1Y5 M"0POY5PDXRJ|I-A6^6G29KA-VGGPDU+@[G-&[1=<,N%I@48UXR8X2@S8Y#T1
MH3JC@OI *KE _SK**AVAGRU0F(/#1W0B"?AVP|N-Z7";2=F\$SI/-# M%D)C%TEO=07\$|R47A%|UA;M: 75XA-J<V=O(S\$0G2' V5)-
FTHCU8&^+1,J%# M%J%K%Y|Y)B6#C|8" ?3K7 WAS>G! LNE^N\$ZK) (?=^5@D1,1HN\$1/A'PO M JP0: %L\$AG+O_7:::#*<75 RV>7+102
HIY64!TTO*BO<<7+!4WF@SF=&OI_ MJ"JFT DNU-VC=PA8BG-?UAA>N,J33D.
MO)2WX4Z^|[|:NN\$G1V99UDNRB=?WEV69XEZ|Q)"KXM|O?:WM|@?V|R.F H M'JL>|O2+W*L;G)*DL RUZ382#M
|P(+/2)JH>|PB>OZTS67/7CF\$V70ZTS MB;5X\$00;M\$T>:HH@SA|GC@F33YT5JSD\$:\$^\$WB\$N:@H%6M%HXQ)V@.GOIT=1
ML'H|S|Y(U65U'Q4JOH>F|YDRHPJ#M|AC&UWQO%8O'AR/X. ^ M9E5QF1BSSN !|H5>)<5EF>'G XOE|Z&2<-8|5<6&J3/P/
XO\$|G3A+K=VX<(NM6QOAUJF,2"8@ *0\$ MET=>Q7GT5DKV9#XAKEU:E<|RC63E&\$5Q0=/R N!6J%&@#J2LS\$O K#>S/Y
M7F<,-#G6K'3Y%8XIY1,CP30,7KF50^&<1"7!P&JOMW) \$=%6FA1=91ME7M _YD)?X5*KJ):"J?|(G.(\$;@1;DK/L!>#HJHOE!\$QOEQBO
M++SVN%I'Q^SZR55%9*:0*IK: 9 !% .Y %ZK% '1KT;&H1 MB;R8=%9A3%UILS:83/Z,|X=E@/Y(ZZ2A|;TU=7BH_3V|(\$1-
#V1G1>KZHX|R8./T|&V|NAVOM#6 M*(.2(4|B+6Z A7O^Q0&:L|Z4J1M>E<2|93D6|T8T3E>+R*44|K>E>)>O(^
MS|B:DI#X\$=&6DK8,.0|C1.2/S5A0X%H6CV.0^#\$Q&1%Y*>="^4KVR2 MXO EZS,2R6_3I@:::&@.
|DX;V!P1P1*\$CICZN23#.WC&K8()GP4!/_VF^4R/_MY%@:S|Z9XB\$VH+4-5|S|JERB,3-WU|JCGI&B2'K01 J,:#|-+>)\$0M#Z" >
M|[[JKBORF)>I4@M)AMOJH;U|0VLB#|IZY)AT<"761C,ECVFB2<|H"1.7EFZ1S: >#-@|DEJ|X:/"O93-T9#|I|=B=Y5";|5&DK29X8/X@B% MER-
CA,S-EK%;|O78Y?MV|BKQ1FW|/FCGWF9 9PP|JAWT,@9 #|, J.&?U58 M)P5 4=AY1/RU%.MC -2B!+!1?-(&LUGNEABE2;U\$>;DHR-
|/A@THI^5%L&(!@ M\$FONO|B..-K4 2+G|GC6BX%?A^= M;|7|(&=!&IG0^0C^&5B|H|EMB;P|:0DV,H
M7P3&W@:F^U\$5&%^W|/SD_7BU! A5 ^L?7'10R&H#F;F3@".S/5.. YR\$%2\$O2@=@|=="^0QUO*%X|Y729_X(T+9M0)
JC7H@W(N^O28L+DKL4%#9!IWXB6-4W/2;V M,W|VOJFH#R|J:0G7OHO\$OG &59K7.INJ|(#-+FL|/DW7J0O>*G LG9' C-RCC7*-
JH66*6PT9Q%USJN4, BWBE M 11AXF/Y(6R|@G4X4"!K7 XH?>KXKX%U!9FO P\$#<,.M<*2<+/&VFY1Y M|8" ^CGC4%"A
UN|03F&C.8W!ORG&+?:Q7+A1MD?TKAA60@|ISW#V.N7GZA- M>%FV|3C*AWG.Y H%IT*^DO^6".(8.M%&(.XZ'BV|JUCWQVBW0/DD/?
O6R'7M^G|J&570/Y 2-WD2Y+X3C|6%: M9KIZA 2-D|G*!1XP%UR&EU%!P\$^DTPAI/N>@!LR|GHM^?/| D|2< H8 MG'&I
|3|+;J*0M;D\$H|P>%FF%Z(C.)4%"R20Z0T<@<48S\$B#|ZD4#
M<21V(^|17F)/%KJD|.3DJ&.W5Z#K<:=AO6M'M>MEWK%HECDE;%DJB%5H/? ML657;"O+X55,XN,X.4|O|7KB."#9T|G3_I50XM:8\$S&.
(M=K:48X3+8M|E- M|S|(?+9!TT;O8+LD- M;I*|Q%E7*6Z>II05AC>(|L+/,UEUY|Z'P)%4@W MSP.(*)@|PB> :L|G# ^ M!12Y&E,P2ZJ?
S_ \$C+LB:=7>BY|+4FG3^8L;|S^Y:Q#CC7<|D6?!"1|T^\$R M:\$NF'BQ1R7G>9T61-Y4RC0E0Q6B@2\$EFJ2U.#"S:PHV?AZGB+C%D6<#7F-35
M074GRA/Z"9&@|E|A'LP8RM|90 UK0^>V D'LH8.+6L"S>, CIL2" &|Y/OC MO?|B;5|T^7"6K'|+J?|)IM. ^EK G|
|;DMT2|O2J1Y|O|(SH@5<^D- ML!^3C>,UV|0E6|84CD/2|4+1+D)/44- D Y(\$2 @|IND:LP(>|<4B;^MMV^|WY>9!ZQ|ODZ4P;NC"=>-
&***TT C"Z@O(9|YE:/90 &R|YQ2!XBT9!! M1|&@^D->&V0=Z2\$!H8|DS-W-57FS/E I/ S\$8|V:-"SV90^>T| N@2(. M%7T6<".5/9AD*S'B5?
B2@6-
%: #:PG\$3%:24XVU+ ^|Z|J|V%8/#Z4H Q:V>I M63M6ZV^:7|D:(C&9%T ^4"|"Y|Q.%&ID8M:OFV GT>=1K&|JCL*=4C;3H|T<
M5=VLP0|K|C|B|O|E%P5WYBC: LIA|J-ASE>^%"\$8|240IIAY|WA:G(Y)*17*MTF|J6X\$|@Y76&Q/H|Z@|HB:QW*IDC%N7Z"&A'V@/|%?
=K^B W|U|C^YK! M4\$L#!!0 (#, .%F#/>O|P .O* P 5 9V|V>"TR #|T, #DS %|P M&UL|7U;<|JN|EN|(|J9K D|SS\$X<)|V=KMTS|=J2WI-
8'EM|,ON|*) M2.)IBE #|I&|UKS| *-FR30 +O| @A*4,\$L+Y,*V|KC: QL\$K?W"- "\$YS| M O:HI =OWZ LPG&2+7Y ^X ;8'|/GGY|@W-
PRP,4YRAWJ|JF^U|N :^ M>@^((R1,|+MS3|FIV| ^ MO/ P,3@Z|H|>|& RU-LC|X =A12|84QDM/SS|?+/%|N|J=CQ| ?GJX
M(^E/F"S>?7C _OC=COKMEIO &^#?/|/VKOOGPD??7H'ALMT2H,DHPC\$G%>|/;+3|B|P+V%4=N-&D(+ %>S(M OY1?(KOZOP%
M_GX 3M.X|OFZ,5RO(@PSD*CH|LS N" CP|@:I|9(A2UIGRV4N"YK^>7#| MAV#W#|/Z|OB|RS9C.%|JMU|BZ^V^|31|E3RB|>LH^V-
)S%COM0|4 >L@1 MFY- Y8I#AZUE/ 6KJ,011%&|NOXM14KZ= U+"4\$+ OC7>98G^89-|S#)
M=J|+PSN4 OY6!7%3'@?0!NG#5;FBI|/FA|L;|X M,:/5A\$;Y?9R|:#-#E^Q7\$;JBPF|XG85W*5+Q^H|Q(ON?^MCXAT1M,F"3P^ULF
M3:|OYH@0% ^MWBS| ^J6|0G32R;D;/PGV@C9%#-#USQ|>K7!V MFS=X;|-PZ?+2+N91D= :*CNI|!|;|5|J|I=D+V;CW&MX"\$C-|BO+2Z*ZG7G
M*T06#(80!/(EVO|UV\$FGI|2ZMYY04A2=%6L|A 1,0A\$8G!\$^40)*=M9%IB(ML:NEZIVWRRS"A\$WU4B@LM|)J37+|-9B|=VD&M#/#,I+PRI-
|O*3%<+MR)4S7 MD1N5N%;7KRPEW|FKDZ|JYY MFX4/ES&WX7>+HH(P&(X^W,V2 MO%:O%I\$8X,K
(5)&V0)=A(968 <,.632W>WF|4=3FO8JOV^@Y" &|R'A^R6= MX>N"!Y3M"=|D,UTTJWF5%W|VD:4CJ=EVS4BH-J0K|*L|T@|WC3-|'KV8[
M!-.|XV*7G0"YRT5CC>&K|O@P(R'|=Y4>6+O3FW,FBNR+< ,8?,"DV|D| M|JFD#74U*27SLYK02, RD>YHO*7 X&Y9-SH,CMLV!@?
G9C#6D|I_> (20" ,+QB;7UV" M1AFT 8.FLX.PB*|X*+=N"!P+, %2D@1IP;|P1>Z|O-G!@?|)99#< \$2T15Z+ M\$5'YT^H:
(N|=BX@N2,/#H>VL&LG!|W'1P+1^1;M2<#HFV1&OQ|J3+0='M2%NPM1X4A-01" &G9%O|S|O<2N>4?
N(H|0CXY1X*XGM@B|BDERKCL>#X^*2 M="NN'7T.Q|D1>?6 F|O1'Y%Y2, "4?%\$;,N)46CHLC%EU| MTO@3%KT6" H@|PV|XR!@_ C>
(TB7FEN^ N3'GEMX N\$ISWNN!\$0 "JPV" M4'+N;E."8Q|61/3?6!;|PU">^2,D31|4=D-;Y3Z,RS =F2%267R9G8;K M) 3/5E9U
UP0|/JH93M7R^>RR^#XPSY4Q3RIR<:@% -ZG&0C|TY NJUG, M|YS_6;"M(\$6|YEM^&A|R82K= ?X|D^3;NS,NU
I^U0B1/2#|@C(C/+H6_GGO& MUO,9Y7-QJV6#7H*VO" F3LFG%G|S5; _YCWXH'E- W|BCFC;F"4 VF^1*3; M|JY|P%DE|E|I|Y?J;H#4|F<?
UES<9S-XCS7Y0-%H: A'F,DC^>:J2HY8XLO MPS57;I@*\$ R|NHG1/MR@G"DN#X/2<8.&LJDP6)5!%P.T|S|S|/8\$W|5S M|?
Q|YX|58Z|Q>JKV)5TFK10|@|H\$G;|I|S=ER)=(WFU> EC'W;J?F)X80T M^B*|J|L#K>,ON!|T@(^HA;J?>N+!@U.' #*M07-
79.M#4>, #3Z810X#U.S810; M|G#T ZOL|BQ-%XEEA|P, #D\$;L% S M128J|+?F"9Y8%V9+JK|0|RC_4DF ^PH>@BIK?
JNB&VPG4;F7W|E=O'LT;Z0 MD,/*C1H'W:@\$5;*&AE= X%3&HX: K7N3|UOTT= +W|HPCF#|IDEB|A|HC#5 MN" BWE?>|H9=I'?
EH2^;EWLEV9\$*H2DN98!K1 H%&X33;E4|VJTG0F M1;|\$|GK?*18W!-1B 'V8#|>U|Q=\$E|J?> .?6PG(MO)M%IXJ,J?%2%A'M'
M;UCV,0H^*^@/8A2XM=M|J"IW,3|0/7|KMT0ANZS7U&G|R) :K44P;H03K MBK> (2YUBLFP|J|M|AK@>8 ?+U7O,
49 HJ!3%*Z#K'SDR7FIY7W8=PJY!+ M%2#|GX2TB0",OZ,UBC77U#&5D)O|J|RLNXT+R6VC5T3| J|L9;0G|O+T M" CWNXXJHZ VS#F3D!#-
M^A=X6R|90DM3|60?;K0|VX9PQ593PXM#L6A3V0 MDQOE_0IMN?B*7|W|6|S4,C CA7S,B7J9!^|ZG,V:V;(BP2D5G'!^*345)
M|PSWRKE=0SD4XCS|L ^*!0"80Y(O3PN; ZPYY&G!54(>HLK^O/P0=BWOD RGA|T|X3E>3JW27>7>+=)=Y=(C|AMCZ) MG9LX4KB
(KTKL;5W08DS17^&1,|RWM%;#!+>BN|4;T.%MB2|M5?KXR3S M\$AQ6#
G, >O*|JWLK029&H.5* *R#BPM|'LVA=O4M|C1(G8%T|I;@&|MSB M*CNRMW"\$+/K&|AVR&FR|>@N0WE
M|+^A _NY7|@Y0&T,|J^+ _%94Z06=8P%XYR^|"-K'Y56%LH9?|Q0U;N)2MU%\$ M|J|,(5->

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|3FV;K*0P70;[+8AD8E03FV<|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|=O W0. #H^E)H?V!*&@" [YV1 ^=3W<0GC,=NF%)Y6C5SH,.IP6'K%U M MBF0L. #^*6FO!{;.%.%09'QO)I TR3/3.8!L% S; (U.;P9&O!@TOMPIXS MNJ*!OE>6SPU? Z^IAH:N&4>9/.5?^J7JEK4787Y37: XPZ9HG7XR^1&26)%36\$LS4#KG=ZZM[2WD^\$4TYS>+MF6 M? L)7 W6X*8%5WG78S5/[F]@Z AX,E)IISDXRO\$%5V.ITS2=[<8%JC?* 666 M(Y*LKME_N)KE'.:I/SM3.3IE[J- #6.9!SFY3K>GA*R#&DOI=G\$O>=97 O MF7%"U\$=#">.5[M/N14 [<=9#\$KV?-5/L767V4@5ZA]&=J/X 1IG\$UF1;W@ MC4UNJ*Y *3OU<1OYOA6 U(8 B1KHBD=2N> @KPK> 1%72M"MO*#:0SDU4 M8X^F,NE3L=Q/[T7J#7TJG1KH3I:@T(ND=9@0+> X!M#HADY=? 1JK(A35<+ M (%&?"VZ!AG2Z .EI)S=ED=XV5V,B(>N B2^/D^!+&3.090'N74)+O'#!M@ #?C+(,IS7! <1'4EW*+R#V +*V^((J,S12/E(ECV)?3VOT#1.L+&L D9T"? MAO>+V>7>[K*Y0F3&C((J1P+D:6-\$'18<%ULAL/ AA*O5*UE!X-X/WYGAO MCO?F>,&J=YT S*<2ED?XG98X=#2]S/500+5S/2VTOA0J,K@?HO(\$9>EO! MO?>U!MGG0ZCK)1UTM7W)A?%7G:O*% <J>JWUW[D7+4T"]>U'30=C4ZV#2@>Y MR%>L,[08(U(0+F74)-G*N\$2^AF@'0%>S5+VB _J[M; ^=F=3/299D"WJ- M2!EYHXS,04C2Y5DKORUC+T\$MPF=.*CJT&2,2H4 MY,#>APFH#HD:&U\$*\$^*^VRM!7@GR2M"8E*#>+57'F4?G8;U8:. EK<4? 1GP3_BZ5BYMDHD>80904C)@>,>E6. M5#<!/M\$1%L@'-.?52I*ZDUVCL\0:X,F, ^NKG>S'0O@V_8 RE1JAY,:G7 MODUJWJWS ^2A-G'- A0IK^)*4=DFM%OIR">FC.Y3'9J=[#3U!/*M8 P50"1GE)9%-AVQFOU)95V-GKC*EY MJ*M%,<%- %&4PKTS<#3>=@!W0^T0DOJ|O'S7Y|/Y?+.OR!6Z5Y#|S!-=",F? MN.90%?H7&:LU\$>27TOKV^15X;N6.RUD'&GU)9/:+XR=BA? F0K1V73?K1V M3M;WEOWQKUX>RF2-1 M^/[M/1^S5DOBOV7%RD8:+&D[%Q/ TX/1YG9%5E@-9?: (UPBD# =IK^Y'EK@0&?9X8" M[6BRR)Y\$H7LJS"*<'QRQR'-4Z3*\$T9?GXJTL/D/WB7V'X37CQT?EJ1J5 MMS<|C0|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|US 8 MH-1 C[5,JN]8@S. +2\$U\$&M71O/-4KV:IO] KMN"!I(E,.GO.1?>P9J,12G^_M35.-9W5YBK%*LB M9,V)SO!;Z%2+G/V>XK*DR2+J)RM, N2O[G-A5]Y K>[J4'VZR#P?&4A1=R] M<:EB@W=?Y71*TD"!M+ C^>IDH@[W2,E'3WZ0C#5[LRS1G;TXPJ]37 B)H/9 M5D50N9JN@!@!G]PGN/"V36 ?- R^V>!/J[A;P%IXZAR" H.P%U^>4!I'M<4* M5V"FE-5Y=RO5S8<6!Y6Y7II,7)XSE4|7[8G0MJ' EJ= (E KE")F-3,]2 M6@90; ^*: E:"9ZN*YJH9T> <^":>A7ZM/[WV6235_1/+?A>X2QJ M% B/ZNF5WK Y0M QPBA>KTG\$WW: !ZM, -?06N QD2Z!+1X%ZJ9F 9JUD ^JJE(D MS3DW493P &1Y^O@4H5<*NWT%V5K8\$")*J: D(J)D&::KZKS-)@L%C%=O MI>C52K&MO/7L="J+W4JRDIB"Y1^U:SJ4O&S6!SL8\$O:JAMPZPG6:RT!L : M#V0>V#)WRX:\$-H6I.4 AIHV I:@=Y0X@TE!@PERDW1&TN!L<0:2/RO1.S5 MUSNSG9LH8F,)4 +\$M)8U'H *THS>1DV:5C^4/&JS#:#=|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|CZN1E8_H(9X@'XMD!1) M@\$ZMIE? W1Z=:4WFS0K Q00D'BE< 9K 4M#FR#:&=>UGF\$3-S XZ\N;G? MLB=YOD3? 00('RMFQM#"A2FRT5=%VP4ZO*&C^X8A_4SE6OX>A\$*+:J[3:=P> M\$X418=L+C+%ZZHY9NF:\$!5|L>J IFG7&Y% L 6%5M^F8/>BPRJ@[9DE[6! - M.F#R- TIGL: PAL\$D'S'T+M48/0-X=4^JQDQ)VOXC&R. %: M')7 08M\$LI#9.*SA* H5X\KK\$4GK- ÜSG;"A;M=,VU+QI.4M- FJHB[C((7?^!-Z+.8+0=|86#W&SPH ^"M=L+!NV3*+JW[J].0+E.FQ. X.0C&| M>L I]#R%,-"V TOOEL#U>LF\VRM/[W: "K3+ M;%\T\$<|K*>*L>6/QD2'YLH.U, >IB3?>'1O+9_ "IWOG MZB, %G5W"= =^9X8:(4|UW_ :T7?\$.10843]AA\$DIXD1 (9#5VH57PD15E^*^N&Y MFT9H 5H,WX=,-7-\$1X/LMN2MM_2(YV^J9XU4(A+/J75)T FVO#HO@A6F M*8J/B 9UD\$ M2AL'C*V#@- UTG,J/R%+!J%)%[%+ -# *+("X(\$A8H/V?X M F%E2)?8I+!JZ2\$:@C&81*.KU1!4/ME;AR+65>ULJN5";L4<7>NOUT M.02LH04]J>&F>I, E0H:XED,7X#-.^M_.3J1K!-J[1 X70242A2S,<^C M1[9A#81K(JP,=)Y(MGZ B< 0A) /UYR0LC-ZCA) ^2-/K+) B #H_DU#S8&6 M/F?2>S:3CR/JA+ECS&K>-%+,ID5, !S" +DVO1R<|J?J/>Z7X7R DS/ZA% MV=MMQ99J+:L^ V. @R\$OEE//H#OM&51% I:/71;?YIA;9:3(3?&H++L6>S M H_ O.AD P=O4 ^C&C*J@<^)9ZBZG.F7-TBBB@O"2G? 8HF8.L=>R;>0:=HUKMOL<,.09>PUV;N'!T!5T@#X+ MW-0WX I.M9X%#>+INX!^BC%\$0VXSH" D3%G5<1.ZDLL WV;@X9JN8 -(H ? +H#)%)=6 GR3T\$IN \C7=3;=G@.:!.%KR=(KB88%>W2Y:.. M& W,>#!VG7,OP!1APO+&DT'OK" @A1 _R&A7=[=YFC4)P!#]N+\$'6XN"S? MGW47E[KABO;L@8RH/H18<|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|G% M!-UMQ/<)RM \\$/8F FHO0HAU@N07HCU0P78H<28%H%DU&O!B@O1U%?O; M(VZ"SEO+IAJ/->A/C/CDI=1>I=1GB 1MY#(@?)K@A= (UIT)U JENZ%TN#E?0<|HIT F,A/D-(WXVR4M+@1+ZZU01J/7,T M*YFHR&R)ZKU/J5/WP?>D70 K!>2HPUI% />91 #OGTT|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|N3P0!AY]S)WTOD>X/A/Y/WGV*FAI3JN>>: ^? TG%W!)VLE64E- MKO, O&R|X4)N, P08A(M>E/JT=HL7RWK"JU>?B*IB>9) (T\$!V", 1.MU M):F10T0L>DGNGVZ<33|Q=+?BWH_ J-

;
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|SCY+&Z7.GV:?-,-ZUJ\$=83VEF2.#VZK=)30\%GRT^3; M!P@2[ZC^4%.*F^&NJJFH51S!N(KJ2? \$1:>3@O%Z,Y0>"PB0%Q MT!P BOHZN&2CZ>A3W0R/43A.OS%VH@_VD(O M2Q.OQKXBEBY3^G^WPP0>S'Z:V]03 &0FPJ=|C<7NMDP+A%X:@'J;9>S [F]& M08/ ^T/T?-+CSW\$=|/ <2:[W0B"E, 'J%LC+Z:T-@+TB*1NL0\$!-A, RQJ,T> M]J%9S@W1FSYJ\$&O@R78S9_<7HG>?8V +J1E8@%>BB\$1P-H!;&C*PO" M/P=598\$@J2J 00&H,D>H2A0.?04 :#!-B4BF>86\$S%,R|5<6G;<D%=-Z MJJ>I6ZB8*OKK>BOIYY'G^H(J,MYRLU\,#OU(Y)X\|8J/D|U?W& SKO7 MG<>(U Z@UF,;.F^"3Z(TWOB%QIN%Z)Y,3K#KYD34PP/BKO3RN7,3LO MJ50&[#S)R, NR4/ZRRHC1< -8:8M[1J].O*%/_< O/C){BH.G/5K12-I(9MGYOW%TU&ZH=V8#F/3<>[M4G] M[5FVRVMBZ#\$C9!9PL:AFLW^&1..\$6)UOY*P(G/-D, YI&%*J%J/7@SP:HP\$[^ML^KR+R^AJ4E,+CU7: /#EFL^Z9XYL/E9.8+M#&B78WXPZX)O1IGH MBYSAW M81A>@JA: "4HNZA22.(NF/V1Y|=, >YK?O^: ?T:IPJ), / MII5[4J]\$/W5W*-\$-FCN@-87T2K("E/98N5)HUAUYWRFF10%M'VGF+IO%W/MG6+*OE%,V46*W=FZ/ >+V/S.9LMTF)#M\$J3*5*50;7^W\$=.07 &=K#/3*!/3ZJ7QU20"@MO&Q9>7:5WFAO:#P MJI FW 1%/_+S1W7H-\$]+OCTC)#VT JI^):&FY0%M3?/67B.!Q43P)E84 M=G.V<[M8M>8YCV@3J|LOOFN#+12I-#;O-UL/8MOP6JMDJ"-B4A_G@",5MP+SM=J\$1YY%/>"Q,O-P1K5,ZU%,\$?4ZU(N5#07%@^J1U<;JL-)>&J?Z>+5> M#*161+J=VS6 -KJNHEVMJ^>XC9,=LP(MM,ZB\CKZGCV?D JLEY8'C6" M =#3|T>U7IZ3-527|S2Z+EA,W@J|Y(UHOK=5%O:;TK8789>J %IZ.O:/M+LL? USKELIJT:PUT&1:,(5Z,JU7,8M0,RE7,:Q1)BU4%"Y2WLLEBZU->(MNJ^F/^,3/\$G|V0:9X|FO5'T<7FR5VBXP1105\$M7VRO>-.7WR,\$VW M K3J&^BV.S:8203DV/1.#E+VS/-8:KJ6WBXO X6=M>NZ^2\$Y160K59;VO' MN7C[0>K,P.R3P17%+>M*L5&PRGR?.JZ)? 3^ZY@QI?*X4FPD8W6J/90)M0HU M,,:XMH^*3/3,X-I<60A:+,;J|A,VUB|IX5^V5G;V:O'R;!:?S>R>7^Y@GW)A MAPIS"! YHOEA*-ZP0/306"X\$G^6H IAZ_CH.+%1%!, C &M"BTYRIFK,<:= M^E!JLW3B: ^!VFIQ\$>IVAWI|QJ8@!O&|L>|UA|<=O;>D-T!^B?-.JOF C2MF MV 5'MSXEON:2SH*LFR(KOO6@/0:VA0%>D8+&P% ULM3C:1'40@8%L8V/O M&V 0MVCZEX,9!Z*X? 5#99V\B:O0OZ%R!L>*%.4,0YT>O7\$#RGDH9;C M,4@FN\,YEZ&F!>V251/8Z.*H)T,XF#*D7R%*.&(\$O!D4UET9T5Z5O?RE-O MC 1/*(9'@R&6H@W FC1%5H#,SGX2@R6R!GFN:5 V|Y|S|MPHE@"POK?/[& MG/&MB277%*\$20-P&,8NS69,FS-%OY8QOHO>U!K\$Z,K8+J7R-8T30L7GG7[3K?,>= <'UB!,N!%>:,:9^(&M&&6/2R!O2#H&3;2,=42A3]8=,=DA<@L=, #%% IKIXB< M6"95/C3IGYT:HDTUX/KM":J#&ICX0G M%\$3RT3C,LUFSRMRHP#KBQW0(C35 MVCV?S9-:J|P|(*+0'-LF5L8>.4/TPAOVCA5TY%/.W AJL@G/9U?+?30 1-? MZ^*=(G(ZVTU)[35/!04G"U&B-&JX"(0JIR0:RR2":B* L,-&L,0)D'M!2#P"STR?HW&>*N84>.F#B" VU4T1,+-4J,F M%7J1?7MED>*T<|G|V03&#FZL4^OO?;S,.)3@<>GXB: M;G;NO,HEU#Z02@XN+6"PR\$U-&S<>HY5- 'VC-NYVW G\$?;1>3CSJ MNXJ:Z@.M\7N/ZB,K06D|P4 XWV !%3ET B7Z=>WGP;#X8V4*+@,RMU|YE M#T|Z,*4^N:Y/[MZ|XIN^9; Z, GBCP(HJ/NF+> <\$S@.M3W EC?4YJ>L^>W5YW6!6EWFIU6F[1,Y] OKS17 M+>YI+ORR2!|X,(7E|?TW|@F0Z;C,3=@*!LD1O J|>.*HR/BZ'A 3&J= M7+@& .^8'CR4X8C+, -VLR*5 , 7 18+?E?CZ#/!K7M M@0|6JO,X^NX="Y'G?IV3*#W@E19/GG4*FT'0)T0> ? "C;SIVIN_>U3 M|." :(&" +WGLB7J!9>AV./\$D< ?L9KS7G|JW5F7=91='40&A.!02(1TO*9= M^"4|4V1FJB3"?I&(#U= C>|E,T>4F-J%4/E? (0A*ZMG#>SIPO2 FN'8#0(Y M C#1H- @>3\$X>7- =^T&W;A8EZ0 .^TJ|_ @^Y;JW=WG?(W?@J?F38=T;E%F=4 P\$44CM =\$J;PW/Y#,2J+Y MVDJ+LY\$H:YYW]++2T,HC'D@-&OYZB"KX&XJ(X-N+I^? P5NL'U+ "B'V=' M0R:XAL1L0U(S./JW,9K-1/%JCN1H\$?)7PGU2:3U"!A#:A8D0,18*UN1 M>HV'59X UHD)5TI@(001?+QDZL/2D.J>B31'9VTZ""+;0Y,E@DUE@JTXZ3HA M>6|O#T#JS,=IN1/!JP!GX4;@1093\$!5-Z* 'K;M#V=>Z,-^TKJG 6DD5, MOCR;<5(D08U|ITG"/09I(G!&1T3D=#VW^MY8",GZ0U|ATD/-&@7ICXA;P/ M#*^G1*Q88/G(GGO) /Q=J"5RR*QT6SQWH< OH\$E,RO(O=\$4N+3#EP% (MH,+DC49NBP6F/(71^V*[18K1-J6D-215;Z M3 P!-3" T:A+>5;@\$/Z/O*P/T/5=B)=D.YPK+&J%VC&XZ&3N -SUTSP5U|UOOP|4X*1?A^|I;7U9JVCV7C, M=3|6/KZ, G5! <-L8>=0X.J072G*Y4I&U^KRNQJP#WS(HE=%|,NNV/KA MX;G>UE%X2SB2\$9^ EZ&VZ&1 X,>I906@.S-;.,MZ>@\$RPTCAC_? (>=5IUB-C-?9TW,.^V^|C0OL)).C)VU^T/T:;G0"K\$)(O,9>+@UKL# MB0V00A&ZE WO6QEJ)R+)\$ 1:Z#;A+Y0(CPR ,^!G\$%C4GY4"!T7ND^P UDR M;IW1+CY78M^ #1|(K\$V/ZFE E_ JKA94^*&#WGUW@5|W 5<9)4BH OWJY M5% /5' 1NVM ? ^R4(L_ ^5%>5VBE<1%\$XVG2 (R.&X*"\$M, T;HF8?J, "4F M9:A\$KCV+ CY(3I @40@#F9Z*.K|AP_ (M1CX,1K!21&R,6*CB*QMYGE\$G2JA^*A?IC'SSKL1?_J|S,B61T?**6M" T MXIK/V:NFF&Y>2G8P4V|U"!O0(RJ- JAWIR=%+N:-7J<9GGT7HZXJ|J|V/_ @ MVF(9%GA>)@W<=2|T;3U801TYQ%<,ASSX)?J|D=F3, #<|0W7SA?6L,LE567 MTD:O2/LJZ@/CF\$0,58 .HN<(>Y#|73Z6984,=(|Z7:8X?OO"E-M;&ICGH08 M,IE7C.O= O|O0J90|ZS: 6VV>6PFC)X*CRH9<2H*MR6,S(WNF I?,ZYFG, J/ MOH%C2@.A'1, N%Y 7COPTS/Z\$J|I|R;M(6H@(F;"A&=)\$56.J,@?0HR|<09 M@D55UB=8%G;*.?6%4E3J;^@'5GB58V+H%?R; (3%Z%*R&@/8 GWN4Q:71 M%1K(E,2)H\$ 14C7LL&T)TFT;?"L@T+? ZJ_00L|!*,D#C6^ =XZ<*PV#RE&J M8NQBI3RSD5D(A=>QKP@8L)5,(QUH%#LDB2=H*<TWU UB= [B5V, 'H|'\$\$BNF.2JVHTQ@? #EQ_ ^" , .JGM|) # MV(OX/8AKGW6"=5+W J*OB:D/ >.(F"3^4T08I#ST/&@ORCM#Z0*<%?H)"ZA' M9_ ^A C3&D| >2WZ=I-*F|I8G@N|_ 85V:B4420|4|EM! /B@-E#=2LLUP"9<"IY1.=V/)IA \$! MZ09* (VDI%&"900*8=PP&RHW3C,L^I/C^O'(0X6>X?7#%AO+*.'@E#"KL|R-Y MI-SGH)=|I|U1.#L_ 5P.*;^0Z&S%\$A0*|L! (I&RJP28W8TUYTCN*G)2Y+OS,>C MZPT3!5,|^"8W8Q0B1GPW&S=IX^WBTRLV%#CW+H2|I(CZJNOI5PG6,:X^IZIE50=;,<3^9N@KIP7.8MAGYD5D/HAV.&=NO P#'+ MMNPA-OYLO=0/+%@A"YR1/E, 7CZ(YAZ3,:5)@WBC=C:13JTR8!J|19>8M MAVOOJ0>90K\$,(,PX9'X?(*\$^0JD)2Y1%2-7/ = \$.K|B+\$FA2XR@|QO R,03ON/?\$VXT&F|40,7,7X]>CNR^?LK=.3 CK|JR| M#C=G4V|Z^;J|I'+LA(L4PV,NQ07;F-C,B|YI=6Z-|J, E;J7G9:V?-\$-U' MUH?^:9RZA\$FUF)\$QT=T>C;JE#EY,@2ZV'|?J)+-X#G= ^%J+73,TN2EHX 3 M0 AZ<9YA&@|7^~AI?KYNX0;H|N;3NNFTJY| MMF#&WIL5|MK>8EF291EG"V&NK\$T,H_C|'G|)1+ENNNS|K7+W'A_>J#": JM7A/Y7* MA))"Y, C6'7?CT"PP%4-0H)(I%': 'Q@? >MS! M&2;ZT=F,R#QD_770##BG\$&2L8_ QQH%&?-V0_ ,_JR:&?0&E=N9(SI@*L6 M?XW64_RHE&0T_1FQV)" MS/5- ZOEO+#+X:B8AZ69+4N#|AIJ:4)I"3XKA,ITOTL<'.N'E=<)J|D< _O3T2VP^&S-0I^>%.OJ, ^L%T O#13_ <-\$ M@|B& |FW_ J|'"60H@:I0 GNC/(3\$WS^)7Q82^S|P'-MGTJ|_I|J(D"7HAS M(<|W6IP?IDT0T|I3:Z(3.6HZ60Z MJ-N1J12- P+7\$W)=R'4AUX5< MWUT.%GDCR3Q)=U*G,+5U.RHT\$V>@IR*80#Y|N.GHD-?*\$%A!806D/H@=WE M8)\$=DLS#!>WJ+/WO^P"KZ%/"27DAZ(>F%I-19#A99(,<&%A!<27DCXG>7@6, +/I-0/ E RXIJ7SE1|6'+=81L%)/=R'8A MVW>6@V/9/I,D>WBRO?72LQZL0)CK62*|+D2Z\$.D|+=)%C=+XFY??,E=K? MMJ|K|5(GF3- 8U.#M>>VUG>5QVL@ "R#S+8^+97K<\$/#3J(Y!"0#)*0C+/SMCA MHT 6'W_GJOS: /?Y+KYN2V!9#@_GD,AO^W!>,JO:RY:- ^W6!Z_U+Z|OKIH=N#+Y^8U2,<6 M:7|MM3J9MMPB5LL(V8;4 M88AD&RID*K# F5>V|J1@%E+7SD\$ M=9RY+#MP/_ #_2NTGG0|60=J=4U;V5 BWQJ: MRZ+(W^>UK:ZU>:K C5"SSUR-#TXX J0|>?T^>OQY9?V+(ML"0W2II|S+BG|^WKXX(H>AQ&?NE1UP!<|JRAY3S^ MKMLA+C8"2U*V#AEMJH F7H(3)^R73>E#EB J",2? #OSK,Z5&FH4@5C49-1 M/MLB,3>*P?>%;SH"O5E+4DJ9L#,Y5J5P!~8, *_7(UYX+|E/YL&@:, M4. 3CQH44/E@T,W6G(TQXVT:RJ+!RWH>H,D#V=<3 M=Z|Q732|K03J2A(BJK:D8X2T(H" <|J|S19&/5- "E61:FI#TM3JUL16 M5E+&H>G9 V:)^J|>XTL4=8T2:EL+PZS&DMPI-X/W+N%ICMHN-O\$F%COVF^U MSH%P6ESJ-%9V:0N0+D4KS:DL@CT|M0<+| LRRN|L^6^9DVJURM2K:SRBTR. MM-R,I, <74, /E#MO)RYX#W.T|S\$8<&0MEQ(U&4U;W.B+QW-F +.060N\$; MNJKNJRE25:GP*UXXP,VAPE1=W1,L&J|JW|J8B53^ H+<&HCN=6?+RE=Z = M=/ JHU:9HGW%EDKIQ&E8F4WKE|R697%F1^1%57\$"2ASX<+ENLG)Y4%LH MDE*Q2;5Z?<W9JL,FR : (69J""Z(N6#U M,,LW<%#4NN:I"K;"VMQ@0*W+*N"5H|P?CA7C@5OZLXK1" ^G6 M=IN+W*QMYF95LK87+;IN\$3;78U Q31*L7)4E5>5(G&2Q|Z<+B|D:519E'5 M7B10U)2JU-4',-CA3^@70", O/4P&^ 7:#N91*> (F|30J|X#*FC2E6Y M+BDUX?5RU|PW|S:W+*0-BP*GII441I2OCL6):53Q_ OQK/X#OGH"GG"TY&V!1MB#9V4VSF MF8-%"I|X+*:J2L|_R FU=IHZ<=R0,K|J:4X&2P,>JX'+X5)Z,D>1 ((9BX|J|9XL#C *91<8"40P5F5C&|Q8X2+P28 M3 |R"TR.K, (#7|J|WL1FFA9"1;<)G@((YB,O|(\$5Z+90>MS(EJP2@80M-1M1 MJPZ(>^6<1Z1-B9P5I8W:D'U4(8-<80X1|UQ JBL|WD7VP"V+L JL2H%4DI M;^> WEFU2DF)=&JG=J@/;3V@)L"J:QG6GA +MCM|5|JPCO+|-FUQKH MED/-ENXYEO/HIU!S\$8%F)=E%?.CUKT? NY.9Y" W^>5.4:K65R/BD M|X%#;K.110KLB;5|JOS2|+DU%*YUP?, 2L7:RF* RI2#72W10%\$,(MB,"1 M A<;N\$0;H@WNVN! (0@@3/S+O4Q6<6.8'-R9 YH% (6R|FNQNP"Z WIE& M41\$E|I9J,692)Q,&A=; -I'8!6|Z|@)F9IHB"ET5R#3;^>N-9Z)K89WV/?! M-8? 86ZQS?08_F-3V;MWV0KTEZD^ G(ZI@_KSH22C'5DK"(GC9!=;AM332S2 M0@IF!@5P>)-MMBDENF&X?3!"AIB9|+@|-

I&X""43ZRJCC>(P%Y>MOW4M1W<, MBT7KX =6@^9X7I+GA<@ 3%LW0>, W7WY -O1-'YD ^> _,\$9C/X\$M-/FN MR|
IIZ&5IWHQGC:0:FJVURUY/O/LCP;U;7+WY>:[MIDOSK:F\$OQ/DQR448S# MR3_O/05&1NY=1TNK]/F^U?
RMU+SLM.Y/B&X_ZT, D3/HHCET8DBGI>CN5'1 M^8Y-UY/DID^651M? OHX/8I?+I+G\$8FOIBOV:L^O+>?'&
L9,S"/ #>Y;GYN2^3YASX>%LLW(\$>W1 MNFFW+@A[M]>7UTT.RT<#WT<"3= 3) ^J\$E'0JMT>72"\$ M@S%KME**Z0%
IGEFZY&D#4YVL-6FMER-0)PK20K2VP(8:2 LJPQJ3^PPPI MYZ\$/O>J*P0V3FINJ3^+ 9T516/7^H5FJ(Y;K8C_E@/1 6M0Q8:V-
8:ON& M==ZH6;I?1S1O-=\$D@62Z+YJV@%:X%-:">#=D2:ER? *7@#47L&YD"VA% M%.B%DR:OM PR3+EZK&Q+?2IJ/ADIMC?
5I\$ 4=@>X7+C? MJX0+-,=+@*ZN%+(P&%&YZ9@78QJW(O-NM0AS32K+JE072X <-<-9M5"50T* MOVQ5:J1K4/J&T09-
D/TJJC5"EG?*QRS2E52YYI4KL ^>,29 >@+1>R>E<| M; L V*14:XCBUV^).1;NA?B=7RA#O5TFS=NMFW, L/..;X1+==!.>U:&BN
M2P%N7'PMW/5LZ54IP+6)H03"JSD!+?)&TDM*Y*RQ1J9BU;W6W1U&|\$M&^26 MK SA99VJ-7%+M:)(M1K_M;
%MQP,MV0E'B_KSJV%6IJ?%F5#:@*0G"!5IJ M<#+#++7 G(WG)9DJO:BLZ*TQ8.F/4:<@%.8V&L4&DTI%IE>RO&
M@A4.F15R\$BF6@:@+8@6E(-=LB1KVW, "2|<,B,D)&@LY>|5OPMRN2\$|I5WC M/8Y>48,I|BO=|X\$'9%JE?
4H6G1)FJ/0I^1^":DYBZ6MRO,+AN/P0I MX,HE7,R\$5>+#18&5Z4JU0"OJ1I'I_O/ UYQW3 X*CWZB?A/K>,\$ NL.FDEX\$CVRQ#
(HB M9V79+N|K+?:>C5-K.#K^C@N(M" V"3%62E=Z(O)=6L"J1%4G;@2)T M0I7L% X DL\$A62O'ROJ%0)3OYC,PN+B45F;JB7
G#TF^9:6@+ ^M-I@5% /UZ M6VG-AJ3(.V5X *A/3A<+DDJPSML@YEP5S" W>H.%Q#EH0^'RR8Y^11+ ^9, % MLTE-
EE3!)8)+.*2G\$R.I5S*@KF\$N 7&77,I-18(N9 9J:-(T89H0/0AVA" I M @XV* M# V*| IZ7ZWJ|+JX&|K3IA@|VG3:H_IJ-V#/!BY1_4-
18ZI:AM=?!6!L2W>R,G)72|B6B/OU*6R7 ?^\$+PA> /&O)&3 M ;I8@R.W M4 1611NB#=&&:\$TL4-
M<!116#UL ^Y;!M\$=DYB6'0:4%-751!NB#=&&:\$T ML6_J L KJH|^4RLJ9(!|6 ^*GW7(7Y|_|:"%L61:88YULF?I=SAL?<1=\$I
MZK61J-QQ;N,9;SZ?"7F2&X0CSOZN8R%=&3C_FJT'8P,>V=P7#,N1YS%R|W MB ^R.4I;K 6&^<-PU:GUQ89-
XWA"D<+C@# &X:S 2:VN/F|6P(A SM&K, MYQK@@4Y,JO!):-Z,2'X3JA^H=|MEJ JW8|^ 12B=5:4R<%JM4>-'O&K%,%LJ5
MK#S7IJJD>D!65FU(59FCC/O^D'6P0,|+*)(KV&P/R)I4DQ5)*7/EJO,&K(% M0LX,R#OP^<N, <Z,20/V8,73.OIJ-VJ-/ EZGN
M_ '(Z;IJU&@>OJ9J;Q= F.0V\94\$XNTD(*10: 'W&2;4J;AAN'JRG1 (7 MW(X F@<1)=030NW)850,=?8VNY>B.8>DV1
^P#KG_O&V/A<+T "8MBZ M#X"Z ^+YMZ-|JL CRSUG<% / "&(GJ!%/CEZ5Y+YXUDFI@ZME>M^2Y MSI_&M2VR=V7F ^ ?
YKXXVP,I#Y-J,S-<AY)JWGWHC1_RN ^:55^GS?:OY6 M: EYV6O?J:&?Y%FC <G0B2&=DAZ-YD8=O)R2V.G^26; 9/GC:6CCJ/S
M^4B>QZ1&O/8N?V_-IR?HRQD#\$/|F3S.|P04F1(8YQ*+.PG,S:QCCXT/9 ME);M|U_D^OFY(9\$KFL@1?SC8K1Z
7Y?EU89>PH7:| ^WEY?M,I;V.% _%17E=HIO(FT_071 MJO.?K8SB_7='TT+1-V'UJHO7K(B)FNB?F4:52\$?
YRE/ KN#W1C1#WB%)#+ M'7PT6R#.ES%+J%,V@19J!B9&7U@TC 4'(UT9>*D.?6Z&94VW4S82\$+EW62#53K:Q3F=|MCVI0U!
(L:#\$3BOPU|HJ= M>J6C#S^K#VD7 KV O,8L+ M=M5>BG(8-F(I0?TT OZZ(I"VJD+NNZ\$3"0)I*T;:7>Z998LAYSK VM#P1(!
MN<.&W 7M6H8EJ)N VMJAUOHKM((A-|M'=@#5_2TO/E#?GG+>YX,|6:7;:N M&3H
;F@1IRIH!,#4UL;^,F!WVJ6H<5)9XK:DE3_FPGF<(15Y^| 8'K8.)P M\|7R2U\$PF4SOC'ROI:H/I.10GHR>J-6DQ2^H_S!K\$#VT>
^ J6N"=47\$Z M'=>+WK?BJ;"(%8K@>OYN*ZMC.OOFA-ZHE_=I(=N%..+*(FD90RQJN)!-(W MC/2<&B;J?66HW|- MOQJ)I4 _HCO=(&0LJ15-:E6YVH3J*AUPYE\$;^3#?-2 MN2+5 *:QM\$!21R|/Q|UF);+OQ4T9HKWP^9/^|V1V4X\$7@(&SDR3+FK|3M
MOFS9):J>RSF,%4D05N'BX^W(E2H>1%ZH.C/3N1YQ_?NEZI|@N|J>YJYH<1_HBPXK=BK)BKAA'4:D.2-9%\$P\$IS_(
^ZP"0=042YD&:><8 M0G@5/-@!:=&Z:XY=|570JG#UA!\$V OOO,BOG ^- 3|5<^H9^# *S31=8:
M0B@*|B|Z("^.^,YSCK|8*|JPR#E%*QP;D&1BP7C5Z781-23B %JFV^XP5 MKST*O/|0?V +U-0MIL4MJ4.O:N5"\$(J)@5PEK?
(&OOW>D|0H+RMW(->|->+T388/N?N.9!P6" MPA?=L.UCIV'A_I:@P-'+4?@T/+6"(NZ (9F#/% X+!\$@V+Q0*7#C-N?
M_OVG=H*X^V>1>A,:IK_#?V G7'7<7.1#!89>M|J;F;("TO.F>O. ^% = X M\$2Y25_74=|VF|Q2'4#6I I?B_6|07AO.*:F
M+LDR&U^RWS:O")5RT RRK\$|YRU+ MJ&^XVJ!X? T+(%:FA_,-?W\$4XZD^X'X
MUZ,4@_L0I'Q"V7F1WW3/Z"45.">%;D,I'Q\$,LZ^O#VTJS,\$G<+=WU/\$8?B M9I=|FO/9*WZ1F*V?*JLH4
#2|*7WV*2@2I,*16P\$*@LPZ%6->^C:(A5 E3:I#OQQ'B+RA+:HVK MK6TBFX*3:(HVF&FF3",X9TF5QBC-
PM#|JGG#9>1\$HU9RJ"50(+!:TN2-5EV M|-+*O=4%59DGEN)M|I !XLWG,2*8K#^Y(5E-1"=IE!7<^"G.7Z GY-
3L|SPBS|>X57\$|T)6#W^H.UB0YZS> M3X%|RO*Z(DZ%/(OWXD2'/1(J.2 =+YS:CTL%#W8G)QN2%J5XQ-
.1OH@%R>@2C3R(5X\$64:#XG; MV:W|4C5LLA:X:B|4BF"0'5 I M12S|/6PZP| H64,+%*F|9^A0XDFBRJ->US,1%1I7!?-
^>P5OTC,4<^;S/00 M5>-V#, U|JFKG>&O:&OJ'WW8,V7SVBE|^RZFL4-MX6L1ZZLO|U;(DESG* !%5
M@&7KO<)Z;|G4.!0NVITJC7N?IS%9I7&:\$1D10XUH.MR=@F9M91Y*J(8UD" M.T2JB9H. #7#Z*5M2/ZC464\$ ZBWB@_S?
\$#975E*-11%&5&F @5B|B2", MS%?3I+&NK8QN3HHT5B2U5L.%:Z|YX6:=PM:)?SH, UAE&(%Z:(DJE4N,707JB%XL(C/2:(H#O\$:
MKM (8..X4OCVH7BPR,J)*5@_&:(MHP YSR#/6;R? OE61:0J2_4:5P>.<+QG8N|7|T65QVO.XV<|QW6%#8;)7& M>D-2RL*FY*
|Y0"PL%#S8E16M2K<9Q0BYP8.#RS00 M%1JY\$"ZB0N,A43M'E6QC/5V4TQ*LL.0.LL>T5>Y+<:D-J:&*Y"Q^FN,G0F-C
M:TOW0J4/(MD/E5+\$JKJ0"ON,|JML ""51G;=! PV2Y*, ^YW!1-1FG%=->S M5_P, OJ (FTP-\$J;:@=OS. ?O=HY/MM66H+@MOU#-
I^JXI?LC>=J +&LR'6 M4U2NKE2D(MZ88->MT|97?|OSQ5Y N>|5^
MU:6PWQI+^S>\$WPG ^&ZW^:ZV, M_04%Y3;4B5.G|B@Z/RFKO"GM-N'1XGYCG0 M|959D8I:H*HBR0U-*JL34^O/+^<,5&K
MSCB^K>68U&\$3_+B8"SP%U4/BO+IF/T_2|JK2NU4V\$L|^?@5|5M<<&NVDM1WN)&+*6WYI'S MT!6!M%45TU 3D!NW9"
|H%W+L(1T\$U!;|ZB M- "1N8EN'MI^<Q/E#?EG;O:Z75 CSM106*&*&@H1:
(M4J%:E;Y2@'GS ^ (K7N|7.7@YL);6PN|U|G#!+#41ZNP#6?N'ZOC&L> M=E&I!+=1H5"1-5@32!=)CI.?
L4E*RIILDO!G4N=BG5ZI+6J\$DR7V5:|7Y2,! M08&>M1T|1OFEA+):E;IR+D:QU8U1^|WI<7700P8BP|/|>EKL41O/S(DZQS M-
.22K,3%L>CM@X7?JXIO-'OEZ|7CN&RJO|?D2R)Y|X:8X?U&<=C5\$HZ0,4 M<,XO?T5 'GOS1_O;^4/?P8|JZYR+I<^UG#
FH&@0*N"?>X'BHZ%?E(M" M=73"-+BW+ZXKDBR+|X@Y2@?@)GX@SB/F0|" (X@/ MB=HYZB3KT(0UN|GB|S|&CO
&EF"FS2J>SX\$E5K4NROQE'U8?X@O#< \$ M(2|1D|@B: ^>S5SO'8MG,5!+ M"++Y|16_):S M:T+;6G|S2>JEL&|K\$D-A-
D3W\$NL6"J5UBOB&2-?>G^>XV4%1SEFL M7XYEQ X*P2 |PB!+JI1RSHKZ%_P"4=5PL<.?Q|OO* P@Z?X8.)9HL-E#L M<9Z1V\$
A,M|X0&*.>LXJ|'68(A(Z-X1-//9JYWC19RZ%|N+J@A^VQ%D|DK M?
ODM)^FAG%/580TQF2)30RM20ZU)596C!\$RQ@4*PWBNEU,P8ZEPJS|YST>YL MH-C//W#13:C,B(&*^
5W+3N|ZHV6(U'DKO&Z5); K M4EV|I|R# B=H+A|IZ161L|/L7B=H+W,1N)FLO!>6T;8?EHNS-.-'VRZ>^ (K MO^YXBNGR-
:MHT46.6AU|J=8XVAQ2((4ZASKC+Z?C K#N3\$1R MXD!.>9S!|Y+8QU<0B+:2098"/Y_6YX D!\$A#:#UGW V-V7S|=>-' MEG_.
(GS)"^M|J/M/1V=2|+COWHY>EV3&>-9)J8.K97K?DN<^S/OK4MLG=EYOO
MW^: #.ODE^! FN1'9UJ|P|D|S|U1K'6N^:75NGS?OY6ZEYV6G=GQ#=?M; M?B)4.
(JHT|DAG9(>C>9&9@<03U)Y|G|DQ5OZ|7V?.(Q%AY%CNW MY)>6V,A.8P9F, ^>9 : "XJ/# F-0YF%Y63?WGUB4B,><28Z<220
II|P>Z MD7Q?GN&CV63T2->#P/W= +Q|!>4,:@?"36HA JD% 4^@(&F#^4-42^FX06! M.QBUIAR#E)X7| "Y>3'UZ./O2NOVJ^6|RW?
SS:8WVY'SVYN+ MUDV|=4'@4_OV^NJBV8\$O|0| ^=:Z|3|24Y|I: DLOKVS :V^KF^>^."H)G M2|T|HRZDE@%RM5R?>
R888+Z8FJ,F|R3XV0K<4L\$T#|=?#1;* S-K76M|I" B'!P?G+Y:3V\$!^JF0*@^"BZL>:0;EDV|D|1:@%_QLX'N M1(C+K1C? G1AFA#^!)
DR>U'NO'!1V (+18K2,B.R;1^RX0YG^Z|#2|91,M MOT+&CZZK&N1)C|MBE^:@IE T7|U1+.AHX&APE;7((I8-%;DYMT*5|B_4A
MMZ)(C0I>9(4JW M|J\$A'YQ,WZ>SWQ-VI?+&N\$U\$0;HHT= #JEMJ#9SLG&EHKZV^6%#LJU2CM85 M#. F!\$0;>*4>L+>&R|
LF6<|J3KNLS7 F&|X%*^"1G^OG(3JJR.BKOAW M*>D2HW/Y4T.<+3 L, U;4ZYUZ_>@J^2Z|Z|WAMGJ.2KAPKQ|TO?C>M#N|
M.M M,XE^19: ^& 2H1XS0|Z@30"Z 4)(<*0B|A@VR20:W)-DNM|VG|7U|B!*|FU;Y-4PS?(DU3JK*1@VG>-HYK5' +K8'&
<EJ|F:5&LHW,0MO:\$P?G9'3?0;:*/|X;MM|J.)|LL8XN\$QML9"74 M+6L83|PE?I L(9S8|J|Q2#)G>
<^628U/P^>J0\$UVCD%8WV\$;/5PV^ P%\$. MN2|8:7VLE,-):@&6P=8Y24R3RK6Z5^UN:QDIBV'N|P: 'FNJ=(LKVX?WV|+ M@P-
YMXQ-4\$1V&%|10QJ_*C5416I4.?)P|E: |Q|B0BT@8VQRORU*149&J#, 'P MS8M#O|J|I|T<->:|X46B:4(CD*X1=1VS
GA7B6T+RR\$RYMR%>L0?CXB#>FP, Q9|I6 M3|4JUB\$&Z-/IMK@2\$(|U|J)HNNOA ^"Q&K\$HX:T&>S' \5%<5Y91XU-
8:#L+OG@|J+0;7).+V!E0%&A M\$M!P@P"(-WBM%@=5M(HDRUP5^\$.P<+UR*V'RP+UJR>*(GO OEM>?JW00
M+20)=BSV|SC<-LJ M9|1GAW U?/F|K|M&J5-DJ:Q4^5/&J8"!EN*RA4%8. +\$5VG4HUU M)Z|O|U#_LC9|?
+*)DMUGT2Y. +*!%;%G.O.&O.%J|MM%>U)BD:1PEG7 "5ASX< M, +, 4445W%6;9!1M@7TK?';!AP-
+!W\$6)GD8F9U"O@H\$1>=\$5U< J|O-T MO;6PEJ*0Y+HJ54:\$|T|MM M<"0A#MRJ|B#T**RX'3|Z;<4'X#|@UE3D:N#'/F!1BR?
07&(|CZ?5#Z60%\$T M7?#?UIC|J|0//,L|J(D7FHXY^4|JSC18E60.GBA@V": "JT7HZ<|C_>#V|B MVZ7&JEOP)45K2 V-
IIJ\$W.%R|ID@)E+*2+I= ?X8*):9T%:I|U|EIWE2,D? M^.)BL@|N|Y,3/2 /%.YT, 'SH=LF H7B_ ?SN!#N*/B- 4Z9R9*U(-BIJ25/6
M*!M'40#|@>NKJM?@|S|1|Q^Y83DC-N"QZZP87ZQ*Y8HJ5>K; WMCM8,# M!'M'W.5, YA+W0_F4FM255&FFJ;N&=Q9(>

(BAVB#=\$&=VUP)"&\$IS+74Z'P M^Z'X** :*QK8*Z8;XN:\$*L:/V|\$JI+E0:X+.KV M\$BBGC2KM\$%T6P6L)KU4SPP-[P6O@053K-4DN;R|>NAJSQ?;)._CIX|I#[^WN M\$SR#^TSKZ>S=NVQ5'_=6="^8|E4-*!WH^&A_4)&TZ M" &C_@7I\$ ^Y"32219|KJL,#5BM0HUXC?TSWHP?06R' _&M."R;^OYH,P?>MFFR./XWM*)HNA^IL2,12EWA2M*04*PHR (30\$"8X*+ON2AR3.E@/&3ZQ M\$ PKL1 3T#A!#V^JD=F)VP#F(H:M^R ^[KY] NUH6C+(LJ194CG^A0E: MJA/8TY/ONNS =&@MDWNOMO|S;WO=D6>2+9 MIDE^=%:.)?>B-Z:[YI57Z?-IJ_E9J7G9;JR=\$MY_UH9|H)S3S'3HO MI%*2HJ'./D|X>+I'E\$8JP)BYW;VO+^3'&OL8, MS!>|9;"^KVC%5';J!/:\$K/JKX|Q+Z ;WYK)=?_S6R)7-^?Y'/.AI-.M=^/FMM-J UW(^>W-1>NFW;K 3^W;ZZN+9@>^7%I=-&_KYK7I-V'!IZU;CKM MK715C=LI1000T<':PI\$Z(7?VBJ>8DZRS;O8S+P)^X!|81%;E:G,6CT B^"V
MFS;_8F_U=D0H6((#9'OL,C0S#*=90^S#Y&G8J-KJ-T?Z\$;R/4NFLRFV4" 2" ^<\$2/0S< M+?0OHB|:0)I#^PM,(NR.IQK!.^P?N%NK_K+^1:?X Y A_H6 +5JM_A;H' M?T=#X'V8C/ 4TQTB< #+A.^C3PW \$82H'N\$+ UX9+E\$QU4F>4P.(+! AL M8(&%9?0<4*,/Q0);7ICLYWH#UV,V%JA9%?8B*T_Y5/!2WL(O%Q1^A@.. MR4Q?69#. "GSRW-M>TC<9P?>YX4XD>2D>FCWB?-R|+V'LT6R* MMCV%JWBT2STB7/HIP2UTM^OTZ?1^ .+V[24%P+ M.#KC(2%ONZ[!3@P%]*D.%N \$WH7@BO)D|@5B/GH#, I@0\$-/QV?5LDU4N MJYWXZ,?X ?P,<DH2 >P'SQ#LMS01|)+LY5|1E5XU-'50S":\$TT"/OPV<#2 M")Y/D%/1@(>.X\$ZT@6?1 &A.K8>H\$?N)X9-6X#L\$?XQ&< /1W+DQ(P,DKG MW^1R6T&,"ABJD3RWI0J+J?79241C)&U/GGF7T 'O@, F%U2# !P\$*GJH
M.OG""+PNIRE5@5-1;X;JZ.W9ZF HP|F7@ MH?;IS|\$GW0Z1)7!2:;<+5PTVR>./\$U %?HCS1_0!;LZ#IJ<?PRL0% 71!=/ M/0SS8(2>C80Q04>>\$MQCZ8Z!/SW0"ZDUZ9R#OE0|P+"!\$'^F0GBVKWP=M%|G?< N6SVK7@0^-
(74_A'F\$AX.>"PWY81=8#L_*@IT%:4'2@WH[ICNAP M\$1D).C '81VI)=CVL "CS,F-QH-JI>=Z@/O9^? 9JUL.-@Q4@+LE|E%<3RX
M@%5H)1D'3.FHT[6T" &SW-A3H@/I JZKC\$,|#, -? ^)CWXI?7UA?WVOX M-D
N)9|\$/K0@/EZS\$88=29I2P=/ 1\$%L!WTAJGF>BY,*WU"-F'BR: 6\$A? MV+^ .8X&()@YHEHEY:H*J:#D@16KE4X9|QDKL.3:6--A.Y1, M"UH.:*<(%YC+IA "#HPVM,-S-\$2, \$:1|G,80(Y5N/B%93:9TV'0YU/B1T/J8 M-&DLK[3TOL|"J+",Z)5FE@6L9D)0!|U#!V%:(V:7
!IBM%<4!=!Z0;P/W MA;O'64\$|Z/D!/ 0'0A&(|.X>('5(8P?*^G(P*)^"K @^6%**7>MOY<6R? MI..L2"3T@Y-'14*J..J|CV\$W.N'Z-
O_63 TZ\$D)6WA&+P ^1GR1^*^LV HA) MHI?OK;PN>[H-YIN%\$LP)FH8?C8>W7(XP8&J#OPLL ^V: P8V=B-PI*QW/1H M
=:LNC%K^ZT;J=JIBI BZ@<8(DH#L4< X,F(>C(J..BBJ|J0?^|H?=Z M:#(1>09?
*+I."<<4 !V@W0<+N\$1H\$ "I=^8K\$%,\$. @1)&@6+T"Q1+^#A<4. MM%@KZV. "#&*P!4|P*@S|LE"
IV/4=!"Q&?I^*LE@N<..=3JXHD@W4%>:#"VMS<>: M6)*8Q|=ID+^9R')TUXO:8*18:\$FECC?X(HX?K3JZ*R)TC..!;V4BM?IR?XR?7
MJ8F.3W01D438=3" ^1N^UF/5J.JGPQ\$(/R9UQ>R\$,*"7EG.GP>VYHF|A:#PW: M;"^ &SK1 C=S&U
800.U>8% ^3\$##T)R&OPOA#%,C5D6S !^D+S&KLP5T> W| "P6=> A|00CAWNFS8&M.QC(M2JD)P-9NA\$3+ ||M#D BZ '5%=>#?
I?_0@/JYP8&V@H*XB|QK@3 ,CNX6, /M|GT +8=&P<"SGA#Q.#/|\$'0Z4,P70@'L?0(K'GL,\$ LF7RCTE<"8 BAQXJ,8=.9
M0:9D%O4GW;(96P(=?4G-PHLH.GE8VOXM&VS%L".ZT)?P:N<"G;J%@NC, #(M\$GC@N0I#,UZ>YP7B-D\$6:)2^,(2?
B=2CLXI/(9J3>L0@ MFJ!E"CL;STF:[S!P!&1 T.140|5'S'1='9,||(@BJ|5*HU&M*\$I-8|L&-A4? MN6=+D!.ATXE>|T.HI(B@H .MIZ-
\$Y.JC<)%N(Z5NY)HPA%[\$ICG@ "VHH ^# MCA9H(8-YZ&ANYN>1;EK2;VW)-Y5F_5FWT;MI|R@-+D89UJ,K/ZHF5GZ664_1
M=F;E)T8 81!@J@#H22;F#F.=!R3V;J'EDE:(\$ (WT8 KHB&&%G*67Q3CE VTC?+|CM;0W5+PFL2;J9 ^W M6X@B,?^F\$B<-
M,W(>R2!%5>+=?Y<&C%*%I9^*Q4AZWFE70:I%#+1GQSV: M=Y#TB;IP%T^Q4WH4DVN2FJ=JY|=AU7:86>@FU5-
:FZI0G5#5ZVK4JUZ M*>G+C1T|P8&*O!T<4)J6KB;) M98X%! [5K%#235U7G13.06I6JU11#^"26 M)|E3 ^1TWB&J0<*7RM2VH '45I-
ZZ ,KO=XX 4|JH)<>R:S*W*U+G&I#TE2, MUHD6G^6M*EY>NB6X*^\$N|8W> CJXJZQIDE+9WHD1KYL*61IA3A'K>RV6UIF
M.>Y'CK>=XA\$' ,= =GYYZDZ:W+G^+.DW3LL*@K("5R)H^|5L06\$)%'+O+(M1?
KL@O:^R",7>>2"40>N<@CYWL|I%Y%5=##W'|GM8U&B_1N M9^WY|^R<=%5R9C6?^U@U):HB+MSO_33W^=(K97S M%.
(ND@!"C|;%^ (&NF<)4KY%:)6H-J2Q\$%1?F? @_@ 5/9JJWAMY>S% M|?)M2Y+U5J9(U|+5AH?.+0M#MV5EHA#-
^U/BQ1/.5LUY>N^/J7W1#5TW6 MKBE25> \$LLCIC@-.NR68*F&J|601K8^15+DA5>L-CIA^|8|W^/(RA)\$&UUP MUP-
)MCM\$%^(#P!^R;%M|*@9V02VF|JXPS8@S.QR|&><%"-V.8A=#F*7@|CE M(8YB%T.8I>#V.7
:OR&FUT. \ZOE@RTG" N;SY1'F>GI+EUU|M>KKS8CZHH*P M
&SA@%VZ(F,!@'VM1H,B5Z5:36P|\$.D0D^HOH\$:@\$ #HEM&0@VTJ4;+^'\$ MH2CC1YPLG0"8%>=\$7VO()> G577 7EK*(BAZ
Y5(PVED|J6O-&:YQCE", M M=P@+|Q=TX/J6V%*WKWE&.=)HY92 ^-@4SVPJ&.6Y6W7TCR0I,FCO| ^#X|-7. M<406U?6 J#95N!17-
2ZQHBM4ZDUHG4.JXR=D1JG4BM\$XP@4NM\$:MVN MI;-I0PJLN9)HW(*|MCJVN^@=W-26JL?90%;FW=1M 09.C8IJ. ^69?KJ0
M:@I'NZ8X7. 7V\$7LKG\$^|2PJY0E3>/H<2.M>A+\$PDH8^L9//|5HEY@UI2*WZU5
M,|RAM+TRP8Z(E2(CC)>SLK'GSX^G"U@_>AAX&ZUJS=N \$>Z4-&3>QUG,) MU|AJO*9 JWO1>O|LF'(Y9X=S6V|=|DT?
PB2|Q0X<(Y%G2BS?1,V1Q3G+*A7 M2HK)J+6E>, #V1" S1_ %L\$Z/LGF?.1+L#IAO(18|^? M: I+T>TK| RR*|@:
MP3V0:"2K2^K"PEH(SV16#J9)(TOU@DFB%WGMN'67"|(8E|OIS>|SMJGS* M?F&?E=, /Y-D*>D1WB/XZ-%Z!|9>)9C6 -T\$?
KL:6Z? #UG,K-6>%>9S S- M- GXI6|0 NO.BHYQ)3061+*)J%EO?/RG&WKLZM)GZYL#QJ! "YB/-"H0:CG@/1DJW7G\$)&F//,*I-
|30_1[6%#9=W)+0 :17<,>MO%EZXXGUHEB3CYL,J2F1|ZI M,&4|J:@?S!W^3SS\$&|O-
|M0H66LJ;V75;"A=Q=U"!FT"*\$COJ(?)=\$#K51A6 M1<1.E..P P \$.@"/Q3,&KOIRD 8P9.11FR+,@%IB2J|8'XELOI|3T/-)%^C&
M;F" C9ALXCRX"VX+>A|0GX; ^%6%WNX" T:< "1+B@; MN|5:LU@EW3XTD|D:(C(E(+1\$X'D\$9|G/< #0; !_@ ZO, @K>1\$G-
^"XPP) ^PTG MSPJ&|UBRWV,L^2-A_A6 \$="W009<@G1VTJDCK"J72-UC GJK&3Z&P BJFJBN2>+YH6' M3'=.R\$:-
@|TT\$GN^YGZ2PH\$P3OF" _5@Q*D@R* =6P)II4C9FE&D%N(04<*T MP-PL= #1BXCACV\$T:;%N:Q RJI/^Y=
\$O=3!BO/YXFS,Y%GWOX MK8(QX?QX9|S|E%5)*TV"PIV4T3:+6-C#9IUDHD_A..X0XXR K|JVK7 M;4*XS6A#6(FADGZO"XF
?F(MA+ICBL2=%G#I=S00 8|E1I1IG\$A?KGV|2 M,T4O;P7L!-TY#JHB'-2EW+I*SCBH*?H?BO^)YQ2
4;?2<|B*SX#BJU"OSV3>;=K@5/DF-L&W|H IMJY|J=L'M^|SL\$=C,(CF8+"\$'AII 3I0:R.)CF:UN>>9?30
M_@#++#RQ3AZ3WX*!M43DF|U@E. #.%1T#J#LX09RR5FE|^T4R)OT(3EFNN: *W4 ML_5W:4I %TC-K/7E9);8H()%L^K:BU2KSIZ<-
E=IY|BRTS; SLR/4I8EM:%F MV'0 N@&%+T_U. #*,>=J - V\$:XYTZ*&=.CC2&B|=KTE" L2&&I+0415LN= MV=4Y4+2J|9?AT@B?
GSHR\$C0@ C\$.1^3RY%# ?J1^QJ+N(\$ ^9*H4((5.5JZ, M9B6C; (3KL\$J|71R,L.%JN%-=W/M|VM?1)O-NNY<6SO! J.X5*Y+
>XT:V\$ W&O.85 =E0I9H6XV@YX://0; ""&E| M?4@>0#7" L"V'K2)@=, X9D@ "L_(P)-1B00&0<,\$P" @VXX-SW0L=\$D4=QC708
M!:">2L(JL!|IBYC?@YXZ|4,6P0Y>H7.3U\$VX^ +YMVQW87;Y<(.!R\$ MKLG\$NRX|JW/W1|<:F|VURUY|O/LC^C8D+LO-1^ O;
|L|K<Q:05"YHJ-5- M_GCWJ3?R@>Z:7UJES >MYF^EYF6G=0 @_T,) \$P6NS%|R*\$30SHE/1K-C8K5
M*^*|J9|D|D62E5|Z>CC|#O^OO|@I67\$|.?GUY|SXV2K|WZP|@COEIS|1P1 6!2G<44UQ?705 M4V8A!OZK^KC%HU61P8@-
L#:9JSC8XTW%T ZA=%B+T, (OL2D T@HTHLL M|B, HFY85@-.-YAL#Z42BFQ0" CPD^6#(NZ\$0ZZGHM@.324) (@/+/#E\$18
M!9V882JJKAJ"QIE+8+*:D>F|=)J J"8S|H|X4C'Z/(0|>6VDD3%#F#SK8 M|<4\$*HF.B7=2*|X|X(JAF#^GT43\$;H6. 2X6 MC
YD9QR-3<47PGR-PX;XE6<#C*O|K6/^@OAK|QFG@FX*7 NGCWQ%Q*T=M9 MY)6&9*-M%#OYE=7ZBWJ*^AG%*D8*
7ST30KRJ9XG.!&CL,Z.R54T M^@AF&P.JF:U\$|H@VOH^RRFSG@CXHR\$!8S87HCQ|WI#&W6L,7X_W|L_07\$ M771:D1>YJ! !%,
(0%7>I2=, "CJD_?Q(L+Y >UXE19!/I5'\$>3.S\$'I+XW? M"!, 3=M&B99ULE_I>JU.5_&BPL8I#7QWP&G09P/(M.MAY#/F!-.)&E,7=
M16W!55,7MY|H)NU!MSC|U80!B,60K/ DU>.9F(L#U*O3P8:S7/46^D;ZX? MI(D| 76 "/+MD%NX!*/;2-TI6C:(X-
\$0LLFM2+&\$BAJ|#7 7,MF"3VV%#B" M)*JB,Q3+I*OZULA\$QO& -^LF%\$880X,=132TKBTS|O'7Y22,0%NN#&6!%T
M, AI&X&1V+&270GJ/8|ALD;|GVB#&#SA-1AB'J..%DMBW#R,D:ZLZ\$D|0 M&&4|U5BV4X2, PHRWX&1|7\$YH2T!^
LGEX3U/"NQF"GO'@O29JJW06&.V2 M;.T|>A UWJYK|B8FCF|H!95@G)D816E)J#/@J-C/" @E:40>,3JDF" TS
MMI(@_1/Z00Y822!/F2T%DIII/N3N+O!WE*L" @MSU!A@-P%F>S|3PT,R4'| M/B; "R+ "1&X%R^7("5-4%TH49M3-
6GV+DOPBZH AL&H8ORJSK*G0L M9R@E;J%0<2I7|F#0!YB232TVP60 *%D0)7E_ZA+70\$@?"7&J4K)=2SS! M'YS
&M'9UVK&U#?J=|YX!B(6|1ESQHA, \$S|*C5H.7|CDT 7?)G:DT!BX MH+; ^C.9.FQH>#1#:|C+6DK#?1JP2RIJZ P#&
(=AR>MK.8#TOZ>9_QQ_1 M(W!C+' BE='22CD>B&%\$1A2 ^ 8TBW\$"?+YNE)6"1BKV*G9|L|I@G\$5<\$1ES M:-
VQ;Y83412"/M|/ZP_JCE2)%^@|3#7,>*X>1U71;F2Y6CB3'NVB6!& M,:(\$&RH;U3XX,&E)SN;O#|JWS<(GL-
L|D|O!=OL<90;J2RNA%VP^E|JKH8|S M,(7)LC, GLMARO%NAJ6J#^VPP??, BT>EO|TK1LGED8^|4:I02FLSW|)K
MED@I9W!X|PSNV/A TB|P3R02ZM\$>YETPZ(DF9(M1_E\$3A2(N)"MPP, L|N|X&X|X#)?X%;J(104-/S/DY?&-*|JRI;Y|J7+&VD/.+*?
SK1F:41# MD\$N7T0;0G_1IH%!J|G-TCDZ|W: PGEKAGZT:<|CQ,;8 ,2A, /&TP(Z\$U0,OSD MJVHM-U5\$S1I& FF2@' >8SIT?-
<+L^X|JPB5>6*5, TH7)|+0&AX@U|//G|FCPBY&17 M+JX"8GKD7V4%4 ZJ,61_ JF*#G%9WMV03G)0MYY.P?
4_S|#H*2B%J7 M7> M:HZBIC_NIOX05^I2538)R3E!@7KN@5F@2+6|18-BS|R3F3@C=/, MH6E0.&!QU9 F"A?
F0>TX0SSMGWF@R469!^6<\$\$=\$13'W?3 M/*AK:-FRE56" M& ->6D6J+D'D94V#G(C!&R=9F ;+FP8Y48%U4*:*%R8!N7CC#C-

'ID&XXV| M:B5E'4QL;|)3J0_W@O!X(+I) ^VY?>B3+!\$* '32JXQ+GXHGI_4J)WOF\$U+OPJD=S2O-JF:-SND@/YABS=|9EII_N2U3^! L.M47"SOSV/I>+"RCUL;T\$E)*DT7|<=!Z/R+\$'ADR"^-I&#J.10M..98B'L MO-IIY9P0R00FYSG,\$\$#,T4S&L)*%&=526JO.- HYG|J63Z<2I3-(I*6CVS75+4 M.+E/U.RO"KO*SD1%#:;8WX1_S>903;_|^+WUN&TGR ;SS5R#|NC>D%Y#, M^VAI'2%+=K?? V\9TC30|I-<D"R*:(_&X=DSE _|J@%\$B (G41I# OW6V3 M(%#RLH)? RDUYX.HO4(,.'9Z"3VTP00&R%NYX2GM*RWK=|O(^3/(BKE-0) M- ONMC9UF5>S\$"HUK%KM68N8(0Q:#U2>V9:DX:Y+YJZW:C M" JT|L|!U9/21BKS>J|=|^M=:;>9/VS:@JK=X: I3G!;2C9M&Y,AGJM)5)64 M*GM +TI*#;-G|I:@^8/7>CQK;OAF=K'C57A6T5/@W6|V8T\$C%8I\$%).^C M- NW>KK3MVNK;TF6#*\$4NU(YM)@7IUXP#3A(KH&4@^2(F,L9|19%?S8(XZ, M!#DB5NLB0VF!2P94'0L16R96=UR& GV++9*V|>*!^, Z&\$N5^9K/19(V" MY/6.*G>4W>NN!D=KEQ5RYR%O'G#;34%V1-YZ/.HAS*9/G + \$% +#V2-MS MZD03Q+EL.O: I=,*'Q)@WESC*|54#,(A)F7M3=3I%OWLW;J7R3WZ,6L\$E M(V_6-745PL!P3VR=K#3NN9^OT0#S MIP7HVJA166Q6;?YT"J/-"7.O /S\$6:- M3//Z-N#*(G7&#UJC=,W6EN(J>SUI<5.@?N|_G|NB+W8M)OW5=D;V(N=PHZ8 M9R#G#MJ+G0)O|O|T*J&|B! JE'=6.J_4H%>R >[MJG0*W8GVX;YVWT;)B'ZW M:W>J.8-T=M#H,V+J'''ACNR4SO&8L?^=XZH>+*)OJ M# (W"DN1)MC="1(&RTCX=,."HZV-:JQEKF'OSLT/ION\$G&M=ON<"H8+ =UAI= M4/*&8)A\$#/HB|8\$:(U33>3DQG7C G^- -19E*>+8.(,381BH0CK:CX M<*Y9@!)A7..RE^&LJ*@/C5W>9JIA#F/5(2|0\$**M7B(M)\$^05)(?V63PV?I0|=,JW) M:T|_BS6Y4J04S%.5:V\$LHFAB@L(O:I>J334/4 B".0D8K/QS?K18V1-NJ/* MBQQDZ/NDSJ,?04"LFJGPW%)A?4H_A42H-XZ|JVH:&? QNF=8A3<>0 'I_0- M8C'B-QN@Z6Y"JAP#"^XF!&C F^H=UR8L-%0"+I=5H;8B+7XRR@)YS@HY%TW M!;M1R,6?A-A TP*KRU,WLYR00V\$YQ\$JA0&Q;D&3TN-*"Z-BJ-29N; BY4D@ M=#0Y8SP(9FE&Z:)-@V* IDTE LAJT*BP;MR+1F;\$NE-%N?^& I? 5/3"A'M M@Q>!,T2"UMX 5B(R12^AII'BXB:0Q&2-&*!40,X.05J^)G+81(+#ZUJ/&7O)*?ZG+4,*EN^V=CMIOWUEYNP.JAJ8 MYND*?Q.\$#J07N AS@/C.B.)@^)NCW A#Y8JU8T;+5/^|K"J-CWCY<,GLAT78 MM=: RO:-HDW7FQ&(50ONC+4FRJDF+->BC#J:Q ML&.:,ICY/_QO@JOL*7BjW+M:MY+Y=,3:X6;J5:V4HZ|E0>1860 ^WE6\$- M%<=ORE? *TRHCSY/WMULB=SM,JI|D>L>MTJG2=5APYC*R?L V= MG-:E|IPT*BUP+QNIN? I?;ATUE%6/5SC"9M) 7F\$93_DQ#1CD.N%PKJ1>5\$ONXNK\$@/6/T! Y&..G^4S Z=K>W)-|ICU? MWH,2,MT30^J/.|'P_56|JPIC^+* K'1S459*>1*>UYHIG7V2480M\$MLH|3.9 M|R_1JE7-DIY1'8/0.G&(KNO71NE8W=RNCU**9#E|500 P#B^+45+O M5U;)+EHEG1);2)AE4AU",2^HY>H>/F10.0RNE5*ZX_FY MO/5D7%X:FR1OCETI->?^%6R12"?9+(N|A B):AJO)C'RB.E5M:R:B.G6=HV1 MXK%LI13%9< +Y<7C%"X!"XOBS&2.U"OE+S_PHV1K|&-CHZ4V2)Y"=\$1A5&S M|S9)>>D5|G7- MO#_AV40ZNLM=|/97S =96/9WJZVA=,I&"/S#R46XM8F3TE M-GMZ3;Z93% IJJS0CI@J|HML|S\$L(PYV:07IS3J/>R3*\$F6/BC(,.'O)+; M0D4KW40CK*C7W6)=2|UK=UO=TA@VS8T- F^=L=#OG//H'T&1FTCO"1 29&^(W"3D:58;J,&IT=!:E\$<+8%J M+5%MVNU1 ^B+SAMHM\$:SS9540||JWLY*AK4YJFA"^-!/GH|YGL[>-< M?OMZ|&X-E>PD<:#E5*C !'MOF4RB/6!YXGE04? A=>IA(&(5+P-M:-)|SE73 M<|B8 %PQT60XV%P|G\$/U8 30<, +AA+X1|NAP:/: 3M?AZ@&.Y2TTHY20L4'W1*SNM-MV,X^I M@\$B);ZB|7(\$73YR8QC'_P'U@Q25_P6HP;WPNZ|I:(J&V\$9%*C\$,J/"50 MVIC=%1/GJ>-^<39KN/-*11;8)U (39G,%RE#15VEX:CA2'8J|8LR,.XHA" CNXR)B@^QS_WZFB!5T7S4?/5N.< MM%/(GK0GYNSS/VS3& <|HE,8+K;S1PZ+7*I/B@=TJS+SK?^VP^ZUZ?BU?GI9? GCOA M^V/F =M+3'KFAFB@FC>J M2/ F=7>SD2"=<=B)GPAK' 93*^42 "2XD\$G|NY876&"@|^H+2G14J*3P M)SH;&LP|Z+C 'U|MO(LM'MN&H,%DRI^>? SH|JO>M&V<0U(<6P@AC(^D#->-9D0&< ML&1J0R0@SG=^+T;3.6(EG#"ZZ+W2/29);3D)X\$H1N/+<B" B'M@4V:*R< MMA,C@UK0MOA\$O|BKD&?0L%V:L^CKK&VMJ'90)-'E^"JX? MOHH80PG'DX|>PGLOJ5&'UD'O_UVN?M#Y?)|&()F5I;54B9U00\$2M0*,L|2I MO>(2>0.7> +N!\$* "B88CS#MKX1'G9C(\$L4C@:>2UNNF0T|=|X @(.%!:) M<&-.%@S/YHNE+ NCR91F8F8*5,="L:)F\$(: -+;K+#+S!J8J|4 M"VW|@M|'SE&|J.|J4'Y\$D80%\$T.A Z.T%6HGUC'7|Y&8;B3*5A-17VF"=? MO6MTCG." L|V'KXDS=2B.4\$X\$.CUAZ'K:>=M.8)'N""&&>JH- H7J3YUP6. M&Z|OOSBP*IGA=JA4WCJQ3=?+&Y,B;^#4**LHT3#|@>WT4->JT5I:#9Q4;N^P1N'G/JO(235.3&\$0FE M95XXIJ= =7W-JZL:R^EL8C)A?*Y&2-*%Y":N(|2E2X&35-5|_P..4VB&\$S) M4 JW.2';0HRNG! W3(+;W5J?;O4V2X/6[Y|N!=4:|JU?LVNY|SLNBL" G1J@ MZG0?6W^H9(GFU^? N5\$J#IO(IF C>4@')\$|VWT+^A>OR M/C@TBR52|1C+<99>%6?9)K1WYDX"QAFUN< 7"8G>O!"% (B*^&="X+U:ZY M7H)BP4,ZS\$0ZIXH"J>&0' 8Z1+.N,I2-54V8*FR 9|F;) U;MPA,|J(G<3% MJ,@LB'&^EX.6,:T&^"0B, (O#,KYMZ2NQC:YFZ9JC4_6<8QXII88J9P-'PB! MF6'Z|8AM(HKAT%OI.CM%!AR3KDDA::!=;3%H/\$&Z'A#(JPU7+YQ=(U<JW% MD"Y=>CTN0QQ:0@H>XU2|I/#P|SR\$N!&C,>-)6M: YKNJ'> -&|FAQ.#*I< M:G|D,MF1:H7?#Y>%+X++N3&G1#|=MUN|G- W>HG\$4K|XW.XU.G:O M4SS6.K=1B:B"KY@U.O94T8.U!D8;F&AJ)?Z2KF|4.96--&B|MC/*GK??@OW' M44L00|V Q9E)ZL98!G? D_CB:N"-@PU^ V5MW7M%&O(VWK &B= (">%N*5*| M9;+&2%*R^@R+5|FP|4 B ON;5+O|213QF20 UQ0QG"FIY(IANK06F/- %T14 M|J@"VOAKLVX<+V'EB.7|MY3"2TMTKO%N,47M4&O.%B@IV.% 7;T1'YE#& MYY>5|D@S|G|E|T^W.2V(34ZE#: <2%#6= T90IGMO>; %&DIXX;GPSB0^\$)4 M=RK+ ^@JLQ_QZTGI-GR_X8|>KX4#I6-6"Y +J|5^"M:D\$|XO'3U#E:X B4&2 M?G" IR+^%@;7H: 2RF8D_N?IBR=!=2S60*WU=1V(|QXF?IKD6AF4;Y'ZFS;EKZ'K>TOP M'&F%JX4T:RO? J8.(:?08#|QO? 0M)CO\$FZ3MW-BM#|J4(A1A 7Z&6N-9'J M^<|J:RV1H>UFK9,>8'6PDP^V+:<<0Q\$|8LB&<8|77XZ!:E| OHYOSN%"8 5 M<8U2%6V:@RCA;+ZZ@Z|I7J|=5'N)6Z"SQ2"9 *5L+|I|L.Q36F(8|OF^Z< M^&9,A9|*QX^FBJ-N3G3-@GGB*)90Q /YPS|@X^NM+6T5_&E;V;2O>IX:WQ'Y,N[6]_-G\$L7N>+| P4T1AZT#=N5#.W|Y^T|G.GMSH<^M MXZ> 6*7C@O2GB!;8"/|AS61:W4&KB :?F&J%5.|*D@?A= ^F15= #M3B,@L'M MU9/Q4K""TNAJ=+-(RK H|D(-)JH3!4N \$- F<+L _S^W^H8V2V=,I02\$O|4|0 MH622YI5^R8R4L)SAD"-RN - ^\$%&2X0"2OBU<3028?90>J&G.&Y?C<4+0 ME- X:<|XU>K"FC[?<2/ H&%W!-ENR+OU@/@|TOI"3_->|,F60%")|Z/ MT|O+Z R|+BS\$ F\$9RSP30QDAK-LRM|+Y2XR-CEW/K- M(|T2TK@_ AA/T5#< M*?T'+FG/\$N+RP^DBZ^&BQ" \$"LVM1EJ)MUWNU|*5(5|TEED>?@^%6KI MS=0R,Y=? T'WWR6=+F R(.|) ^A<4 Q|+NGB2+@:3(X)5/4,+XLDKT4?/0; MW1/E'OH,>#*D|O|UZOJFD3E7P|T"?"^5CIG|8 Y/04VUZCY9YCSPF- G^SP,U8 MC5|X:IC(OLI5XR-X(E J#D(JCL6Z8+ 1!DEL@5!E)WOL8>: A|T7HDL!"ET M@:1#0>E8E7D7-R+M@/RD;%PX\$BL?,Z"9 M#GZX: &#=>"7ZD*UMS1(N:WT6:))V1GK>; M*;|N!)=WI ^1&Z(N,%.V9Y MWU- K#|*M8C*+^FO9%"=>NVUKDZ\$RZ|E\$8HLLXB7|&LD/(MY|B|>.S0;YV QG MDDH;_F) ^4@6E S\$2E1>8@-!|04F8>))\$ F3_9\$HY@+PXIO NX%W=|O|< M+T7YHY46|PC2/ C1-L>|&>P'ZSP|K0,0#Z1FIH+#+P+-JH>A@T>)U/8P3KBX M'<^,C7%*DHN8L< &FN\$33Y5|!TH|CL|O'.?I+X#;!D*W "%Y<8V|+Q3B LS MB'KK|GZ*XF2L>8+36=PK*D#*UI- 84I91BM()HFEA#T+*R78/#A&#-%ER U1 MET> .AGBRO:&R=C%>, Y*^X0D&S.^X,3JQ+V> /4(6B-VD?5L|9ELCQ#<+!1B M QU>B:(52PDM%@O@!,H%Z.M+?LJ*Q)7XZ.YC MZQ,J|STD|/S|ORT?5|ZDVU7X%|18PP4^, CI0C:41Z?K\$H6FK MELR#|Y@;6)VL)@ONY6>H1KL#=TFFR|X@#,IE9E!,15Y7 7X>HCF8C" @*CLKMQ M|(&LOD(&W\$X\$K8BWV"1NKC= M!|-6|DYP|ZOL7#|J"70>3;^"OS6<^(77+807:50;3(=R_B)P& D8*3=EG M&.FBC2*|D" !'8A"6|S)T.O\$/|ED)1& I=G|7ZT;@X5+W0+4;(W_!Z5IH!IIQ MNX U"\$.EC,9S>1W@#2?4RYTM(-C-|SKOY>1H(D,_*(|L,XGP,O.=?Q MY:B&W@FZI=2T(H;?Y>N"J33BD :;"|I9ZP13S*&>(<M+;!7^%IOK*9|91^ MF04_K,D#9VN|WYPZU- 38N! %W/X\$MSLB9@&83AQL#UX%+.@LO/D.('P: MYUC Z|@HR DOE|G(5E>?W"01)>2T J?JW0#O^27(5;1N_RYN/1*6YY? \$M"30W|O/SLD."F(Y290,R4; J9/6I^2@%|CLOVB+AGLYY :^JD& MBE,=+B2@!|UQ\$4E7F(9/A-\$-3%.%EJ7C? X0@9)X&8"1/OOX!/=7&P<3E5\$E7,& M^>"&J\$|K<64N Z)J-O,Z>E%:& L'39!"EV| P|L(O&=NMJ4VSXP"RA\$ MX=/1IS+P:ZEDQM|JX6^SRI+9FB=**B5N!%J:@68#>NT3=B|S<^J!@/\$#Z'> M/?#-@U08T!1&8"="^X8_2+?,&I8\$H" |O!:9;20XNIE84T\$6:)Y)-Z.3FA MO|JX?J?:J,JY.SO%5K>K|YD0(:D/*NRR3P5U#|H-275?#O+,-^V2!)4C(& MR.OV,73_? GDH7L2E(@_=AI+2B2RF)?O,I1U)%K,!Z(= M7.G&^D*)"(IGP*Z'5NV|ZD6R)1PK%MTOFHJS|R6X+QP:\$@<2EEA0Q9B0Q9Y M&T%5E,!Z"R_>I|G|V#>0|M|J 3@%O%7H-E,@?BA<#QD&L+A M9C@,0X)U-O&@68-9X H,|=#)C!&P".3J#|IJN:#R|'7WDQYT% <CK#E#_ M@1X^P^#KP>D|F(17|D<7VL0!C+<DI".OB^2.#=//?O"SP M.G@PZ0KY|S|T@Z--&DE5(9%J/18T) GAB%LLJL2,77C4WD2Z?9;W4Z6?D" ME06&2- #6-0THM80DP\$F|J|G|H,PB""|M3U,|PTL|J@0&G9,\$GT7%> H7? MOD"9#6XF5^OA|I0IP3PNKYS;TR*|Y4DXKCM%?"BC72MP(*FT(W:DI%NE\$ MBO3T8(G%BC(PTJI.G3#).%+'I RK\$L41BHX#Y>,%6=HDVFNWVX4+ V3= M@|I&#-3LD=)8L&250%;">0-%,&P+FH@|WY#="8)AG.T'SR1?!=3%P|QZ>?/AYGA M&1.%P00RB@Y|D4%37:7VZMP?K9:8 16HNO#L>^WWE1|^I_2;T/3V4G1G2'UG:&4HH0S8IX%:B:N,H#A4CEADV,E,U M%7:W^0/Q,6&MF ML|N8W(TP|C|(.+IN'C*<.(%)D_<4&VS"PN3|K8|<)+C8+;:RXCU|TM1M0A MO;<|R- G36U=1SX)JY"Y|8%>24:1F**1:A+/#K%QAWX@K@V+J0"!@PVV5!U MB\$Q28(I|J|P|BYD0?CR%HJ6V(%

<_D,B,R3XT20+M+I!:!8A(2>P?3B7>9A:P, .HWEBM VMQ::=0|(DWZZKSOK+..MJMF-JYQN9 M(=?
7|&8\$'HZ2@8>=@B,;BC8]0HN9;8&>3!P/5UVM17<#A!)8P"USRJR?NP(T9U3RK M>(L6;K>M,ME)'L!0
(+R,:103|NHUX/E1\$EZ+D\$XJ10WHN&4RC%I(\$)-3B .K4AXW*1EJ)8YBIUSB#(6,0+I\$K-0;RREONQO&J/RK
MO9#EEJ//H J9:@)N=U46FO@)JKHS!!OF\$>RT<>T/0Y02S1/#/UX-0 "D R MX" "EC%W=5?&4YS*5L|/FI92 /P1A-
Y(E0"=&J45UL\$?OYT?ZEYL|HM.*77. M!;G7#_J5@!%E^D^DS /7IV>FA7B;J:FFAMCFU@ JJBW)S4ZP%O3"O%/_6 M+@)1KJ3L?
TN%LCV4=/!O"!N-F;ZO!%H4Z-@R,S984S|OATEZ;F\$: MTF0;!/VB2?_6/6X, '^E4 E-YA6W+5D.KM WM'XXT-? WRS?KB4&3W4L"
MOR- \$,|IB4.M+:'UWPF96/0+4 B4<7 YSN=/#|Y>'P(7^=S*7TD'URG D M7V9KG-*6(OAEC+5;8|V0 P424L0CD6 4V9;&8'
YJ^PS+8ZGLH@/8!VNP#S M;J2\$4TIN+@|I;PF@;H|5. R?MI=)5@+K|8)PVC/4T0L0YK0EF,X<9;JC8 M9C _8AEL+\$#=
(IMY4E07+4)+G/BC N85X/CK>J@NK'&QJ1MQ-G;I_+'O_ P\$& MO4<#|8MCH>+ SJ1"/G+S;D+(9UM
YD(P)IQL0!GCN5*HRK:G<*D:8WLU")>(V-L5*7D,J)U1J7 E?2 U(=26!2X2I;5/48@EG|R^,-
DS,DI0@:1.%MX/U\$O"X807MC#,+'4C=W2N\$VA"TA "< M6(HBIOA2ZU/42N"IGO4UN&\$\$B+I"BK).LC \$?4Z>@K|!DN'6\$8&9%]
(X;T M% ?D%R+Z\$U\$D- JOK"TOJ?"C%XP+D)J_=E1XD22'&+T4((MZ#5DJ8+J@A*IWP#49" M5%?H MAJOJOW-OJZ5>U?
OFK J).OTP/2^P30 M|=9J)X=C|@/VRCGI84;S(N)&BB=NJ9@VN&M!E GS)3GSN%34AL0PD (14 M,,\$(LOFZ(-&M7)F8K-DFIT(TJ
PDP C%:>9ZPJ=:M5% /VD<>(VM<LC 5*L M%89C4(7|6\$)ER1MG4SO:Y|30 @Z(L8(5)4GTJJACL35L(,?Q@ RTKH%
MA+ ^6X\$0*E(@CJ0A6'&RKB28#3)A" P5PZ:, (J20 VGMGGI;*J8!E9@#|2M MA)8>6)&%, SJV"CDB'0LL>8, B-6(8'5', TLT^&N-
U=22)?W/P!"OL, "K>?& M-IYM"A/YOIV5<:123(L"ER4?%JXDB_.|#6,9^\$Y'0_8!)|S, TV=F-C MJJLL|R8H0G!
|:=+5'FR@%O%8%MG,*6 4@G#(VPT6(3J+I &6 XW?Z0C;J<7 MYU\$:6%+Q'RD),X + DK9JN8K9C9%N
R|CGNBIQE9,*F/TN1&A*N&:CXK^_ M@_ ^P@0", -N:O+ 0+AXNUE6BDI+7%&"FL'1VR)B1;20(OEP1%&0|6//A. ^@BY
M7B/UHTRI89C4II/E4;N9J|PALI6W>0->5CU4,|((82,|..9"0VG(L+1
M B@ (4T9*HV2\$IGG;):I;K^KKC,!/_MBM|J|K'GM!/&:@S=;B8J0)O|0U^6W'4R+\$H8 +7D!|:D4!| MXZJN:&6MY
@&A!|4EZ-& JDNQ/52 M*P963-\$DV2/8@-Q|3UY6 YC*!| +/, -M8D92;|/\$(1MAO;E"?Z6)MH MJ^I6;R-?
2IGJ)J0BD/|TLRY/RJ|<6Z'M-:483>)H,:Y<50+HJN8, "771 MZ8AS#A*+<IXX/*:@B'WD3'T5V:00M&&%MG ^JZ1R-
Z21P"J*1_FQF&/(7PUB MH5XZB:=U\$V!OA<=)&K'!%?0;Z/0I;<B<(DAC>5T09U"X5W:5L;94> 5,\$ M
UP1(J0!C,GL/&0+*1/408'BU^H^XV2H&ZDLS8) SJ>Z'HP>#P6'J-/!:I.G+8D:9^,L,I^ZJ&B^?*2'9) \$Q%&D<^(PJJ
MRIW,6R\$ *DU_83[G1F+V>N|8S#%3|9&JUD, <=CFM8\$CQ\$24|6, +S<IX@SPB MZ1:(A;E52T0Q0QS#"P,?"9)Z0&H4#Q:53?
D+U:28.!\$7G*\$9)=H|JJ&%N MF%K@>4|:JF|Y*YKJ-D9FM:IP|7D=^&JX@WW9L MG6=LGU7O16, 2..AZJAH1E"="8
@U,WS3*.D3"YI-Q<5"K M6@V.ZZ,=0 W@Q\$12C&L %=4+;+\$5ZB-G3%*S)'&0E1/4'VGR2TD&*:C;F5/F1
M1HE8J01AOH#NBVU.BZ4MJCA) 0:N--*P+JYET:1+A;A6@+1+IH LNE5R?+# MJ9UC8Z?338Q"J%T7\$&|'TYO:BJ|IJ=< RWP,) (JOP
K" W(PZ@0)H6&4G<3M M&).XR?Q<'GAMCEY=&) M&CVK>3 \$|G'V5. \$|9U9!%0WA M7F#>1<|D5|:?*6C151 :C&&?XM5&
(G;M3P9T*<TP2D:A:DC@;3X,OE=3U,C MQ1F/R=ZE?@39WH!H&?*X:0#?'\$XA0/MT^H"1SE4*@W%*HF:3NQFYX7(0">?
M|L?;,TE=3Z R.8*Y%&:7)(#^ETD;"J|JIRGF7DC1 J8FZ*-KZ)4G@, \$IZX MUZP'4|?*|>JXIN\$KE!Z,4@'!@5RQ&&43&?.TR|4#(HR= M6J1I1NE/|T-7%&N|NC'YQTFBF_G?16CG&LCs^E2QW-K_-@:B|.#0R2_=65:MGQAJ/6UZ,,VH|(M4 M@)X,*GWM>
<:K'OG3)&%#S M!MHL;S>AEQV\$E@:6D1)IMJ159Y,>6'90>Z^ M78I%X#0)S|1*PX#O!(D?R#)?
X##XP3LY=L"YZV4,*O_&STWO'(8+V<8% /J MB=%L@|N0J|KK@K|J|T4" ^\$0OF^FCT5:2%#13-\$1:DVW<|0AA(4KY)#|
MA>X'W2G' ^|UV8(C0)S%3 W1RG&JFF4HA)LUQD5\$3-G%/:!"W/E^#XPWY79 MIV)G%\$U/U2G"+
<4J6A%=:C1<@O\$(WG38@|R1%+=)T/2J77YZ1BANGK: 7% M!J?F" G^J;<LZ=W^6=N ?SS:NMW@|SM&AGR= (6 |?C0<:%;I/D@B.-@ ^IA) MY(7\$|F-FT80P.1I&9;<12.F" GQ*U,UY,.9C9H\|_7Z|Z=WL|C|&P93^/^=5< MJ9P2'EX/#N XX?
1/5^*!/&A/F2-FR3-FY=' J|U0NH!PL+Z@-(BL#|MB8%6_ MO/-O|P|R*IG/"6+;N=9(G)?U0B|SE%7J,2>1N)/#1LGD6LK4N?9^"J|RRE
MXK/|/UFSXK_*SYZ:STXIB%@:0|T|T|Y|X^F5^RO\$1<3AX; "#J,.6-4|@ZS| CU'Z|_+VXR?5CVI^:0/ MSYQEBDJ@EK" |O;|=ZK6V2)-
GW92*/Y9XX*C:^O>|I^4|_R52X.TVZ>X7K,/# M=39'U4D:UC.H9+ ^9)=(O10|B8TMZJ<=:G6.P,+:G3_0 _LOVV M%"
OO|W"=1ZW!4.P:=[J#;M7(D.P!/NP JO>L?NMKMWOIJMM?TG;WFJW|ZM M79I-+Y%2+G+Z' MTL*8L: +FY%?
69%O\$AOE.LX>9K*T=Z|777K<;K;I=[W:V M=OX?D|WOYRK*BJ+'K3J;-O=WYYE7*#/TMH M-
%6IIJL@1ARL17AY94/MIW3HV9U6RZYU;I7"JA1665@2M)7=;6|OA+?WFU . M5967)4%\$-FM;=:#-WK&*P*CCX'\$2RUSPPVBBK?-
"S1X@/VG:OW:+;6PP2&:Y. M"?;@|6SY]@V;LN?=@L:=K?5MNO=714)JH:(R|KX\$S9|X"QVUT?SV!>|_IY5Q5>5EOZV*Q*L/8
M'50IJX@M+XBV7G;1W(*=-*42\$"5Q+OX1*00M'L\$(&?<"D5GIV? MSRI\$X(K/GIS/*D3@*CY?
(0*ONQGE"AVI>M>T: V:7>J4)8D;J|)\$N%"%PA I?%\$*QW!JM;:=ZVRL.*.%& MO(!I:&>=^Q>O^H_>UGJ:G?J:/M=
(@3P\$BGF"A6X0@7>|SZ+IMWMM>QV>XN ME_O>9%/.5967)8\$= PV|T=^!GLA=W'0RKJ|/+G0|7|M:G. +&(M5.|KN1,LK
M5."7|1WJ??" :W;M61E1E<8J#T 66GVIWJMXLN+)DO|DKU6S>V7J.BMYX6/5 M=U ! Y?BA", <1?N|L'.V2IH:
43^|Q|O|GT;HMKSJ|WSAMV '6_6JSK *K)1 M00.7|HCV,65;GO-9@DW8 SWO=%MVKUF>R;TEV(7W_2#=JII-QJEF,M0(BU< M>
<45/-#+B)<= -IV"X&U;OP'0/BQ4T,<6*6'K80%W: %>; ^GOIW=V|P(MRD)T.C;G59C9|Z< 9N^0
;M@69HV,00"6(RLGQIVM)>W6|T6W>@GC19B MPS713 RQ0|B;VU8PA@^(R)E1%\$P=|W| :T+S|0E03^Y. #O1|#ZVKB8B% / H
M^)<5UCC9G)4#@1,|@;OW4:K?L?JUM'72.VS?_O?JED?KH% X_0O| MN.C(%(IBB)%K)=!(FL6ND L(+,5 M!_#, *(IP=PI5
7B|*1|:3S. I:T@08Q;UT?GTHKY: CEKQ_ MCTZ_U%J7=7KE %84RONN! +|O,O|V= MZ+#)MY-
?/QRIO_AP|O>CDX17'RY^L1SOUIE'RN+! (DO_N_TQIHO DX#/#|M+ M|D/^3XW^EOKU(R-
.@F)NW%O,EZ=GWYV >|L^100!B/|NTO(AK M&H\$YYBN^RC/I.+S^"3365PJ+;?|S ?+T#V.LKLN|,9.!?% (9-1=O6:W^WWK MH-
\$Z(BM)W070-MU'Z|KU/-74?B7;U/KDKS K#Q|I3|-@*1HE'35.DK6Q@ MT6M)@1GC4;-
KG7;_JMVKV;W>TUM% =VGQX" ^SS\$X^(9X|AFK%AEED,CE@G'B2XKRF&P%@VTF"UQ3#/#@Q MV*>#A,?JH)GK1/#F-X|KT2?
X8-> 4JAI7EL+18Y//|A>+*D)/Z42EHF7-9& M'HHP=L#:J@.2;Z<5NQ&49+ZJ% ^<.3|#/PL.K..T\$ 2:X3> G|1KNJL CP
M=MW%|QW=O?NB >?; 2MR1&^5J?.S.5^67 ZP|L9HATPV/E3C|=D"B@ MJVA+<2!=>213/
O_%N2V>1D#^"450D4% /+V PYSE,S%&"H?RT3I^"LB!'#|U! M%=> *JZ38Y(G@:O,\$OSI@%3S1J|UXS9FW5JEE:#XXF2UIV.C^OR-
8//!O MMMPV=I_ V=*>0@|KN)MEL3*:#RU7>/HEB6:ML=@+|B<|NPAHK!-F6P>V|,Q+E M)=8F;5\$1G9*/0^8=_& \$&
5KIO&"/I|6|BWGCB0>OYRMZ=KO?L-N-|I:&E;#+ MY87Q0,=NM8\$'MMK?7% KYO/?
@I #H/X+P.P6;V478;ZF|SN.V(H@:G;K=:%^6. +1G|^K(-CS|3H|Z3.JV?+W| -9W9;|V V>6|XST6-R
MVC|ZP_UUYL1..4.5=B=MN"/"RWV7 '9C0)9%1&N(L*YRN6KB#D8/N#&W\$ M=7L"=;3N?YA-56S>D;UC V>42+IM??Q4OU/?
Y:=>Q@X9P;N| ^X:!*:>0" M|28;=;N_U<:#;GH*V@#8|M.Q>OVUW^A5PW LS+Q<|>JIGY KJDJ0Y@/|O3 MWF:AP9/*X|+N=|_N|
|MEV;|2B^>79AJ = 'W'VY5 .X94N>S^6-IBWU&G;| MM;WI&L/2% C.5967|>(V+EC-4W*|.C|=|N-
!%@W>9TVY(BU)5T62^>1S&JU4= #P!AI,-HR6Y,M;DTN|DFVJ65^E!L M +8X^ !#\$T<#RIM*4%K\$GQM'-U@CL! 1|0H%VZ&K=>
(9H5P*->8&L_8G80 M2,@T *|CWUD0#_SB|K 20 J->|PX_K6% !K7:::D'\$@P!,(CCHXWH9,X6Y" MI^8=-
+8J|O2Z4G)LNN= G!"TD#KNB?&S0G,-C@%APHE_ 6%D:R'=/S|O(5L0 M,\$4.0L|L"6' (F9 SP'
L1!."=SD#+#?JF&CTI#, 71ME5F>,UHT?,-EJ,>L"O&NK=AS%PG@L\$&:\$|I|G@(H|IK)+/-2WDU@E#H%"C M+(D?(ARZC&L\$&N'
((BBA3|2EN|_@W|Q|P7B?,>*OOA)P#&O"^.3#=>AK&"93VV A!@G=&%W W@ MUKJ="|J426BY8|K-
K>MY_A9Y=V#VTC=|C0%? E|T5@'!+IC=PBK70I0XGLB MXBT|O>Z>*=@0+@|H:A/|097S@S/BD0 0JY&_ @6C\$T%7?
&9@E#!. #Q8^3 M. F%?AH|>N0B92)Z7UB(.W01>@R.EQ/KUQP"?5V?:-U>|I: XRS"?T4D!, MT5-L10'UZA/JHSA(W7.0+;?">
1<98)P|F. ^#|S|>|ZKTPIL>L_EMY+Z60 G M,-:H22'<|Z+&*G?2CH B:|D|?<,\$1_E+BRD(W^DZHZJRXV@N"7R^L%0^16 MWX|7.5
M|AD X D3'Q)+&U'P&4C=PRL@'P#^IU,XBPB*I9%?EJ#HP4/#Z(POAWCS0;@R'_&|I. MP814 A 7,?<(3W:H4\$(6)X4 MV@|7X;-
A|3. 5.!=";<@Z>S)O BA)X?"A>UWL+5C>6NMA*9H%:S6-XKTQ M@4|BI=%)|'&?<|I:='<@/!<4&M.TE_7'9G" W, JTH)
C>Y_P\$5XJ(Z="W- ME&\$46W QTR7X890V"SC%EQYKA#9EJ|_IF2F 7CP!,7@>SE, "IV*(MAXH|V1M| M..E0^3)090Z5, R2PKU-
|IUA\$5/L|JOI8GA/0^H/T4.%D7*6X.F(H0|S MN7'9;+TWO?B!N38=2;|P|3B,OL02";*V3'X+DIF*-R(I-(A S O.VE(MXJ) "#Z";4EK"
M03?<(C6TX(3C@1_02*!@X6"!+7# FA0\$Y|G24"26W)SG_Y@LNB,81D->A9 M;K7;(|\$PR(M ZBBPC" M&K!P0H0|-F2D|
#1R.E..U@GFYH|3F5C;S=)C MZ2JPUVV",>O.R%64@Z,-=N|J,?=>+1,4^*G5XDPI:8%J"X. MZ(59G&HSLHTDLYHJ@&
(5MN6Y4S>VY>@_P%_12|1BTRP)A,|T|)H26Q88@PT
MX<60J<))50X| "UDI"7#H;Z ME%*1W1BP30+9!>8T@7W@95&PKO!HWGB MSZ7-B+0,|I?
PKBT%76S)&NS.I\$Q%R|A0%>OW3^9YZ@_ G FG" A6YG0Z_B>& MN^M3Q*>&% (IVOU+,51M/(^ CTO=9)66:S*C&X."@B8R.O""@-

>OYV'B37?|F MP#TS!'GB20&J TIP(|K(6N#-3>=J7,O(VD4&_25P,)N0U X,W#76.:SWO+F MWZ 9J,8581|CG+G|3QD0BYW00HKZ/_13K?41<%_S_D0&FJ8E&*(0%.-#*=^X 77:@/D MA MYC!=/Z(M\$A&F>'@WASE>BJK.CXK"|-7PJ2R#1 f%1>W-Z<1H|^MO M#NWT5J/_*I"GWXO?YH..-\$ ENB/3*W0\$B/T+8G*VA,74%H@4*B K9MU M!U Q8P^
00H16=P):4%"=%#33>#NDNF;J7AM1OCUOI. M#7#HU7JH>B=UW@J>"V%!R9E MJN4RA 'X4:#JO(BM,NO"XDAIU,Q%D? =B9GP219..2TB =)%R8\$.FO-RHST M.W&PL?&-(K+T2^ILO60?
UL',R6JUG507MKJL T|H#/-44)S\$1#4K)"VL93!0YMCN"3A1F.6.HP^&A.R1L9W6# M9%00U8MG*A759+;BP'=JZ
HMA3?5:OG>2.5+-Y+Z+X_EDC'4(X.)CN\$)M+/RA&X)I:^@YIM2LZ\$O:90*0@<-?@I^+B2I"-7+%;Q&+\$8EJ3%*S@"F?* M#43? P9#2C811FB0Y57+40&+X!KEGSQ+,F5\$&2DLVN(V5)50J44I6)73G<9=S(5G%F4VM&<"?/ M#3.QX(K57CRKR>9"YD%HU0_XK2DD9A024*,N6*EKLO18.'D&*F,Y#M*M;M;M6\$0-94^E6%YSPO\$&K++39>IW59- G'K!O-7EIAOXO)RK#2S1CY?ED3JN5(U,*MZHK 3*+8*<?STKMI>#=IUA,K-9N;IN'G'GF!P%H.UXWS4!&OW 6WG.1 MY5^J^T>"E9*O@R6E)*@ T I.1.^O*WJ//RG6*01>&O? M?,6DQ&>U1=V,M^Z|SZ "97H4I*1%EM0&X.7C00647-A#W@R%..// H@B=8S/)-*:!9P#H4C-46P6A%9A.%<(6B M9#IU8W2HN(+;W.9MFM^&,%H&@I@/M6JS=,W-\$TYOZO_R/K*OR+TXKJMS(M,J@?8I2RK^1S>61?C*)EBJ^B_<<L3F2>1.5L91I,\$(LJ2W?LJNXN M6.N4JTI\$>ZC-5+&BH&(U-I)-%D>S@W5R>8)J54E=2F&6R5,OPL05 M8R !?Y!VYYC/.U.77X+L75XYGC61UT&B9^?,#X(WD)>KEK PF 6NK(D\$012 M<\$OOYLU9X=N)&NWKIV0'JW,3TJ.U|SA>5+*&M"9!EZ(2A2P58&"WA)82 MML&043+#(KM(U;&1ITI)/R>4S=!=&B5JZ,? D,EIWFIJLV3U;B/..V'EJF%KE;M',DWI>Q5.YN&<>=XWE66.V@60\$SKJ1^R=\$/I@J03)DNEI*
M#+1! 6|EHZM|ZHREH2%26%/"I"J>\$&=&0 M>A1XIRWDBTP5N333|T<|J|A?+Z0;,:0%@:FVJR :I(6& @&)(N GB22CN M-, WTGMR=%7B;CETL)I,3: X0%PH@#.2^,6YWX7#+^T1-HZ70 R_-OB19 M66_-PD99100 JT8SZ2B_YD@- ZHHW-85^(-0)0^#L(DHSB *O 31AQ.ZB%U,0!/*C MC=%,.16C@CTF(M1CTM5V3<(\$U()J&N/0.%"9 @N4QF,AQ&Z@D>T@#*24H)3+A F5..T+ MDGTS/C<H6YXG|1H+U'9GC-70WVXL#Y|7A^>7DZM/YUV>&2JN,_"&STN"/".M/ M\$B-+@M5N\$#*#!Z_QY%<@10ITD*#7T25;X|APR)E;I9 ^&J,\$K(<#O?" M3MG(%R(E*#X8P9UD+N@V<-3+1G+K>^V8N? B0M>6.0VR-MJ)^!+D0213K8+&YK1(N#*Z0BSR3U0X,1H..%=<@:MPXOM85,W 3NB,P?O!
MM,6C0Q^#XRN1L>3=&H&|^R?P?Q2VJ!V^K 4,NR, W<\$56. CAHJ4F,&F@Y!M?_. EKP9U%&NPF+(&^A0
MN3!V7,D8FZ*>!,CA:KRTN5T'(13N67;G,3<3/Y@W8U RM;Z, Y>2?R2^K ML8&GOW*T2G,DGJ,B;M'@L"=5TZ8P%:Q"A- 2%/"S20\$/\$X#V-F(ZM>NC @ M|I79 K4 U*\$JAI<- 16KT+TS9=7V YQ Y1STZ|JTQAM6(X^N5+^I7 MV(%S/KX*1R=A>4_ N!%P^&O+?T7Z^&6,SE26BH3/#0L3@:OZEC><2S, M>W@LSZFH%|J,2P WTVA5K6QFBH\$A?3^.)JX(V#U7^! M5^JN^.*SIU7 M=, ^HO?J2: J^E "1'Y,&%,)JFN&TZ,PCJ)G%L2B)4ZI:(HK%H? \$ M8#,K(O)H MOS-38)N47# MT)UE7(OJZ*|- O/GJU,OFWQV, M'E-^Z/PN\$#2R?B!J&U\$IX>,"SNM=LM'KJUV KU%O-K25,|1J4ZGUGXM M?ORKTZVWVHWC230IE?&6- 4(B-2+X,./CIT05/XLDYQY,4P/(VY)>\$V9V1ML1## ^@>2L^. 1^. ^IS S7JS=IS' J M7KOY#)0-<>="H?" /-EX, # I8>3096 /-8NURO02!N+L QKEV! 4\$+03 M-9\$NZXW4*V DT,APKYUATQ3LKA5U7HL+E458JRS"1^#07:+, ^JX| ^A|V*NT MJ/QX5Z|QOU^G FPT,TWUM*U#ED<-Y@3MU5 O?8JN/B1A" D&K'QOY .WY| MXGDN89G|Z@4# I'CGT>Z1XMP4KZC15LS;K9CW84F|^G'Y,:=>Y'Y6JU&K.X. MZ697TSUFOY7(V@#DMJB-5F'DM65JZ|JYEQ6L/Y+7&SO#.6H9? Q6NEY,7&M#LFUM>)I0-Q6IUG /+X/D5@ YID76^V,PP1*V0|/W/J7, 6T1SHA /%J1 M^0/S/7S- 6JU1L5!#V2^W1%T,P7Z^N,&>:K@YGTZ>ME2=GODXJUH-9-O| X M, V2V(+6631,%"GRH"Y8?O#-O|RJ+<-V@KYT?@H, YV#VO| FS^W(X\$5.G MXH1XX33D|^J0FGCC=4+7Z?7?8K)6?/%H?"VX>NL49H2Z%5L/#5M M/GF FFSV01D(K^*(Q^> (OD2L66..%DUV<(8T00..9T%5 MNCBF>?X-9%H)4?>X/XKR-&G!O ^|D38ZB^<>8!L)6%T|7A*50844"MMMI\$531PY=0!K J8)3.%W1H1AMJ,:=BH%"9HJM'F>|5LS# L5AQ\$1%ZGR7A M+(@8GU0&ER.K7J=\$6R.GPY8FUKE<\$(:::0#U|TU4W- +="Z")C+=NA' H,(- M118JUQFXH+?ZEA>%"<I".CPJLCD#D"9C9(>@3)G,>H1B#H14=XJ@+?D, M0_L D7Y>QOYE,I0<4N%@+@C"OE&L.S8IK'L@UK9%?-9FF MW8IMJLTV9?%-@N=CA7CW)M0_B^2<5116_4XIV. <JLMBG,4Z\$UXIT0+40) M|54HH4>1+D/!RMJ|EIU^ GESI^+/#Y2**Y6X1)?,\$T:=(0L/OC|F,:KAF|P MH@LM_-P)CMU"RW?H|& JG "IVLCLR>@>%JH-TK=9-.W0\$X-13#|/,-< MCRT,J/^P4BE7*/6A|E<0+5|X.NJ|2C&^01AB% ^UZO&JY5\$/.96\$2'6_0? MEOB_- CC >2 K<|G|RJMZ|/7TWRLOU4+KS?V<>DL?S?%1|K71RDX/+D_+J.AO<>J|1 #D/ G(M|<79Q|NCMZ?7UV-?J&NNE6- XT"SQUEY, >T.AUJ#IS/+XXX?KCV-P&>=^ MX.% (V\$1.5)9"92FL|=J/QE4|4ZJ-5!W8&#>CIOQ=CZZ|J/11.1'82OZ.9C0< RNL_- SBI-MR/(DICZ?7%X=I=FQI53=QZN+A<|FXZ,PN%W^\$&|OUMVY08W3>PUL-FPA-P9 MD|2.+\$ 4 - 8 - " 3D1 !E>%|W-#0R M.,N:1M4\$! A0%# @ X|L69)E7)P!0>1H T M (!=8&5X7S"TR, #(T, #DS, "YX"TR M, #(T, #DS, %|C86PN>&UL4\$! A0%# @ X|L69K7PU\$*@ IH # 14 M (IPS &=O=G@M,C R-# Y,S!?9&5F+GAM;%+! 0/4 00 M (#, .%|EIF6"U 3D T5 P-5 " 3I_IG,W9X+3(P M,C0P,3,P7VQA8BYX,6002P%" ,4 " S@&O9@SCWKZ0L #KR@, %0 M @ %JE0 9VIV> "TR, #(T, #DS, %|P&UL4\$! A0%# M @ X|L69XRCT,OM0 *9T*!0 (!0<(&=O=G@R, #(T,B, #DS, %O, \$N:1M4\$!@ *H>0(&)X 0 \$! end "XML 55 govx:20240930_10q.htm.xml IDEA: XBRL DOCUMENT 0000832489 2024-01-01 2024-09-30 0000832489-us- gaap:SubsequentEventMember govx:AttheMarketProgramMember 2024-10-15 0000832489 us-gaap:SubsequentEventMember govx:AttheMarketProgramMember 2024-10-14 0000832489 us-gaap:SubsequentEventMember govx:AttheMarketProgramMember 2024-10-01 2024-10-31 0000832489 srt:WeightedAverageMember us-gaap:SubsequentEventMember govx:AttheMarketProgramMember 2024-10-31 0000832489 2023-01-01 2023-09-30 0000832489 us-gaap:GrantMember govx:BARDAContractMember 2024-07-01 2024-09-30 0000832489 srt:MaximumMember govx:BARDAContractMember 2024-06-12 0000832489 govx:BARDAContractMember 2024-06-12 0000832489 govx:ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember 2023-01-01 2023-09-30 0000832489 2024-09-30 0000832489 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000832489 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0000832489 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000832489 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0000832489 govx:WarrantsExpiration4Member 2024-09-30 0000832489 govx:WarrantsExpiration3Member 2024-09-30 0000832489 govx:WarrantsExpiration2Member 2024-09-30 0000832489 govx:WarrantsExpiration1Member 2024-09-30 0000832489 govx:StockIncentivePlan2020Member 2024-09-30 0000832489 govx:StockIncentivePlan2020Member 2024-01-01 2024-09-30 0000832489 govx:WarrantsIssuedInDecember2023Member 2024-07-01 2024-09-30 0000832489 govx:WarrantsIssuedInJune2020Member 2024-07-01 2024-09-30 0000832489 govx:August302024PrefundedWarrantsMember 2024-07-01 2024-09-30 0000832489 govx:August212024PrefundedWarrantsMember 2024-07-01 2024-09-30 0000832489 govx:WarrantsIssuedInDecember2023Member 2024-04-01 2024-06-30 0000832489 govx:May2024PrefundedWarrantsMember 2024-04-01 2024-06-30 0000832489 govx:December2023PrefundedWarrantsMember 2024-01-01 2024-03-31 0000832489 govx:AttheMarketProgramMember 2024-09-30 0000832489 govx:AttheMarketProgramMember 2024-09-30 0000832489 govx:AttheMarketProgramMember 2024-09-30 0000832489 govx:August302024OfferingMember 2024-08-30 2024-08-39 0000832489 govx:August302024CommonWarrantsMember 2024-08-30 0000832489 srt:MaximumMember govx:August302024CommonWarrantsMember 2024-08-30 0000832489 govx:August302024PrefundedWarrantsMember 2024-08-30 0000832489 govx:RegisteredDirectOfferingMember 2024-08-30 2024-08-30 0000832489 govx:August212024OfferingMember 2024-08-21 2024-08-21 0000832489 govx:August212024CommonWarrantsMember 2024-08-21 0000832489 srt:MaximumMember govx:August212024PrefundedWarrantsMember 2024-08-21 0000832489 govx:RegisteredDirectOfferingMember 2024-08-21 2024-08-21 0000832489 govx:July2024OfferingMember 2024-07-12 2024-07-12 0000832489

govx:July2024CommonWarrantsMember 2024-07-12 0000832489 srt:MaximumMember
govx:July2024CommonWarrantsMember 2024-07-12 0000832489 govx:July2024PrefundedWarrantsMember 2024-07-12
0000832489 govx:RegisteredDirectOfferingMember 2024-07-12 2024-07-12 0000832489 govx:May2024OfferingMember 2024-
05-21 2024-05-21 0000832489 govx:May2024CommonWarrantsMember 2024-05-21 0000832489 srt:MaximumMember
govx:May2024CommonWarrantsMember 2024-05-21 0000832489 govx:May2024PrefundedWarrantsMember 2024-05-21
0000832489 govx:RegisteredDirectOfferingMember 2024-05-21 2024-05-21 0000832489 govx:ReverseStockSplitMember 2024-
01-16 2024-01-16 0000832489 2023-12-31 0000832489
govx:OfficeAndLaboratoryLeaseAgreementMember 2024-09-30 0000832489 govx:OfficeAndLaboratoryLeaseAgreementMember
2023-01-01 2023-09-30 0000832489 govx:OfficeAndLaboratoryLeaseAgreementMember 2023-07-01 2023-09-30 0000832489
govx:OfficeAndLaboratoryLeaseAgreementMember 2024-01-01 2024-09-30 0000832489
govx:OfficeAndLaboratoryLeaseAgreementMember 2024-07-01 2024-09-30 0000832489 govx:TheNotesMember 2024-09-30
0000832489 govx:TheNotesMember 2024-01-01 2024-09-30 0000832489 govx:TheNotesMember 2024-05-10 0000832489
govx:TheNotesMember 2024-05-10 2024-05-10 0000832489 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000832489
us-gaap:LeaseholdImprovementsMember 2024-09-30 0000832489 govx:EquipmentAndFurnishingsMember 2023-12-31
0000832489 govx:EquipmentAndFurnishingsMember 2024-09-30 0000832489 2023-09-30 0000832489 2022-12-31 0000832489
us-gaap:RetainedEarningsMember 2023-09-30 0000832489 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000832489
us-gaap:CommonStockMember 2023-09-30 0000832489 2023-07-01 2023-09-30 0000832489 us-gaap:RetainedEarningsMember
2023-07-01 2023-09-30 0000832489 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000832489 us-
gaap:CommonStockMember 2023-07-01 2023-09-30 0000832489 2023-06-30 0000832489 us-gaap:RetainedEarningsMember
2023-06-30 0000832489 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000832489 us-gaap:CommonStockMember
2023-06-30 0000832489 2023-04-01 2023-06-30 0000832489 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30
0000832489 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000832489 us-gaap:CommonStockMember
2023-04-01 2023-06-30 0000832489 2023-03-31 0000832489 us-gaap:RetainedEarningsMember 2023-03-31 0000832489 us-
gaap:AdditionalPaidInCapitalMember 2023-03-31 0000832489 us-gaap:CommonStockMember 2023-03-31 0000832489 2023-
01-01 2023-03-31 0000832489 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000832489 us-
gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000832489 us-gaap:CommonStockMember 2023-01-01 2023-03-
31 0000832489 us-gaap:RetainedEarningsMember 2022-12-31 0000832489 us-gaap:AdditionalPaidInCapitalMember 2022-12-
31 0000832489 us-gaap:CommonStockMember 2022-12-31 0000832489 us-gaap:RetainedEarningsMember 2024-09-30
0000832489 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000832489 us-gaap:CommonStockMember 2024-09-30
0000832489 2024-07-01 2024-09-30 0000832489 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000832489 us-
gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000832489 us-gaap:CommonStockMember 2024-07-01 2024-09-
30 0000832489 2024-06-30 0000832489 us-gaap:RetainedEarningsMember 2024-06-30 0000832489 us-
gaap:AdditionalPaidInCapitalMember 2024-06-30 0000832489 us-gaap:CommonStockMember 2024-06-30 0000832489 2024-
04-01 2024-06-30 0000832489 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000832489 us-
gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000832489 us-gaap:CommonStockMember 2024-04-01 2024-06-
30 0000832489 2024-03-31 0000832489 us-gaap:RetainedEarningsMember 2024-03-31 0000832489 us-
gaap:AdditionalPaidInCapitalMember 2024-03-31 0000832489 us-gaap:CommonStockMember 2024-03-31 0000832489 2024-
01-01 2024-03-31 0000832489 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000832489 us-
gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000832489 us-gaap:CommonStockMember 2024-01-01 2024-03-
31 0000832489 us-gaap:RetainedEarningsMember 2023-12-31 0000832489 us-gaap:AdditionalPaidInCapitalMember 2023-12-
31 0000832489 us-gaap:CommonStockMember 2023-12-31 0000832489 2024-11-12 0000832489
govx:WarrantsToPurchaseCommonStockMember 2024-01-01 2024-09-30 0000832489 us-gaap:CommonStockMember 2024-01-
01 2024-09-30 thunderdome:item iso4217:USD iso4217:USD shares shares utr:Y pure utr:sqft Q3 2024 --12-31 false
0000832489 false false false 0 0 15 0.001 0.001 10-Q true 2024-09-30 false 001-39563 GEOVAX LABS, INC. DE 87-
0455038 1900 Lake Park Drive, Suite 380 Smyrna GA 30080-678-384-7220 Common Stock \$0.001 par value GOVX NASDAQ
Warrants to Purchase Common Stock GOVXW NASDAQ Yes Yes Non-accelerated Filer false true false 9436069 8592523
6452589 547574 0 1729326 1433153 10869423 7885742 171615 209689 71010 1187788 11112048 9283219 2147952 2802950
460220 716931 2608172 3519881 150000000 600000000 8609308 8609308 1977152 1977152 8609 1977 129588694
110125146 -121093427 -104363785 8503876 5763338 11112048 9283219 2789484 0 3090161 0 7402884 6947979 16105480
14486896 1241176 1651775 3784559 4562293 8644060 8599754 19890039 19049189 -5854576 -8599754 -16799878
-19049189 53191 190936 91611 674835 14083 -0 21375 -0 39108 190936 70236 674835 -5815468 -8408818 -16729642
-18374354 -0.91 -4.75 -4.52 -10.42 6404797 1769604 3701145 1762856 1977152 1977 110125146 -104363785 5763338 6703-7
37493-0 37500 269032 269-0 0 55422 55 -55 0 0 0 103569 0 0 -5850132 -5850132 2308309 2308 110265884
-110213917 54275 220000 220 1209318 0 1209538 1650391 1651 1387712 0 1389363 0 101640 0 0 101640 0 0 -5064042
-5064042 4178700 4179 112964554 -115277959 -2309226 2741463 2742 15518135 0 15520877 1689145 1688 976082 0
977770 0 129923 0 129923 0 0 -5815468 -5815468 8609308 8609 129588694 -121093427 8503876 1755664 1756 104995301
-78397023 26600034 7246 7 74993 0 75000 0 228039 0 228039 0 0 -4037916 -4037916 1762910 1763 105298333 -82434939
22865157 0 226013 0 226013 0 0 -5927620 -5927620 1762910 1763 105524346 -88362559 17163550 16776 17 137483 0
137500 0 227114 0 227114 0 0 -8408818 -8408818 1779686 1780 105888943 -96771377 9119346 -16729642 -18374354 73727
51956 389299 813499 547574 -0 312840 707084 -1116778 -986498 -911709 2333791 -192319 3478660 -16921961 -14895694
20653 29997 -20653 -29997 135000 0 150000 -0 16730415 0 2367133 0 19082548 0 2139934 -14925691 6452589 27612732
8592523 12687041 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr>
style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: 'Times New Roman',
Times, serif; font-size: 10pt;"> 1. </p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-
family: 'Times New Roman', Times, serif; font-size: 10pt;"> 1. </p> </td> </tr> </tbody> </table> <p
style="font-family: 'Times New Roman', font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Times New
Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">GeoVax Labs, Inc. headquartered in the Atlanta, Georgia metropolitan
area, is a clinical-stage biotechnology company incorporated under the laws of the State of Delaware. GeoVax Labs, Inc. and its
wholly owned subsidiary, GeoVax, Inc., a Georgia corporation, are collectively referred to herein as "GeoVax" or "the Company".
<p style="font-family: 'Times New Roman', font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Times New
Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company is focused on developing human
vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers using novel
proprietary platforms. GeoVax's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which it was
recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of
GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials,
being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers
and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in
patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients
who previously received the mRNA vaccines. The lead oncological clinical program is Gedeptin®, a novel oncolytic solid tumor
gene-directed therapy, which is currently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.
Additional preclinical research and development programs include preventive vaccines against Mpox (formerly known as
monkeypox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), and Zika virus, as well as immunotherapies
for solid tumors </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tr>
style="font-family: 'Times New Roman', font-size: 10pt; font-variant: normal; margin: 0pt;"> </tr> </table>

Summary of Significant Accounting Policies

We disclosed in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 those accounting policies that we consider significant in determining our results of operations and financial position. During the nine months ended September 30, 2024, there have been no material changes to, or in the application of, the accounting policies previously identified and described in the Form 10-K.

Basis of Presentation

The accompanying financial statements include the accounts of GeoVax Labs, Inc. and GeoVax, Inc. All intercompany transactions have been eliminated in consolidation. The financial statements are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of interim periods presented. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates and will require additional funding to continue our research and development activities. We believe that our existing cash resources will be sufficient to continue our planned operations into the first quarter of 2025. We plan to pursue additional capital resources through public or private equity or debt financings, government grants/contracts, arrangements with strategic partners, or from other sources. There can be no assurance that additional funding will be available on favorable terms or at all. These factors collectively raise substantial doubt about the Company's ability to continue as a going concern. Management believes that we will be successful in securing the additional capital required to continue the Company's planned operations, but that our plans do not fully alleviate the substantial doubt about the Company's ability to operate as a going concern.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Recent Accounting Pronouncements

During the nine months ended September 30, 2024, there have been no new accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements.

Basis of Presentation

The accompanying financial statements include the accounts of GeoVax Labs, Inc. and GeoVax, Inc. All intercompany transactions have been eliminated in consolidation. The financial statements are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of interim periods presented. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates and will require additional funding to continue our research and development activities. We believe that our existing cash resources will be sufficient to continue our planned operations into the first quarter of 2025. We plan to pursue additional capital resources through public or private equity or debt financings, government grants/contracts, arrangements with strategic partners, or from other sources. There can be no assurance that additional funding will be available on favorable terms or at all. These factors collectively raise substantial doubt about the Company's ability to continue as a going concern. Management believes that we will be successful in securing the additional capital required to continue the Company's planned operations, but that our plans do not fully alleviate the substantial doubt about the Company's ability to operate as a going concern.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Balance Sheet Components

Prepaid Expenses

<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt;"><td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; padding-bottom: 1px;"><td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 18pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 18pt;">Prepaid expenses consist of the following:</p></td></td></td>	<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; padding-bottom: 1px;"><td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 18pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 18pt;">Prepaid expenses consist of the following:</p></td></td>	<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 18pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 18pt;">Prepaid expenses consist of the following:</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 18pt;">Prepaid expenses consist of the following:</p>
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; text-align: center; margin: 0pt;">September 30</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; text-align: center; margin: 0pt;">September 30</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; text-align: center; margin: 0pt;">2024</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; text-align: center; margin: 0pt;">2024</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; text-align: center; margin: 0pt;">December 31</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; text-align: center; margin: 0pt;">December 31</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; text-align: center; margin: 0pt;">2023</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; text-align: center; margin: 0pt;">2023</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 68%;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">Prepaid clinical trial costs (current portion)</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">Prepaid clinical trial costs (current portion)</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,706,281</td>	1,706,281		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,282,746</td>	1,282,746		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">110,695</td>	110,695		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">13,045</td>	13,045		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">10,000</td>	10,000		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">26,667</td>	26,667		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,729,326</td>	1,729,326		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 13%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,433,153</td>	1,433,153		
<td style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; width: 1%; font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;"><p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p></td>	<p style="font-family: 'Times New Roman', 'Times', serif; font-size: 10pt; margin-left: 0pt;">\$</p>		

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30</p>	2024	2023	2022
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">December 31</p>	2023	2022	2021
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Equipment and furnishings</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">\$795,411</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 0pt;">774,758</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 0pt;">115,605</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 0pt;">1px</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 0pt;">1px</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 0pt;">1px</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total property and equipment</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">\$791,016</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 0pt;">890,363</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 0pt;">(739,401)</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation and amortization</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">\$171,615</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 0pt;">(680,674)</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 0pt;">(1px)</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total property and equipment, net</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">\$209,689</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 0pt;">\$209,689</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 0pt;">\$209,689</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other Assets</p>	<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">- Other assets consist of the following:</p>		
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30</p>			

2024	2023	2022	2021	2020
December 31	2023	2022	2021	2020
\$1,106,778	\$60,000	\$70,010	\$11,010	\$11,010
Deposits	Total other assets	Accrued Expenses	Accrued expenses consist of the following:	Payroll-related liabilities
1,106,778	70,000	71,010	11,010	11,010
\$1,106,778	\$60,000	\$70,010	\$11,010	\$11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778	70,000	71,010	11,010	11,010
1,106,778				

Total other assets	\$ 71,010	71,010
1,187,788	\$ 1,187,788	1,187,788
September 30, 2024	September 30, 2024	September 30, 2024
2024	2024	2024
Payroll-related liabilities	\$ 169,719	169,719
Accrued clinical trial costs	\$ 220,501	220,501
Other accrued expenses	\$ 111,959	111,959
Total accrued expenses	\$ 716,931	716,931
Notes Payable	Notes Payable	On May 10, 2024, we issued 10% Original

Issue Discount Promissory Notes (the "Notes") with an aggregate principal amount of \$150,000 to members of our Board of Directors and senior management, in exchange for gross cash proceeds to us of \$135,000. The Notes are unsecured, bear interest at a rate of 15% per annum, and mature upon the earlier of (i) six months from the issue date or (ii) three days following the date the Company completes an offering of its common stock with gross proceeds of not less than \$5 million (a "Qualified Financing Event"). On August 22, 2024, following the successful completion of a Qualified Financing Event, we repaid the aggregate principal amount of the Notes in full, together with accrued interest. Total interest expense recorded during the nine months ended September 30, 2024 was \$21,375, consisting of \$15,000 of debt discount amortization and \$6,375 of accrued interest.

</p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> 0.10 150000 135000 0.15 5000000 21375 15000 6375 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; "> <tbody> <tr style="vertical-align: top; "> <td style="width: 36pt; "> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; "> 5. </p> </td> <td style="width: auto; "> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; "> Commitments </p> </td> </tr> </tbody> </table> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> <i>Operating Lease. </i> We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on December 31, 2025. Rent expense for the three-month and nine-month periods ended September 30, 2024 was \$46,764 and \$140,292, respectively, as compared to \$45,414 and \$136,242, respectively, for the same periods of 2023. Future minimum lease payments total \$46,764 in 2024, and \$192,708 in 2025 although the lease may be terminated at any time by either party with one hundred eighty days written notice. </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> <i>License Agreements. </i> We have entered into license agreements for various technologies and patent rights associated with our product development activities. These agreements may contain provisions for upfront payments, milestone fees due upon the achievement of selected development and regulatory events, minimum annual royalties or other fees, and royalties based on future net sales. Due to the uncertainty of the achievement and timing of the contingent events requiring payment under these agreements, the amounts to be paid by us in the future are not determinable. </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> <i>Other Commitments</i>. In the normal course of business, we enter into various contracts and purchase commitments including those with contract research organizations ("CROs") for clinical trial services, contract manufacturing organizations ("CMOs") for production of materials for use in our clinical trials, and other independent contractors or academic institutions for preclinical research activities and other services and products. Most contracts are generally cancellable, with notice, at the Company's option. Payments due upon cancellation may consist of payments for services provided or expenses incurred to date, or cancellation penalties depending on the time of cancellation. </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> 8400 46764 140292 45414 136242 46764 192708 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; "> <tbody> <tr style="vertical-align: top; "> <td style="width: 36pt; "> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; "> 6. </p> </td> <td style="width: auto; "> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; "> Stockholders </p> </td> </tr> </tbody> </table> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> <i>Reverse Stock Split and Reduction of Authorized Shares of Common Stock</i> </p> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> At a special meeting of our stockholders held on January 16, 2024, our stockholders approved an amendment to our certificate of incorporation to (i) reduce our authorized shares of common stock from 600,000,000 to 150,000,000 and (ii) effect a one-for-fifteen reverse split of our common stock. The amendment to our certificate of incorporation was filed with the Delaware Secretary of State on January 30, 2024 and our common stock began trading on the split-adjusted basis on January 31, 2024. The accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock split. </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> <i>Common Stock and Warrant Offerings</i> </p> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> On May 21, 2024, we closed a registered direct offering of 220,000 shares of common stock and pre-funded warrants to purchase an aggregate of 582,844 shares of common stock (the "May 2024 Pre-Funded Warrants"). In a concurrent private placement, we issued common warrants to the purchaser to purchase up to 1,605,688 shares of common stock at an exercise price of \$1.68 per share. Net proceeds after deducting placement agent commissions and other offering expenses were approximately \$1.2 million. </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> On July 12, 2024, we closed a registered direct offering of 458,632 shares of common stock and pre-funded warrants to purchase an aggregate of 626,368 shares of common stock (the "July 2024 Pre-Funded Warrants"). In a concurrent private placement, we issued common warrants to the purchaser to purchase up to 2,170,000 shares of common stock at an exercise price of \$2.86 per share. Net proceeds after deducting placement agent commissions and other offering expenses were approximately \$2.8 million. </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> On August 21, 2024, we closed a registered direct offering of 1,360,731 shares of common stock and pre-funded warrants to purchase an aggregate of 339,269 shares of common stock (the "August 21, 2024 Pre-Funded Warrants"). In a concurrent private placement, we issued common warrants to the purchaser to purchase up to 1,700,000 shares of common stock at an exercise price of \$5.00 per share. Net proceeds after deducting placement agent commissions and other offering expenses were approximately \$7.9 million. </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> On August 30, 2024, we closed a registered direct offering of 837,500 shares of common stock and pre-funded warrants to purchase an aggregate of 138,110 shares of common stock (the "August 30, 2024 Pre-Funded Warrants"). In a concurrent private placement, we issued common warrants to the purchaser to purchase up to 975,610 shares of common stock at an exercise price of \$5.00 per share. Net proceeds after deducting placement agent commissions and other offering expenses were approximately \$4.6 million. </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> On September 25, 2024, we entered into a Sales Agreement and established an "At-the-Market" continuous offering program (the "ATM Program"), pursuant to which the Company may offer and sell, from time to time through its sales agent, shares of its common stock. During the third quarter of 2024 we sold 84,600 shares of our common stock through the ATM Program at a weighted-average price of \$2.51 per share, raising \$206,003 of net proceeds, after deducting commissions to the sales agent and other related expenses. As of September 30, 2024, we had \$4,274,260 available under the ATM Program. </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> <i>Warrant Exercises</i> </p> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> </p> <p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt; "> During the first quarter of 2024 we issued 269,032 shares of our

related expense over the terms of the related agreements. During the three-month and nine-month periods ended September 30, 2024 we recorded stock-based compensation expense of \$ 0- and \$54,167, respectively, associated with common stock issued for consulting services, as compared to \$70,833 and \$132,333, respectively, for the same periods of 2023.

655314 P1Y10M24D 0 54167 70833 132333 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif, font-size: 10pt;"> 8.</p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif, font-size: 10pt;"> Revenue from Government Contract</p> </td> </tr> </tbody> </table> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> On June 12, 2024, GeoVax was awarded a contract (the "BARDA Contract") through the Rapid Response Partnership Vehicle (RRPV) to advance the clinical development of GEO-CM04S1, the Company's next-generation COVID-19 vaccine. The RRPV is a consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS). </p> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> Under the BARDA Contract, GeoVax will sponsor a 10,000 participant, randomized, Phase 2b double-blinded clinical trial to assess the efficacy, safety, and immunogenicity of GEO-CM04S1 compared with a U.S. Food and Drug Administration (FDA) approved mRNA COVID-19 vaccine. The direct award to GeoVax, currently approximately \$26.2 million and which may increase to as much as \$45 million, is funding the manufacturing of clinical materials and support for the Phase 2b clinical trial, including regulatory activities. BARDA has made a separate award through its Clinical Studies Network to fully fund the execution of the study by Allucent, a global clinical research organization; the funding provided directly to Allucent will not be recognized in GeoVax's financial statements. </p> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> GeoVax's role in the project is being funded in whole or in part with federal funds from BARDA under Other Transaction 75A50123D00005. Allucent's role in the project is being funded in whole or in part with federal funds from BARDA under contract 75A50120D00016/75A50123F33005. </p> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> During the three-month and nine-month periods ending September 30, 2024, GeoVax recognized revenue of \$2,789,484 and \$3,090,161, respectively, associated with the BARDA contract. We record revenue associated with this contract as the reimbursable costs are incurred. </p> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> 26200000 45000000 2789484 3090161 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif, font-size: 10pt;"> 9.</p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif, font-size: 10pt;"> Net Loss Per Share</p> </td> </tr> </tbody> </table> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. The Company's potentially dilutive securities, which include stock options and stock purchase warrants, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. The securities that could potentially dilute basic earnings per share in the future and that have been excluded from the computation of diluted net loss per share totaled 6,951,395 and 1,026,862 shares at September 30, 2024 and 2023, respectively. </p> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> 6951395 1026862 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif, font-size: 10pt;"> 10.</p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif, font-size: 10pt;"> Income Taxes</p> </td> </tr> </tbody> </table> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> No provision for income taxes was recorded in either of the nine-month periods ended September 30, 2024 and 2023. The Company remains in a cumulative loss position with a full valuation allowance recorded against its net deferred income tax assets as of September 30, 2024. </p> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif, font-size: 10pt;"> 11.</p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif, font-size: 10pt;"> Subsequent Events</p> </td> </tr> </tbody> </table> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> During October 2024 we issued 826,761 shares of our common stock through the ATM Program at a weighted-average price of \$2.20 per share, raising \$1,761,309 of net proceeds, after deducting commissions to the sales agent and other related expenses. On October 15, 2024, we increased the maximum aggregate offering price of the shares issuable under the ATM Program from \$4,486,846 to \$30,000,000. </p> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> 826761 2.2 1761309 4486846 30000000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 54pt;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif, font-size: 10pt;"> Item 5</p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif, font-size: 10pt;"> Other Information</p> </td> </tr> </tbody> </table> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> During the period covered by this report, none of our directors or executive officers adopted or terminated any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as each term is defined in Item 408(a) of Regulation S-K). </p> <p style="font-family: 'Times New Roman', font-size: 10pt, font-variant: normal, margin: 0pt;"> During the period covered by this report, there was no information required to be disclosed by us in a Current Report on Form 8-K that was not so reported, nor were there any material changes to the procedures by which our security holders may recommend nominees to our board of directors. </p>